



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Examining the efficacy of a telehealth intervention targeting addictive eating in Australian adults (the TRACE program): a randomised controlled trial protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-064151
Article Type:	Protocol
Date Submitted by the Author:	25-Apr-2022
Complete List of Authors:	Skinner, Janelle; The University of Newcastle, School of Health Whatnall, Megan; The University of Newcastle, School of Health Leary, Mark; The University of Newcastle, Collins, Rebecca; The University of Newcastle, School of Health Pursey, Kirrilly; The University of Newcastle, School of Health Verdejo-García, Antonio; Monash University Hay, Phillipa ; Western Sydney University Baker, Amanda; The University of Newcastle, Hides, Leanne; University of Queensland, Paxton, Susan; La Trobe University Wood, Lisa; The University of Newcastle, Respiratory Medicine Colyvas, Kim; The University of Newcastle, School of Mathematical and Physical Sciences Collins, Clare; The University of Newcastle Burrows, Tracy; The University of Newcastle,
Keywords:	NUTRITION & DIETETICS, PUBLIC HEALTH, Eating disorders < PSYCHIATRY

SCHOLARONE™  
Manuscripts

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

**Article type:** Protocol

**Title:** Examining the efficacy of a telehealth intervention targeting addictive eating in Australian adults (the TRACE program): a randomised controlled trial protocol

**Authors:** Janelle A Skinner<sup>1,2</sup>, Megan Whatnall<sup>1,2</sup>, Mark Leary<sup>1,2</sup>, Rebecca A Collins<sup>1,2</sup>, Kirrilly M Pursey<sup>1,2</sup>, Antonio Verdejo-Garcia<sup>3</sup>, Phillipa J Hay<sup>4</sup>, Amanda L Baker<sup>2,5</sup>, Leanne Hides<sup>6</sup>, Susan J Paxton<sup>7</sup>, Lisa G Wood<sup>2,8</sup>, Kim Colyvas<sup>1</sup>, Clare E Collins<sup>1,2</sup>, Tracy L Burrows<sup>1,2\*</sup>

**Institutions:**

<sup>1</sup>School of Health Sciences, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan NSW 2308, Australia

<sup>2</sup>Hunter Medical Research Institute, University of Newcastle, New Lambton Heights, NSW, 2305, Australia

<sup>3</sup>School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Clayton, VIC 3800, Australia

<sup>4</sup>Translational Health Research Institute, Western Sydney University, Campbelltown, NSW, 2751, Australia

<sup>5</sup>School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW 2308, Australia

<sup>6</sup>School of Psychology, University of Queensland, St Lucia, QLD, 4072, Australia

<sup>7</sup>Department of Psychology and Counselling, Latrobe University, Melbourne, VIC, 3086

<sup>8</sup>School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan NSW 2308, Australia

**\*Corresponding Author:** Professor Tracy Burrows. Mailing address: School of Health Sciences, University Drive, University of Newcastle, Callaghan, NSW, Australia, 2308. Ph: +610249215514. Email: [tracy.burrows@newcastle.edu.au](mailto:tracy.burrows@newcastle.edu.au)

**Word count:** 7344

**Key words:** addictive eating, food addiction, Yale Food Addiction Scale

## ARTICLE SUMMARY

**Title:** Examining the efficacy of a telehealth intervention targeting addictive eating in Australian adults (the TRACE program): a randomised controlled trial protocol

### Abstract

**Introduction** Approximately 15-20% of the adult population endorse symptoms of addictive eating and there are currently limited options for management. Motivational interviewing-based interventions, containing personality risk targeted coping skills training for addictive disorders, have been found to be effective for behaviour change. This project builds upon foundations of a feasibility study and co-design. **Methods and analysis** Using a three-arm randomised controlled trial design, this study aims to determine the efficacy of a telehealth intervention targeting addictive eating symptoms in Australian adults compared to passive intervention and control (no intervention) groups. Addictive eating symptoms are assessed using the Yale Food Addiction Scale (YFAS). Using a multicomponent clinician led approach, the active intervention consists of five telehealth sessions (15-45min each) delivered by a dietitian over 3 months. The intervention uses personalised feedback, skill-building exercises, reflective activities, and goal setting. Participants are provided with a workbook and web site access. The passive intervention group receive the intervention via a self-guided approach with access to the workbook and website (no telehealth). The control group will receive personalised written dietary feedback at baseline and participants advised to follow their usual dietary pattern for six months. The control group will be offered the passive intervention after 6-months. Other outcomes assessed will include dietary intake and quality, depression, anxiety and stress, quality of life, physical activity, and sleep hygiene. Data collection will occur at baseline (pre-intervention), 3 months (post-intervention) and 6 months. The primary endpoint is YFAS symptom scores at 3 months. A cost consequence analysis will determine intervention costs alongside mean change outcomes. **Ethics and dissemination** The Human Research Ethics Committee of The University of Newcastle Australia provided approval: H-

1  
2  
3 61 2021-0100. Findings will be disseminated via publication in peer-reviewed journals,  
4  
5 62 conference presentations, community presentations and student theses. Trial registration:  
6  
7 63 Australia New Zealand Clinical Trial Registry (ANZCTR) ACTRN12619001540101.  
8  
9  
10 64  
11  
12 65

13  
14 66 **Strengths and Limitations of this study**

- 15  
16 67     • Targeting of personality risk factors through tailoring of coping strategies and use of  
17  
18 68       motivational interviewing to improve symptoms of addictive eating  
19  
20 69     • Co-design approach taken, with both consumers and a range of health professionals,  
21  
22 70       to develop a program that is relevant and acceptable to end-users  
23  
24 71     • Detailed assessment of eating behaviours, mental health and lifestyle factors provides  
25  
26 72       the opportunity for personalised feedback to examine how these behaviours change  
27  
28 73       during the intervention  
29  
30  
31 74     • Fidelity outcomes assessed and cost consequence analysis will provide important  
32  
33 75       information regarding future implementation  
34  
35 76     • Limitations include participants being excluded with severe mental illnesses or  
36  
37 77       complex health conditions  
38

39 78  
40  
41 79  
42  
43 80  
44  
45 81  
46  
47 82  
48  
49 83  
50  
51 84  
52  
53 85  
54  
55 86  
56  
57 87  
58  
59  
60

## INTRODUCTION

Research in addictive eating has increased rapidly in recent years. Although the construct remains contentious in the scientific community,[1] addictive eating or 'food addiction' is accepted by consumers[2] and health practitioners.[3,4] Using self-report surveys, approximately 15-20% of the adult population endorse symptoms for addictive eating.[5,6] Higher prevalence rates have been reported in individuals with higher weight status.[6,7] Results from recent research indicate that individuals with addictive eating have significantly lower diet quality and higher intakes of highly processed foods.[8-10] There is also evidence that addictive eating commonly co-occurs with mental health co-morbidities, particularly depression and anxiety, as well as overlapping with eating disorders, specifically binge eating.[5, 11]

Current treatment options for addictive eating largely stem from online self-help groups such as Food Addicts Anonymous[12] and Overeaters Anonymous[13] which have 10 000+ members and have been in existence for many years, demonstrating a need for services.[14] A recent systematic review[15] found there is limited evidence supporting implementation of feasible and effective dietary interventions, run by clinicians, for the management of addictive eating.[16] Of the nine studies reviewed, five interventional studies were found to improve symptoms of food addiction[15] as indicated by improvements in Yale Food Addiction Scale (YFAS)[17, 18] outcomes. These interventions included medication (combination of naltrexone and bupropion,[19] as well as pexacerfont[20]), bariatric surgery[21, 22] and lifestyle modification.[23] However to date, most studies have been limited in sample size and therefore not been powered to detect a change in addictive eating symptoms.[15]

Motivational interviewing based interventions containing personality risk targeted coping skills training for addictive disorders, such as alcohol use, have been found to be effective.[24, 25] This project builds on a program of work that included an initial feasibility study of a targeted

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

116 personality-based intervention for the management of addictive eating in adults (Australia New  
117 Zealand Clinical Trial Registry ACTRN12619001540101).[16] Results from the initial study  
118 indicated that the program was feasible in the target population. Feedback, received from  
119 program participants and facilitators, identified a need for a greater number of program  
120 sessions and improved strategies for increasing retention. As a result, the program was further  
121 refined with end users using an integrated knowledge translation (iKT) framework.[26] This  
122 co-design phase included consumers with lived experience, as well as health professionals  
123 from a range of disciplines to ensure the culmination of multidisciplinary evidence-based  
124 strategies were included. This was unique as previous reports omit this co-design step or are  
125 siloed in their approach.[26] The co-design process used a series of interviews and workshops  
126 to gain input into the program overview, aims, content and materials. Subsequent changes  
127 were made to the program content, language used, and materials were created or refined to  
128 improve acceptability.

129

130 Addictive eating is a complex issue often overlapping with other health conditions, and likely  
131 transdiagnostic. The resultant behaviour change intervention, the TRACE (Targeted Research  
132 on Addictive and Compulsive Eating) program, is a complex intervention and previously  
133 described using the Medical Research Council TiDier checklist for complex interventions.[27]  
134 The aim of the current study is to determine the efficacy of a telehealth intervention (active  
135 intervention) to reduce symptoms of addictive eating in adults, relative to passive intervention  
136 and control (no intervention) groups. It is hypothesised that both the active and passive  
137 intervention groups will achieve a statistically significant reduction in addictive eating  
138 symptoms relative to the control group. Potential moderators (e.g., participant  
139 sociodemographics) and mediators (e.g., physical activity, diet, and sleep) of intervention  
140 efficacy will also be evaluated.

## METHODS

### Study trial design

The TRACE program is a randomised controlled trial with three parallel arms (n=50 per group).

The primary outcome is the change in addictive eating symptoms at the 3-month post-baseline assessment (primary time point). The study also includes a 6-month post-baseline follow-up assessment. In this study, symptoms of addictive eating are assessed using the Yale Food Addiction Scale 2.0 (YFAS).[18]

The intervention study arms are:

Group 1. Active intervention: targeting change in addictive eating behaviours using a multicomponent clinician led approach (telehealth sessions, program workbook and program website)

Group 2. Passive intervention: targeting change in addictive eating behaviours using a multicomponent self-guided approach (program workbook and program website)

Group 3. Control: dietary feedback, via paper-based report, provided at baseline and participants follow their usual dietary pattern for six months.

The comparator groups were chosen to provide a passive delivery option of the program which would be consistent with a self-guided Cognitive Behaviour Therapy approach (Group 2), and a control group consistent with a standard version of dietary feedback (Group 3). The control group is not a wait list control, however participants in this group will be offered access to the passive intervention (i.e., program workbook and program website) after the completion of the 6-month assessment.

This project was approved by The University of Newcastle Human Research Ethics Committee (H-2021-0100) and prospectively registered with the Australian New Zealand Clinical Trials Registry (ACTRN12621001079831). The study protocol was developed in accordance with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

guidelines[28] and the intervention has been described using the TIDIER (Template for Intervention Description and Replication) checklist.[27] The design, conduct and reporting of the studies will adhere to the CONSORT (Consolidated Standards of Reporting Trials) guidelines.[29] All participants will provide informed electronic consent to participate and can withdraw at any time for any reason. The funding bodies had no role in the design, conduct or reporting of the study.



**Setting**

The target population for the TRACE program are adults ( $\geq 18$  years) living in Australia seeking management of addictive eating, who meet eligibility criteria, assessed through an online screening questionnaire. The active intervention will be delivered via telehealth sessions and supported by a program workbook, and website containing materials relevant to the intervention.

**Recruitment**

Participants will be recruited using a range of strategies including media releases, advertising via local and national newspapers, and social-media releases. Informed by our iKT process, a range of recruitment videos (tailored for gender) were also created in addition to written material which will be released via Twitter and Facebook. Recruitment commenced in August 2021 and was completed in April 2022. Recruitment materials will direct individuals to the study information sheet and eligibility survey. The eligibility survey takes approximately 15 mins to complete (Table 1). Online informed consent will be obtained prior to completing the eligibility survey.

**Table 1.** Schedule of measurements for the parent study and the subgroup study

Variable	Instrument	Enrolment	Timepoint post allocation		
Primary study		Eligibility Screening	t <sub>1</sub> Baseline	t <sub>2</sub> 3-months	t <sub>3</sub> 6-months
<b>Sample characteristics</b>					
Demographics	Age, sex, postcode, mental health status	✓			
Socioeconomic factors	Education, income, marital status, employment status, occupation and living/accommodation status	✓			
Anthropometrics	Self-report height and weight	✓		✓	✓
Smoking and substance use	Alcohol, Smoking and Substance Involvement Screening Test - Version 3.0[1]		✓	✓	✓
Purging behaviours	Eating Disorder Examination Questionnaire Short form (EDE-QS)[2]	✓			
<b>Primary Outcomes</b>					
Food addiction symptoms and severity	Yale Food Addiction Scale 2.0[3]	✓		✓	✓
<b>Secondary Outcomes</b>					
Dietary intake and quality	Australian Eating Survey[4, 5]		✓	✓	✓
Depression, anxiety and stress	Patient Health Questionnaire-9,[6] Generalized Anxiety Disorder 7,[7] Perceived Stress Scale[8]	✓		✓	✓
<b>Mediators/moderators</b>					
Dominant personality trait/s	Substance Use Risk Profile Scale[9]		✓		
Eating Behaviours	Eating Disorder Examination Questionnaire 6.0,[10] Binge Eating Scale,[11] Short Inventory of Grazing,[12] Reward-Based Eating Drive Scale[13]		✓	✓	✓
Participant activation level	Patient Activation Measure 13[14]	✓		✓	✓
Usage and engagement with program website	Google Analytics (Google LLC) to record number of site visits, visit durations, number of page views, and links accessed/resources downloaded				
Usage and engagement with Facebook group	Number of participants to join group; number of views, likes and comments per post manually recorded				
<b>Other outcomes</b>					
Quality of life	EQ-5D-5L[15]		✓	✓	✓
Physical activity level	Active Australia Survey[16]		✓	✓	✓
Sleep hygiene behaviours	Pittsburgh Sleep Quality Index[17]		✓	✓	✓
Health care utilisation	Consumer Services Receipt Inventory[18]		✓	✓	✓
‘Control’ and ‘Compulsion’ associated with addictive eating	Qualitative analysis of a segment of the first telehealth session		✓		

Eligibility Screening = assessment of inclusion/exclusion criteria, Baseline = pre-intervention, 3-months = immediate post-intervention, 6-months = 3-months post-intervention.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Eligibility**

To be eligible for inclusion in the study individuals must:

1. Be aged between 18 years and 85 years
2. Endorse  $\geq 3$  symptoms on the Yale Food Addiction Scale 2.0[18]
3. Have a self-reported weight and height consistent with a body mass index (BMI)  $\geq 18.5$  kg/m<sup>2</sup>
4. Be competent in the English language
5. Live in Australia
6. Have access to the internet

Individuals will be excluded from participating in the study if they:

1. Are pregnant or lactating
2. Report having a severe mental illness (such as schizophrenia or bipolar disorder) or health condition
3. Report purging behaviours as identified by the Eating Disorder Examination Questionnaire – Short form (EDE-QS)[30]

*Methodological considerations for eligibility criteria:* The eligibility screener excludes individuals with a BMI below 18.5kg/m<sup>2</sup>. This measure was put in place to reduce the likelihood of recruiting participants with at-risk restrictive eating practices that may be influencing a relatively low weight status. The value of  $<18.5$  kg/m<sup>2</sup> was chosen as this is below the current healthy weight range in national guidelines for Australians[47] and The Centre of Disease Control and Prevention (CDC) in the USA.[48] Additionally, the eligibility screener includes the Eating Disorder Examination Questionnaire Short Form (EDE-QS).[31] This 12-item validated tool is commonly used to identify potential eating disorders. Based on the research team consensus, individuals who have compensatory behaviours such as bingeing/purging (specifically asked in question 7 on the EDE-QS), who may be at risk of an eating disorder and are medically compromised, will be deemed not eligible for the current study. Purging is

related to higher levels of appearance dissatisfaction, anxiety and depressive symptoms and self-concept instability.[49, 50] As per the ethics protocol, participants endorsing any response to this question, indicating these compensatory behaviours will be excluded from the study. The tools for eating disorders and psychological health[30,31,34-36,38] used in the study have been widely used in research in the areas of eating disorders, dietary interventions, substance use and mental health and are considered standard tools for their specific measures. Study information as well as at completion of surveys participants are provided with contact information if they experience or further assistance with health behaviours.

### **Study procedure**

Prospective participants will complete the eligibility survey. This will include demographic questions (e.g., sex, postcode, marital status, level of education, employment status) the Yale Food Addiction Scale 2.0[18] to confirm endorsement of  $\geq 3$  addictive eating symptoms; the EDE-QS<sup>31</sup> to confirm the absence of purging behaviours; and the Patient Health Questionnaire-9 (PHQ-9),[34] Generalized Anxiety Disorder-7 (GAD-7),[35] and Perceived Stress Scale-4[36] to determine severity of depression, anxiety and stress, respectively. For participants scoring in the severe category for either depression (PHQ-9 scores of 16-20) or anxiety (GAD-7 scores of 15-21), with the participant's consent, copies of the relevant results will be sent to their nominated General Practitioner. While not necessary to determine eligibility, the Patient Activation Measure 13,[42] and two questions relating to previous treatments sought for addictive eating, will also be completed by potential participants. These questions have been specifically added to extend our previously reported research[51] regarding the types of individuals recruited into interventions for food addiction.

Participants deemed eligible will proceed to the online consent form (Figure 1. Overview of study schedule). Participants will be given a two-week period to consider participation. After this time, a member of the research team will contact any individuals via email who have not completed the consent form to determine their interest in participating. Following this, no other

contact will be made. Participants who provide electronic written consent will complete the baseline assessment surveys measuring dietary intake and eating habits, personality, quality of life and healthcare service utilisation (Table 1. Schedule of measurements). The surveys take approximately 40 minutes to complete. On completion of baseline surveys, participants will be randomly allocated to one of three groups (Group 1: active intervention; Group 2: passive intervention; or Group 3: control; see *Intervention* description) and informed of their group allocation via email.

Figure 1. Overview of the study schedule

Following randomisation (see *Randomisation and Blinding*), a member of the research team will contact participants in Group 1 via telephone or email to arrange an appointment time for their initial telehealth session. Groups 1 and 2 will be emailed a copy of the program workbook (printable and fillable PDF versions); a hard copy is available for participants on request; and be provided with password protected access to the program website at this time. Telehealth sessions 2 – 5, for participants allocated to the active intervention group (Group 1), will be arranged during their first telehealth session.

Participants from all three groups will receive results from the eligibility and/or baseline surveys by the research team via email. On survey completion, Groups 1 and 2 will receive feedback on dominant personality trait/s that may be associated with increased risk for addictive behaviours (e.g., anxiety-proneness, impulsivity-proneness); symptoms of addictive eating; dietary, caffeine and alcohol intake; sleep hygiene and physical activity levels. At this timepoint, Group 3 will only receive feedback on dietary intake via email. At 6-months post study commencement, Group 3 will be provided with feedback on personality trait/s; symptoms of addictive eating; sleep hygiene and physical activity levels, along with access to the workbook and website (the passive intervention that Group 2 received at baseline). To ensure consistency across participants, email templates and standardised reports will be used by the

research team. Group 2 will be guided with written instructions in their workbook on how to utilise their survey results to allow personalised goal setting regarding their dietary intake and eating patterns.

The primary and secondary outcomes will be assessed at 3-months (primary endpoint, immediate post-active intervention period) and 6-months (follow-up) where participants will complete post-program surveys (Table 1. Schedule of measurements). Participants will be sent reminder emails to complete their surveys. They will be reminded a maximum of three times at each time point. If no contact is received after such time, no further contact will be made. Participants will be remunerated with a gift voucher to the value of AUD20 at the completion of baseline, 3-month and 6-month surveys, corresponding to a maximum of AUD60 per participant over the course of the study.

### **Randomisation and Blinding**

Following completion of baseline assessments, participants will be randomised to one of the three study groups in equal ratios using permuted block randomisation, with block sizes of six. Randomisation will be stratified by sex and mental health status (depression and anxiety) to ensure group balance on these important variables. The randomisation sequence will be generated by an independent statistician and implemented by a designated study co-ordinator. The allocation list will be stored in a password protected computer file and accessed only by the study co-ordinator.

Blinding of participants and dietitians to intervention group allocation in this study will not be possible. However, several strategies will be employed to reduce the risk of bias. First, participants will only be provided with partial information on the study hypotheses. Second, all communication between participants and research staff during the period of intervention (i.e., scheduling concerns, questions regarding the intervention) will be done directly between participants and the 'study co-ordinator' or their respective 'telehealth clinician'. Lastly,

1  
2  
3 316 statistical analyses will be conducted by researchers who are blind to group allocation prior to  
4  
5 317 analysis.  
6  
7 318  
8  
9 319 **Intervention**  
10  
11 320 **TRACE Active Intervention (Group 1):** Participants will receive five standardised one-on-  
12  
13 321 one telehealth/phone sessions with an Accredited Practising Dietitian, with training in  
14  
15 322 behaviour change and eating disorders, over a 3-month period (i.e., weeks 1, 2, 4, 8 and 12).  
16  
17 323 Additionally, dietitians leading the intervention delivery will have extensive experience in  
18  
19 324 private practice work and working with clients including those with disordered eating and those  
20  
21 325 with mental health conditions. Sessions will range from 15-45 mins. Telehealth sessions will  
22  
23 326 be provided via the VSee platform ([www.vsee.com](http://www.vsee.com)). The active intervention uses personalised  
24  
25 327 feedback, skill-building exercises, and goal setting to help individuals reduce their symptoms  
26  
27 328 of addictive eating and improve their dietary intake, and relationship with food (see Table 2 for  
28  
29 329 *Overview of intervention sessions*). The intervention is personalised based on an individual's  
30  
31 330 dominant personality trait/s (i.e., the traits; depression proneness, anxiety proneness,  
32  
33 331 sensation proneness and/or impulsivity proneness; measured via The Substance Use Risk  
34  
35 332 Profile Scale<sup>37</sup> which the individual scores the most highly for) and addresses a range of  
36  
37 333 factors that influence behaviour, both internal and external. Further, dominant personality  
38  
39 334 trait/s are mapped to specific coping skill strategies which are in turn incorporated into the goal  
40  
41 335 setting process. As part of session 1, the first 15 mins of the consultation will be audio recorded  
42  
43 336 to enable qualitative analysis of responses to standardised questions regarding two elements  
44  
45 337 of 'control' and 'compulsion' around the participant's food intake. These two themes were  
46  
47 338 previously identified, through thematic analysis of the feasibility study data,[52] as having an  
48  
49 339 influential relationship with addictive eating behaviours. On completion of the five telehealth  
50  
51 340 sessions, participants will be invited to join a closed Facebook group from 3-months post  
52  
53 341 commencement of the intervention until the 6-month outcome survey measures are  
54  
55 342 conducted. Joining the Facebook group is voluntary.  
56  
57  
58  
59  
60 343



344 **Table 2.** Overview of intervention sessions

Session	Session aims
<b>1) Personality</b> <b>(Week 1: 45 mins)</b>	<ul style="list-style-type: none"> <li>• Introduce the intervention</li> <li>• Determine participant's main concerns with their food intake</li> <li>• Provide feedback on baseline scores of addictive eating</li> <li>• Discuss what this means when attempting and preparing to make changes</li> <li>• Provide feedback on dominant personality trait/s</li> <li>• Discuss how personality traits may relate to food intake and addictive eating, and what this means for the individual</li> <li>• Discuss coping strategies based on personality traits and complete 'Urge Surfing' activity</li> <li>• Introduce 'Distraction List'</li> <li>• Set homework task: choose and practice 2 coping strategy exercises</li> <li>• Provide session summary</li> </ul>
<b>2) Food</b> <b>(Week 2: 45 min)</b>	<ul style="list-style-type: none"> <li>• Review session 1</li> <li>• Check in for episodes of overeating</li> <li>• Discuss progress with homework task - coping strategies</li> <li>• Provide feedback on dietary intake</li> <li>• Discuss core vs non-core food intake (Optional: discuss alcohol intake)</li> <li>• Develop 3 nutrition goals using <i>SMARTER Goal Checklist</i> <ol style="list-style-type: none"> <li>1) Positive – increase core foods</li> <li>2) Reduction – decrease non-core foods</li> <li>3) 'Eating awareness' – using strategies to delay or halt overeating</li> </ol> </li> <li>• Discuss enablers/barriers when making changes to eating habits</li> <li>• Discuss 'No Money No Time' website (<a href="http://www.nomoneynotime.com.au">www.nomoneynotime.com.au</a>)</li> <li>• Discuss 'Practical Strategies to Achieve Goals'</li> <li>• Set homework task: complete 'Triggers for Overeating Checklist'</li> <li>• Provide session summary</li> </ul>
<b>3) Skills</b> <b>(Week 4: 30 min)</b>	<ul style="list-style-type: none"> <li>• Review session 2</li> </ul>



Session	Session aims
	<ul style="list-style-type: none"> <li>● Assess progress with SMARTER goals</li> <li>● Check in for episodes of overeating</li> <li>● Discuss homework task - '<i>Triggers for Overeating</i>'</li> <li>● Explore strategies to overcome triggers, building on previous personality-based coping strategies and '<i>Practical Strategies to Achieve Goals</i>'</li> <li>● Discuss and determine a '<i>food line</i>' to identify when eating is no longer enjoyable or not tasting food</li> <li>● Discuss strategies to stay below the '<i>food line</i>'</li> <li>● Set homework task: complete '<i>Mood Monitor</i>' worksheet</li> <li>● Provide session summary</li> </ul>
<b>4) Confidence (Week 8: 30 min)</b>	<ul style="list-style-type: none"> <li>● Review session 3</li> <li>● Discuss progress with plan to stay below '<i>food line</i>' and for episodes of overeating</li> <li>● Explore enablers/barriers to achieving goals</li> <li>● Discuss homework task - '<i>Mood Monitor</i>', and explore emotions that participant has difficulty coping with</li> <li>● Discuss seeing emotions differently</li> <li>● Explore coping strategies for difficult emotions</li> <li>● Discuss importance of sleep, physical activity, and responsible intake of alcohol for emotional health</li> <li>● Discuss implementing coping skills plan to achieve SMARTER goals (i.e. consolidate information from sessions 1 – 4)</li> <li>● Set homework task: practice implementation of coping skills plan to achieve goals</li> <li>● Provide session summary</li> </ul>
<b>5) Moving forward (Week 12: 20 mins)</b>	<ul style="list-style-type: none"> <li>● Review session 4</li> <li>● Check in/briefly problem solve and encourage participant to continue with goals and strategies</li> <li>● Discuss topics from previous sessions (participant led)</li> <li>● Reassess confidence to achieve goals</li> <li>● Provide final <i>Addictive Eating Action Plan</i></li> <li>● Discuss how support group on Facebook works and encourage sign up</li> </ul>

1  
2  
3 346 *Participant Workbook and Program Website:* Participants will have access to a participant  
4  
5 347 workbook and password protected access to a study specific website  
6  
7 348 ([www.tracedietetics.com.au](http://www.tracedietetics.com.au)), both built for the study to support the materials discussed in the  
8  
9 349 intervention sessions. To further facilitate the co-design process, the workbook and website  
10  
11 350 content was piloted with end users (n=2) with lived experience of addictive eating, who  
12  
13 351 participated in the iKT interviews/workshops. The end users reported the workbook and  
14  
15 352 website to be highly usable in terms of the content, and the language used throughout as  
16  
17 353 appropriate with only minor modifications made. Additionally, the piloting process allowed the  
18  
19 354 estimated time to complete each workbook module to be calculated.  
20  
21  
22 355

23  
24 356 *Program Workbook:* The workbook consists of five modules: 1) Personality; 2) Food; 3) Skills;  
25  
26 357 4) Confidence; and 5) Moving forward. The content of the five modules mirrors that of the  
27  
28 358 telehealth sessions. The workbook also contains reflective activities/worksheets, discussed  
29  
30 359 during the telehealth sessions, for the participants to complete. These elements were deemed  
31  
32 360 important during the iKT process. The amount of time spent completing activities in the  
33  
34 361 workbook each week, between telehealth sessions, will take approximately 30 - 60 minutes.  
35  
36 362 However, the time to complete each module may vary from person to person, and participants  
37  
38 363 are advised to work through the workbook at a pace that is right for them.  
39  
40  
41 364

42  
43 365 *Program Website:* The website includes the following pages: 1) Home/Landing page: brief  
44  
45 366 information about the program and login; 2) Dashboard: navigation page to access each of  
46  
47 367 the program's module pages; 3) Module pages: each of the five modules within the  
48  
49 368 intervention has a separate page on the website. This includes additional resources to  
50  
51 369 complement the telehealth sessions and workbook; and 4) About us: brief information about  
52  
53 370 the research/clinician team behind the program, including contact information (email). The  
54  
55 371 website will be available for a period of 12 months from study commencement. All data  
56  
57 372 captured from the website will be encrypted and stored securely on a server.  
58  
59  
60

373 *Program Facebook Group:* This is a voluntary part of the study which aims to further support  
374 participants with behaviour change. The Facebook forum is set up as a private Facebook  
375 group. Participants can use their standard Facebook login, or alternatively, create a new login  
376 (a pseudo account) that does not identify them if they wish to remain anonymous. Participants  
377 will be prompted with information related to the intervention for the 3-month duration in the  
378 form of short posts, blogs, and polls. The Facebook group will allow participants to engage  
379 with other participants from the program, as well as serve as a communication method to  
380 remind participants about assessments for the study.

381  
382 To maintain participant's privacy the Facebook forum will be set up as a private Facebook  
383 group with the following restrictions: 1) Membership will be by invitation only; 2) The group will  
384 not appear in search results or the participants Facebook profile; and 3) Only group members  
385 will be able to see the group information and group posts. Participants will be advised of the  
386 appropriate use of language and etiquette for using the social media/discussion forum in the  
387 workbook and reminded at the final telehealth session. The Facebook group will be moderated  
388 by a member of the research team via the TRACE research Facebook account.

389  
390 *Intervention fidelity:* A detailed clinician manual will be used by the dietitian for all telehealth  
391 sessions to maintain treatment fidelity. Dietitians administering the intervention will be trained  
392 by the principal investigator prior to study implementation. Dietitians will also follow each  
393 session as outlined in the manual and keep a dietitian log of participants telehealth sessions.  
394 Further, five participants allocated to Group 1, with their consent, will have all their telehealth  
395 sessions audio recorded. The dietitian log and audio recordings will be reviewed by an  
396 independent researcher to ensure the intervention was delivered as intended. Regular  
397 supervisory meetings will be conducted with the dietitians and program coordinator led by the  
398 principal investigator. Participant adherence to the intervention will be assessed by a session  
399 attendance checklist completed by a member of the research team. Dietitians administering  
400 the telehealth sessions will monitor completion of homework tasks and workbook activities at

the start of telehealth sessions 2 to 5. Assistance will be provided by the dietitian at this time if participants experienced any difficulties completing the homework tasks/activities. Additionally, to assist with adherence, on completion of each telehealth session the dietitian will email a personalised 'Addictive Eating Action Plan', completed on a standardised template, to the participant.

**TRACE Passive Intervention (Group 2):** Participants will receive the intervention via self-guided approach, with access to the five-module workbook and website (as described above), but without the telehealth consults. The content of the workbook modules mirrors the content of the five telehealth sessions. In addition to the written materials provided, the workbook contains spaces for reflective activities, documenting goals and monitoring progress. Participants will be asked, on receipt of the workbook, to complete the workbook within a 3-month period. The proportion of the workbook completed by participants in the passive intervention arm will not be monitored. Following the 3-month self-guided learning period, participants will be invited to join the closed Facebook group as described above.

**Control (Group 3):** Participants will receive personalised dietary feedback on baseline surveys, provided by an automated report, generated from the Australian Eating Survey. This is consistent with standard dietary feedback from a dietitian. Participants in the control group will be offered access to the participant workbook and study website after the completion of the 6-month assessment.

### **Outcome measures**

All outcome measures are completed at baseline, 3 months (immediate post-active intervention period) and 6 months (follow-up) via online surveys. The same survey tools will be used at each time point. Participants will receive assessment reminders by email.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Primary outcomes**

**Food addiction symptoms and severity:** The Yale Food Addiction Scale (YFAS 2.0)[18] will be used to assess the change in food addiction symptomatology and severity. The YFAS 2.0 is a validated self-report 35-item questionnaire. The YFAS 2.0 asks participants to think of specific foods they have had difficulty controlling the consumption of within the past 3 months (e.g., ice cream, chocolate, chips, hamburgers). The YFAS 2.0 provides a food addiction symptom score based on similar criteria for substance use disorder of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).[53] Scores can range from zero to 11, and symptoms include craving, loss of control, tolerance and withdrawal associated with eating behaviours. Additionally, two items assess clinically significant impairment or distress from eating. A food addiction “diagnosis” can be given when  $\geq 2$  symptoms are endorsed, and clinically significant impairment or distress is present. However, for the purpose of this study a ‘food addiction’ diagnosis will not be given, and severity of addictive eating will be classified as follows: “mild” = 3 symptoms, “moderate” = 4-5 symptoms or “severe”  $\geq 6$  symptoms. The YFAS 2.0 has been found to be a robust and psychometrically sound measure of food addiction symptomatology in non-clinical[17,54] and clinical populations with good test/retest validity.[55] Preliminary evidence[15,16] suggests that YFAS scores are sensitive to change and are decreased after intervention.

**Secondary outcomes**

**Dietary intake and quality:** Changes in dietary intake and quality will be measured using the Australian Eating Survey (AES).[32] The following dietary outcomes will be measured: (1) core foods and non-core foods percentage contribution to total energy intake; (2) average daily energy intake, proportion of total energy intake contributed by macronutrients, micronutrient intakes; and (3) overall diet quality. The AES is a validated 120-item semi-quantitative FFQ that assesses usual food and nutrient intakes over the previous 3-6 months. The AES includes a comprehensive list of foods, including drinks, milk and dairy foods, breads and cereals, sweet and savoury snacks, main meals, other foods, vegetables and fruit. Frequency

response options for each food, or food type, range from 'never' to '≥7 times per day'. The AES has been assessed for comparative validity relative to weighed food records and for fruit and vegetable intakes using plasma carotenoids.[32,33] Standard portion sizes for adult men and women have been determined for each AES item in the survey, using data from the most recent Australian National Nutrition Survey. The food and beverage weight per serving, used in the calculation of food group servings (as serves per day) is consistent with sizes specified in the Australian Guide to Healthy Eating.[32,33,56] Nutrient intakes from the AES FFQ were computed using data in the AUSNUT 2011–13 database.[57] The AES also provides an Australian Recommended Food Score (ARFS), derived from a subset of 70 AES questions, as a measure of diet quality that reflects the overall healthiness and nutritional quality of an individual's usual eating pattern.[33] The ARFS is based on the frequency of consumption of core foods, recommended in the Australian Dietary Guidelines,[58] with foods awarded one point for a consumption frequency of ≥once per week. The total score is calculated by summing the points for each item and scores can range from zero to 73, with higher scores awarded for greater dietary variety.[33]

**Depression, anxiety and stress:** Changes in symptom scores for depression, anxiety and stress will be measured using the Patient Health Questionnaire (PHQ-9),[34] the Generalized Anxiety Disorder 7 (GAD-7)[35] and the Perceived Stress Scale (PSS-4),[36] respectively. The PHQ-9 is a validated self-report 9-item tool that asks the individual to rate the severity of depressive symptoms over the past two weeks from 0 ('not at all') to 3 ('nearly every day'). For this study, the question within the PHQ-9 relating to suicide ideation was not included. Total scores for the remaining 8 items range from 0 to 24, and severity will be determined using the following cut-offs: 0–4 = minimal, 5–9 = mild, 10–14 = moderate, 15–19 = moderately severe, and 20–24 = severe.[34] The GAD-7 is a validated self-report 7-item tool that asks the individual to rate the severity of symptoms over the past two weeks from 0 ('not at all sure') to 3 ('nearly every day'). GAD-7 total scores range from 0 to 21, and severity is determined using the following cut-offs: 0–5 = mild, 6–10 = moderate, 11–15 = moderately severe, and 16–21 =

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

severe.[35] The PSS-4 is a validated self-report 4-item tool that assesses the degree to which a person perceives life as stressful.[36] The questions have been designed to assess how unpredictable, uncontrollable, and overloaded a person feels their life to be. Frequency over the previous month is rated on a five-point Likert scale ranging from ‘Never’ to ‘Very often’. PSS-4 total scores range from 0 to 16, and higher scores indicate greater stress.[36] Currently, there is no established cut-off for the PSS-4 score to indicate adverse levels of stress.

**Other outcomes**

A selection of other outcomes was chosen based on co-occurring health conditions. Outcomes collected (see Table 1 for schedule of measurements) include the following:

**Quality of Life:** Changes in subjective quality of life will be measured using the EQ-5D-5L.[43] The EQ5D-5L is a validated self-report 5-item tool to assess health-related quality of life. A descriptive system comprising five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems (labelled 1–3). Participants are asked to indicate their health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results into a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes respondent’s health state. The EQ-5D-5 L will be analysed to produce an index score between 0 (state of death) and 1 (perfect health).

**Physical activity level:** Changes in physical activity level will be measured using the Active Australia Survey (AAS).[44] The AAS is a validated self-report tool containing eight core questions to assess participation (hours/mins per week) in moderate and vigorous intensity physical activity and walking for recreation, over the previous week.

**Sleep hygiene behaviours:** Changes in sleep hygiene behaviours will be measured using the Pittsburgh Sleep Quality Index (PSQI).[45] The PSQI is a validated self-report survey with 19 self-rated items and 5 items rated by the bed partner or roommate (if applicable). The tool assesses seven components of sleep to provide one global score. Components measured include 1) Subjective sleep quality, 2) Sleep latency, 3) Sleep duration, 4) Habitual sleep, 5) Sleep disturbances, 6) Use of sleeping medication, and 7) Daytime dysfunction. The overall global score of sleep quality will be calculated, and the subcomponents reported.

**Health care utilisation:** For the purpose of conducting a cost analysis the Consumer Services Receipt Inventory (CSRI)[46] will be completed by participants at each time point. The CSRI is an adaptable tool that ensures the format, language, scope and content is compatible with the research aims, context, participants' likely circumstances, and the quantity and precision of information required.[59] Health care utilisation is captured through self-report and includes information on the number of appointments and type of health care services used in the preceding 3 months.

**Cost analysis:** A cost-consequence analysis will be conducted including calculating the cost of each intervention (i.e., active, passive and control) and reporting intervention costs alongside mean change outcomes. Intervention costs will be recorded in terms of cost of intervention development, intervention delivery and the operating costs of the RCT. Outcomes to be reported as part of the cost analysis will include mean change in addictive eating symptom scores assessed using the YFAS (i.e. the primary outcome), as well as mean change in the number of health care appointments in the past 3-months assessed using the CSRI, and mean change in Quality Adjusted Life Years (QALYs) assessed using the EQ-5D-5L. This approach was selected to provide a comprehensive and transparent overview of intervention costs, given the lack of cost analysis data in this area of research.[60,61]



1  
2  
3 537 **Mediators/Moderators**  
4

5 538 The following potential mediators and moderators of intervention efficacy will be examined:  
6  
7 539  
8

9 540 **Dominant personality trait/s:** Participant's will complete the Substance Use Risk Profile  
10  
11 541 Scale (SURPS)[37] at baseline to determine their dominant personality trait/s. The SURPS is  
12  
13 542 a validated self-report 23-item survey that assess four personality traits associated with  
14  
15 543 increased risk for addictive behaviours (Impulsivity proneness, Sensation proneness,  
16  
17 544 Depression proneness, and Anxiety proneness).  
18  
19

20 545  
21  
22 546 **Eating behaviours:** Eating behaviours that have been shown to have overlap with addictive  
23  
24 547 eating will be measured. This includes eating disorders, binge eating, grazing behaviours and  
25  
26 548 reward driven eating. Eating disorders will be measured using the Eating Disorder  
27  
28 549 Examination Questionnaire 6.0 (EDEQ-6.0)[38] The EDEQ-6.0 is a validated self-report 28-  
29  
30 550 item questionnaire that assesses the occurrence and frequencies of key eating disorder  
31  
32 551 behaviours with cognitive subscales related to eating disorders (restraint, eating concern,  
33  
34 552 shape concern, and weight concern) and behavioural symptoms related to these concerns  
35  
36 553 (e.g. frequency of binge eating, vomiting, use of laxatives or diuretics, and overexercise).  
37  
38 554 Subscale and global scores reflect the severity of eating disorder psychopathology. Binge  
39  
40 555 eating will be measured using the Binge Eating Scale (BES).[39] The BES is a validated self-  
41  
42 556 report 16-item questionnaire to assess the presence of certain binge eating behaviours, over  
43  
44 557 the past 28 days, which may be indicative of an eating disorder. Each item contains 3-4  
45  
46 558 statements about behaviours, thoughts, and emotional states. Grazing behaviours will be  
47  
48 559 measured using the Short Inventory of Grazing (SIG).[40] The SIG is a validated self-report 2-  
49  
50 560 item measure to assess 1) the presence and frequency of grazing in general, and 2) the  
51  
52 561 presence and frequency of grazing accompanied by a sense of loss of control. Reward driven  
53  
54 562 eating will be measured using the Reward-Based Eating Drive Scale (REDX-5).[41] The  
55  
56 563 REDX-5 is a validated self-report 5-item questionnaire, in 5-point Likert scale format from 1  
57  
58  
59  
60

(strongly disagree) to 5 (strongly agree), that assesses reward-driven eating (loss of control over eating, lack of satiety, and preoccupation with food).

**Participant Activation Level:** Participant's underlying knowledge, skills and confidence in managing their addictive eating behaviours and overall health will be measured using the Patient Activation Measure (PAM-13).[62] The PAM-13 is a validated self-report 13-item scale that draws on concepts such as health locus of control, self-efficacy in managing health behaviours and readiness to change health behaviours.[42,63] Higher PAM-13 scores indicate that individuals have higher levels of activation, and understand their role in the self-management process and feel capable of fulfilling that role.[64] Research has demonstrated that a single point change in PAM score is meaningful.[65]

**Engagement and use of the program website and Facebook group:** Interaction with the website will be objectively tracked throughout the study (baseline to 6 months i.e., timepoints 1 to 3) using Google Analytics (Google LLC). Measures of engagement and usage will include number of website visits, website visit duration, number of page views and links accessed/resources downloaded.

Interaction with the Facebook group will be measured throughout the post-intervention period (3 to 6 months from baseline i.e., timepoints 2 to 3). Measures of engagement and usage will include number of participants to join the Facebook group, and number of views, likes and comments per post.

### **Study sample characteristics**

Sociodemographic data will be collected by online questionnaire at baseline. Participants will provide information on their age, sex, marital status, postal code, years of education, employment status and current living situation. Index of Relative Socio-Economic Disadvantage (IRSD) score,[66] based on the Australian Bureau of Statistics census data and

1  
2  
3 592 reflecting a proxy index of socioeconomic status, will be determined by postal code of  
4  
5 593 residence. Current smoking and substance use will be measured using the Alcohol, Smoking  
6  
7 594 and Substance Involvement Screening Test - Version 3.0.[30] Additionally, previous treatment  
8  
9 595 sought for overeating from health professionals or products used to treat overeating will be  
10  
11 596 collected.  
12

13  
14 597  
15  
16 598 Anthropometric data (self-reported height and weight) will be collected by online questionnaire  
17  
18 599 at baseline. BMI will be calculated using standardised techniques and categorised according  
19  
20 600 to the World Health Organization adult cut-off points.[67]  
21

22 601  
23  
24 602 **Sample size**  
25  
26 603 The sample size for the study was calculated based on data from the feasibility study,[16]  
27  
28 604 given the absence of other intervention studies. A clinically meaningful difference in symptoms  
29  
30 605 of addictive eating was selected as a decrease of 2 symptoms, given this would correspond  
31  
32 606 to a change in severity classification on the YFAS 2.0 tool. To detect a mean 2-unit difference  
33  
34 607 (SD = 2.2) in the YFAS symptoms between the active intervention group and the passive  
35  
36 608 intervention group or control group and using a standardised effect size of  $d=0.91$ , a sample  
37  
38 609 size of 32 individuals per group (total sample size  $n=96$ ) is required to detect this change with  
39  
40 610 a power of 0.90 and a type 1 error rate set at 0.025 to account for multiple testing. However,  
41  
42 611 allowing for a 30% dropout rate from the pilot, a sample size of 46 individuals per group (total  
43  
44 612 sample size  $n=138$ ) would be required. Therefore, a total sample size of 150 individuals, with  
45  
46 613 50 per group, was chosen to remain conservative.  
47  
48  
49

50 614  
51  
52 615 **Statistical analysis plan**  
53  
54 616 Data analysis will be conducted by a researcher blinded to the intervention conditions.  
55  
56 617 Descriptive statistics of sample characteristics will be presented. For the primary YFAS  
57  
58 618 outcome a Linear Mixed Model (LMM) will be based on a model with main effects for group  
59  
60 619 (active intervention, passive intervention, control) and time (treated as categorical at levels

baseline, 3 and 6 months), and the group-by-time interaction. An unstructured residual covariance structure will be used to allow for correlation between the repeated measurements for a subject. The primary outcome effect will be reported as the difference between means at baseline and 3 months, with a 95% CI for the difference. Mental health condition and BMI will be examined for possible moderating effects on the effect size, and if so adjustment for them will be carried out. Secondary descriptive analysis will be carried out to identify whether specific symptoms were predominantly associated with reductions in YFAS score.

A secondary outcome will be a categorical variable, clinically significant change from baseline to 3 months, where significant requires a reduction of 2 or more symptoms in the YFAS. This will be analysed using logistic regression with group being the only factor. Additional secondary outcomes will include dietary outcomes (average daily energy intake, proportion of total energy intake contributed by core foods and non-core foods intakes, macronutrients intakes, micronutrient intakes; and overall diet quality) and mental health status (depression, anxiety and stress scores). These will also be analysed using LMMs as per the approach above. All available data will be used with no imputation of missing values at 3 and 6 months, however baseline scores will be kept. The participants will be analysed in their allocated randomisation group. Statistical significance will be set at 0.05.

### **Data management and monitoring**

Online survey data will be managed using REDCap electronic data capture tools[68,69] hosted at the University of Newcastle. REDCap (Research Electronic Data Capture) is a secure, web-based software platform designed to support data capture for research studies, providing 1) an intuitive interface for validated data capture; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless data downloads to common statistical packages; and 4) procedures for data integration and interoperability with external sources.

1  
2  
3 648 All data captured from the study website will be encrypted and stored securely on the server.  
4  
5 649 All other data collected will be entered into a password protected central database which is  
6  
7 650 hosted on secure university-based servers, which comply with robust security standards for  
8  
9 651 clinical data and are subject to daily backups and regular offsite backups. Only authorised  
10  
11 652 members of the research team will have access to the database. Research staff handling  
12  
13 653 study data are trained in procedures for handling sensitive information, accurate data entry,  
14  
15 654 surveillance and intervention-specific data storage and data archive. Facilitators of the  
16  
17 655 telehealth sessions are responsible for the electronic storage of study forms on the central  
18  
19 656 database. All completed forms will be checked for completeness and accuracy, first by data  
20  
21 657 collectors and later by a member of the research team responsible for data management.  
22  
23 658 Throughout the study period (at 25% and 50% of required participants) approximately 5% of  
24  
25 659 records will be randomly selected for data quality checks of accuracy and completeness by  
26  
27 660 an independent reviewer.  
28  
29  
30  
31  
32

33 662 For the entire study period, any adverse events, of any kind, that might be related to either the  
34  
35 663 trial intervention or trial procedures will be logged in an adverse event log and reported to the  
36  
37 664 Human Research Ethics Committee by the Chief Investigator. To maintain the welfare of  
38  
39 665 participants, with their consent, relevant survey results from the GAD-7[35] and PHQ-9[34] will  
40  
41 666 be sent to the participant's nominated General Practitioner/ health professional if they score  
42  
43 667 in the severe category for either anxiety (GAD-7 scores  $\geq 16$ ) or depression (PHQ-9 scores  
44  
45 668  $\geq 20$ ) if participants consent to this disclosure.  
46  
47  
48  
49

50 670 **Study sponsorship and organisation**

51  
52 671 The sponsor of the trial is the University of Newcastle, and funding was provided by the  
53  
54 672 National Health and Medical Research Council (NHMRC). The trial will be conducted and  
55  
56 673 evaluated independent of the study sponsor and funder. The study is coordinated  
57  
58 674 independently of the study sponsor and funder, by researchers at the University of Newcastle,  
59  
60

675 Australia with the study overseen by the trial management committee comprising the chief  
676 investigators.

## 678 **Patient and public involvement**

679 Consumer (i.e., individuals with lived experience of addictive eating who participated in the  
680 pilot study) input was received on the pilot version of the intervention (FoodFix process  
681 evaluation[16]) that directly guided the enhancement of the TRACE telehealth sessions.

682 The TRACE program workbook and website for the current study was developed following the  
683 pilot study. A sample of consumer representatives (individuals with lived experience of  
684 addictive eating and healthcare experts including clinicians and managers), independent of  
685 those involved in the pilot study, were involved in the review of the program and program  
686 materials.[26]

688 Consumer representatives were interviewed to:

- 689 • Identify what individuals with addictive eating need and want more accurately
- 690 • Gather information about what works well and what needs improving, first-hand from  
691 consumers who may use them
- 692 • Openly consider different or opposing views about aspects of the research project
- 693 • Test resources during development and refine resources making sure they will work  
694 well in practice
- 695 • Detect any unforeseen consequences of a particular decision or direction that has  
696 been made regarding the project
- 697 • Gain support of consumers to implement changes to the research project

699 The opinion of consumers has been considered to create a program that:

- 700 • Aligns to the needs of the people it is trying to help i.e., individuals with addictive eating

- 701 • Is beneficial in terms of delivering meaningful outcomes for individuals with addictive
- 702 eating
- 703 • Is conducted in a way that is sensitive to peoples' needs

704

705 Consumers were not involved in the design of the current study, the selection of outcome

706 measurements, research questions or the recruitment of additional participants. Participants

707 of the current study can request a plain English summary of the study outcomes on its

708 completion.

709

710 **Ethics and dissemination**

711 The trial will be undertaken in compliance with the Declaration of Helsinki and approval to

712 conduct the study was received from the University of Newcastle Human Research Ethics

713 Committee (H-2021-0100). This trial adheres to the SPIRIT guidelines for randomised trials

714 protocols[28] and the results will be reported in accordance with CONSORT guidelines

715 (TIDieR checklist and guide[27]). Protocol modifications will be registered with the Ethics

716 Committee and trial register. All participants will provide electronic consent to participate prior

717 to completing the eligibility and baseline surveys. Results of the study will be disseminated via

718 peer-reviewed publications and presentations at national and international conferences and

719 will also form part of student dissertations.

720

721 **Discussion**

722 This study will examine the efficacy of the TRACE personality-based telehealth intervention to

723 reduce addictive eating symptoms, and severity of food addiction, in adults. Examining the

724 efficacy of an intervention that is designed to be scalable is important given that approximately

725 70% of adults meeting the YFAS criteria for food addiction report  $\geq$  four symptoms, and have

726 significantly lower diet quality, higher intakes of non-core foods and higher weight status.[8-

727 10] Individuals seeking management of addictive eating are also likely to have other mental

728 health comorbidities, such as depression, anxiety, binge eating or other disordered eating



behaviours.[5,7,51] Currently there are few published interventions, run by dietitians and/or other health clinicians, for addictive eating or 'food addiction'[15] demonstrating the clear need for services and trialling of interventions that may be effective at facilitating changes in eating behaviour.

This project will build on the feasibility study utilising the updated program to provide personalised management of addictive eating in adults. We expect that the intervention will provide adults with practical tools (e.g., coping strategies) to improve their eating behaviours and increase awareness of their dietary intakes and potential triggers for overeating, as well as increase help seeking behaviours. Addressing addictive eating may additionally contribute to secondary prevention of other health related issues, such as overweight and obesity, as well as overlapping heavily with validated strategies for the management of some highly prevalent medical conditions, such as cardiovascular disease and type 2 diabetes mellitus.

Strengths of this study include the unique targeting of personality risk factors through tailoring of coping strategies and use of motivational interviewing to increase participant activation as use of these techniques in interventions for other addictive disorders, such as alcohol use, have been shown to be highly effective. While the coping strategies provided by the TRACE program are tailored, it is common for individuals to not uniquely fit into one category for personality and for this reason participants are provided with access via the website to the full set of coping strategies to trial. Telehealth will allow participants to participate from home and reduce the demands on time and travel. Further strengths include the co-design approach taken, with both consumers and a range of health professionals, to avoid siloed research. This collaborative approach aims to provide a program that is relevant and acceptable to end-users, and the randomised controlled design to establish effect. Limitations of the study include the level of experience required of the dietitians administering the telehealth sessions, which may impact the scalability of the intervention. However, dietitians are highly trained professionals in behaviour change and extra care was taken given the uniqueness of the intervention. The



757 fidelity outcomes assessed as part of the trial will provide important information regarding  
758 future implementation. Additional limitations include the exclusion of individuals with severe  
759 mental illnesses or complex health conditions. The current intervention is not designed for  
760 complex co-morbidities. It is envisaged that for these individuals a more complex care model  
761 is required where the TRACE program could be implemented alongside other approaches or  
762 treatments.

764 The TRACE program is designed to raise awareness, and support behaviour change, of  
765 addictive eating. If successful, our study will provide essential evidence regarding the efficacy  
766 of behavioural and dietary improvement in the management of addictive eating, thus allowing  
767 for the implementation of management strategies for addictive eating into community and  
768 clinical healthcare services. Further, if both the active and passive interventions are found to  
769 be effective it will provide evidence of different levels of care that could be utilised within these  
770 services.

**Author Contributions:** TLB conceptualised the study, and TLB, JAS, MW, ML, RC, KMP, AVG, PJH, ALB, LH, SJP, LGW, KC and CEC contributed to the study protocol. TLB, JAS, MW, ML, RC, KMP, AVG, PJH, ALB, LH, SJP, and CEC contributed to the intervention development and design, intervention resources and assessment methodology. JAS wrote the initial manuscript draft. TLB, JAS, MW, ML, RC, KMP, AVG, PJH, ALB, LH, SJP, LGW, KC and CEC contributed to the writing of the final manuscript and/or provided critical comments during revisions. All authors approved the final version prior to submission. TLB, JAS, MW, ML and RC will be responsible for recruitment, data collection and intervention delivery.

**Competing interests:** None declared.

**Funding:** This work was supported by the National Health and Medical Research Council (NHMRC) grant number [G1801414].

## References

1. Gearhardt AN, Hebebrand J. The concept of “food addiction” helps inform the understanding of overeating and obesity: Debate Consensus. *Am J Clin Nutr*. 2021;113(2):274–6. <https://doi.org/10.1093/ajcn/nqaa345>
2. Ruddock HK, Christiansen P, Halford JCG, et al. The development and validation of the Addiction-like Eating Behaviour Scale. *Int J Obes (London)*. 2017;41(11):1710-7. <https://doi.org/10.1038/ijo.2017.158>
3. Burrows T, Verdejo-Garcia A, Carter A, et al. Health Professionals’ and Health Professional Trainees’ Views on Addictive Eating Behaviours: A Cross-Sectional Survey. *Nutrients*. 2020;12(9):E2860. <https://doi.org/10.3390/nu12092860>
4. Whatnall M, Skinner J, Verdejo-Garcia A, et al. Symptoms of Addictive Eating: What Do Different Health Professions Think? *Behav Sci*. 2021;11(5):60. <https://doi.org/10.3390/bs11050060>
5. Burrows T, Kay-Lambkin F, Pursey K, et al. Food addiction and associations with mental health symptoms: a systematic review with meta-analysis. *J Hum Nutr Diet*. 2018;31(4):544-72. <https://doi.org/10.1111/jhn.12532>
6. Pursey K, Stanwell P, Gearhardt A, et al. The prevalence of food addiction as assessed by the Yale Food Addiction Scale: a systematic review. *Nutrients*. 2014;6(10):4552–90. <https://doi.org/10.3390/nu6104552>
7. Skinner J, Jebeile H, Burrows T. Food addiction and mental health in adolescents: a systematic review. *The Lancet Child and adolescent health*. 2021;S2352-4642 (21):00126-7. [https://doi.org/10.1016/S2352-4642\(21\)00126-7](https://doi.org/10.1016/S2352-4642(21)00126-7)

- 1  
2  
3 811 8. Pursey KM, Skinner J, Leary M, et al. The Relationship between Addictive Eating and  
4  
5 812 Dietary Intake: A Systematic Review. *Nutrients*. 2021(1):164.  
6  
7 813 <https://doi.org/10.3390/nu14010164>  
8  
9 814 9. Pursey KM, Collins CE, Stanwell P, et al. Foods and dietary profiles associated with  
10  
11 815 'food addiction' in young adults. *Addictive Behaviors Reports* 2015;2:41–8.  
12  
13 816 <http://dx.doi.org/10.1016/j.abrep.2015.05.007>  
14  
15 817 10. Burrows T, Hides L, Brown R, et al. Differences in Dietary Preferences, Personality  
16  
17 818 and Mental Health in Australian Adults with and without Food Addiction. *Nutrients*. 2017;9  
18  
19 819 (3):E285. <https://doi.org/10.3390/nu9030285>  
20  
21 820 11. Burrows T, Skinner J, McKenna R, et al. Food Addiction, Binge Eating Disorder, and  
22  
23 821 Obesity: Is There a Relationship? *Behav Sci*. 2017;7(3):pii: E54.  
24  
25 822 <https://doi.org/10.3390/bs7030054>  
26  
27 823 12. Food Addicts Anonymous [Homepage], USA, accessed 24 March 2022. Available  
28  
29 824 from: <https://faacanhelp.org/>  
30  
31 825 13. Overeaters Anonymous [Homepage], USA, accessed 24 March 2022. Available from:  
32  
33 826 <https://oa.org/>  
34  
35 827 14. McKenna RA, Rollo ME, Skinner JA, et al. Food Addiction Support: Website Content  
36  
37 828 Analysis. *JMIR Cardio*. 2018;2(1):e10. <https://doi.org/10.2196/cardio.8718>  
38  
39 829 15. Leary M, Pursey KM, Verdejo-Garcia A, et al. Current Intervention Treatments for  
40  
41 830 Food Addiction: A Systematic Review. *Behav Sci*. 2021;11(6):80.  
42  
43 831 <https://doi.org/10.3390/bs11060080>  
44  
45 832 16. Burrows T, Collins R, Rollo M, et al. The feasibility of a personality targeted  
46  
47 833 intervention for addictive overeating: FoodFix. *Appetite*. 2021;156(104974).  
48  
49 834 <https://doi.org/10.1016/j.appet.2020.104974>  
50  
51 835 17. Gearhardt AN, Corbin WR, Brownell KD. Preliminary validation of the Yale Food  
52  
53 836 Addiction Scale. *Appetite*. 2009;52(2):430-6. <https://doi.org/10.1016/j.appet.2008.12.003>  
54  
55  
56  
57  
58  
59  
60

18. Gearhardt AN, Corbin WR, Brownell KD. Development of the Yale Food Addiction Scale Version 2.0. *Psychol Addict Behav*. 2016;30(1):113-21.  
<https://doi.org/10.1037/adb0000136>
19. Carbone EA, Caroleo M, Rania M, et al. An open-label trial on the efficacy and tolerability of naltrexone/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder. *Eat Weight Disord*. 2021;26(3):779–88.  
<https://doi.org/10.1007/s40519-020-00910-x>
20. Epstein DH, Kennedy AP, Furnari M, et al. Effect of the CRF1-receptor antagonist pexacerfont on stress-induced eating and food craving. *Psychopharmacology (Berl)*. 2016;233(23-24):3921–32. <https://doi.org/10.1007/s00213-016-4424-5>
21. Sevinçer GM, Konuk N, Bozkurt S, et al. Food addiction and the outcome of bariatric surgery at 1-year: Prospective observational study. *Psychiatry Res*. 2016;244 159–64.  
<https://doi.org/10.1016/j.psychres.2016.07.022>
22. Murray SM, Tweardy S, Geliebter A, et al. A Longitudinal Preliminary Study of Addiction-Like Responses to Food and Alcohol Consumption Among Individuals Undergoing Weight Loss Surgery. *Obes Surg*. 2019;29(8):2700–3. <https://doi.org/10.1007/s11695-019-03915-3>
23. Chao AM, Wadden TA, Tronieri JS, et al. Effects of addictive-like eating behaviors on weight loss with behavioral obesity treatment. *J Behav Med*. 2019;42(2):246–55.  
<https://doi.org/10.1007/s10865-018-9958-z>
24. Hides L, Kavanagh DJ, Daglish M, et al. The Quik Fix study: a randomised controlled trial of brief interventions for young people with alcohol-related injuries and illnesses accessing emergency department and crisis support care. *BMC Emerg Med*. 2014;14(19).  
<https://doi.org/10.1186/1471-227X-14-19>
25. Hides L, Wilson H, Quinn C, et al. QuikFix: enhanced motivational interviewing interventions for youth substance use. *Adv Dual Diagn*. 2016;9(2/3):53-65.  
<https://doi.org/10.1108/ADD-03-2016-0008>

26. Leary M, Pursey KM, Verdejo-Garcia A, et al. Designing an online intervention for adults with addictive eating: A qualitative Integrated Knowledge Translation approach. *BMJ Open*. 2022;In press.
27. Hoffmann T, Glasziou P, Boutron I, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. *BMJ*. 2014;348:g1687. <https://doi.org/10.1136/bmj.g1687>
28. Chan A-W, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Annals of Internal Medicine*. 2013;158(3):200-7. <https://doi.org/10.7326/0003-4819-158-3-201302050-00583>
29. Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010;340(c332). <https://doi.org/10.1136/bmj.c332>
30. WHO ASSIST Working Group. The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. *Addiction*. 2002;97(9):1183-94. <https://doi.org/10.1046/j.1360-0443.2002.00185.x>
31. Prnjak K, Mitchison D, Griffiths S, et al. Further development of the 12-item EDE-QS: identifying a cut-off for screening purposes. *BMC Psychiatry*. 2020;20(1):146. <https://doi.org/10.1186/s12888-020-02565-5>
32. Collins CE, Boggess MM, Watson JF, et al. Reproducibility and comparative validity of a food frequency questionnaire for Australian adults. *Clin Nutr*. 2014;33(5):906-14. <https://doi.org/10.1016/j.clnu.2013.09.015>
33. Ashton L, Williams R, Wood L, et al. Comparison of Australian Recommended Food Score (ARFS) and Plasma Carotenoid Concentrations: A Validation Study in Adults. *Nutrients*. 2017;9(8):888. <http://doi.org/10.3390/nu9080888>
34. Martin A, Rief W, Klaiberg A, et al. Validity of the Brief Patient Health Questionnaire Mood Scale (PHQ-9) in the general population. *Gen Hosp Psychiatry*. 2006;28(1):71-7. <https://doi.org/10.1016/j.genhosppsych.2005.07.003>

35. Spitzer RL, Kroenke K, Williams JBW, et al. A Brief Measure for Assessing Generalized Anxiety Disorder (The GAD-7). *Arch Intern Med*. 2006;166(10):1092–7. <https://doi.org/10.1001/archinte.166.10.1092>
36. Ingram PB 4th, Clarke E, Lichtenberg JW. Confirmatory Factor Analysis of the Perceived Stress Scale-4 in a Community Sample. *Stress Health*. 2016;32(2):173–6. <https://doi.org/10.1002/smi.2592>
37. Woicik PA, Stewart SH, Pihl RO, et al. The Substance Use Risk Profile Scale: a scale measuring traits linked to reinforcement-specific substance use profiles. *Addict Behav*. 2009;34(12):1042–55. <https://doi.org/10.1016/j.addbeh.2009.07.001>
38. Fairburn C, Cooper Z, O'Connor M. Eating disorders examination (16.0D). In: Fairburn C, ed. *Cognitive behavior therapy and eating disorders*. New York: Guilford Press 2008.
39. Gormally J, Black S, Daston S, et al. The assessment of binge eating severity among obese persons. *Addict Behav*. 1982;7(1):47–55. [https://doi.org/10.1016/0306-4603\(82\)90024-7](https://doi.org/10.1016/0306-4603(82)90024-7)
40. Heriseanu AI, Hay P, Touyz S. The short inventory of grazing (SIG): development and validation of a new brief measure of a common eating behaviour with a compulsive dimension. *J Eat Disord*. 2019;7(4). <https://doi.org/10.1186/s40337-019-0234-6>
41. Vainik U, Han C, Epel ES, et al. Rapidly assessing reward-related eating: The RED-X5. *Obesity (Silver Spring)*. 2019;27(2):325–31. <https://doi.org/10.1002/oby.22374>
42. Hibbard JH, Stockard J, Mahoney ER, et al. Development of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers. *Health Serv Res*. 2004;39(4 Pt 1):1005–26. <https://doi.org/10.1111/j.1475-6773.2004.00269.x>
43. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. *Ann Med*. 2001;33(5):337–43. <https://doi.org/10.3109/07853890109002087>
44. Australian Institute of Health and Welfare (AIHW). *The Active Australia Survey: a guide and manual for implementation, analysis and reporting*. Canberra, Australia: 2003.

- 919 Accessed 22 March 2022. Available from: [https://www.aihw.gov.au/reports/physical-](https://www.aihw.gov.au/reports/physical-activity/active-australia-survey/summary)
- 920 [activity/active-australia-survey/summary](https://www.aihw.gov.au/reports/physical-activity/active-australia-survey/summary)
- 921 45. Buysse DJ, Reynolds CF 3rd, Monk TH, et al. The Pittsburgh Sleep Quality Index: a
- 922 new instrument for psychiatric practice and research. *Psychiatry Res.* 1989;28(2):193–213.
- 923 [https://doi.org/10.1016/0165-1781\(89\)90047-4](https://doi.org/10.1016/0165-1781(89)90047-4)
- 924 46. Beecham J, Knapp M. Costing psychiatric interventions. In: Thornicroft G, ed.
- 925 *Measuring Mental Health Needs* (2nd edition). London: Gaskell 2001: 200-24.
- 926 47. Australian Government Department of Health. Body mass index (BMI) and waist
- 927 measurement. Canberra, Australia: 2021. Accessed 22 March 2022. Available from:
- 928 <https://www.health.gov.au/health-topics/overweight-and-obesity/bmi-and-waist>
- 929 48. Centers for Disease Control and Prevention (CDC). Healthy Weight, Nutrition, and
- 930 Physical Activity: Assessing Your Weight. USA: 2021. Accessed 22 March 2022. Available
- 931 from: <https://www.cdc.gov/healthyweight/assessing/index.html>
- 932 49. Mond J, Hay P, Rodgers B, et al. Use of extreme weight control behaviors with and
- 933 without binge eating in a community sample: implications for the classification of bulimic-type
- 934 eating disorders. *Int J Eat Disord.* 2006;39(4):294-302. <https://doi.org/10.1002/eat.20265>
- 935 50. Mond JJ, Hay PJ, Rodgers B, et al. Correlates of the use of purging and non-purging
- 936 methods of weight control in a community sample of women. *Aust N Z J Psychiatry.*
- 937 2006;40(2):136-42. <https://doi.org/10.1080/j.1440-1614.2006.01760.x>
- 938 51. Pursey KM, Collins R, Skinner J, et al. Characteristics of individuals seeking
- 939 addictive eating treatment. *Eat Weight Disord.* 2021. [https://doi.org/10.1007/s40519-021-](https://doi.org/10.1007/s40519-021-01147-y)
- 940 [01147-y](https://doi.org/10.1007/s40519-021-01147-y)
- 941 52. Collins R, Haracz K, Leary M, et al. No control and overwhelming cravings:
- 942 Australian adults' perspectives on the experience of food addiction. *Appetite.*
- 943 2021;59(105054). <https://doi.org/10.1016/j.appet.2020.105054>
- 944 53. American Psychiatric Association. Diagnostic and statistical manual of mental
- 945 disorders. 5th ed. Arlington: VA American Psychiatric Publishing; 2013.



54. Pedram P, Wadden D, Amini P, et al. Food addiction: its prevalence and significant association with obesity in the general population. *PLOS One*. 2013;8(9):e74832. <https://doi.org/10.1371/journal.pone.0074832>
55. Lemeshow AR, Gearhardt AN, Genkinger JM, et al. Assessing the psychometric properties of two food addiction scales. *Eat Behav*. 2016;23:110–4. <https://doi.org/10.1016/j.eatbeh.2016.08.005>
56. National Health and Medical Research Council (NHMRC). Australian Guide to Healthy Eating. Canberra, Australia: 2017. Accessed 22 April 2022. Available from: <https://www.eatforhealth.gov.au/guidelines/australian-guide-healthy-eating>
57. Food Standards Australia New Zealand (FSANZ). AUSNUT 2011–13–Australian Food Composition Database. Kingston, ACT, Australia: 2014. Accessed 22 March 2022. Available from: <http://foodstandards.gov.au/>
58. National Health and Medical Research Council. Australian Dietary Guidelines. Canberra, Australia: 2013. Accessed 22 March 2022. Available from: [www.nhmrc.gov.au/guidelines-publications/n55](http://www.nhmrc.gov.au/guidelines-publications/n55)
59. Personal Social Services Research Unit (PSSRU). Canterbury, Kent, UK: University of Kent; 2022. Accessed 14 April 2022. Available from: <https://www.pssru.ac.uk/csri/client-service-receipt-inventory/>
60. Mauskopf JA, Paul JE, Grant DM, et al. The role of cost-consequence analysis in healthcare decision-making. *Pharmacoeconomics*. 1998;13(3):277-88. <https://doi.org/10.2165/00019053-199813030-00002>
61. Hunter R, James Shearer J. Cost-consequences analysis - an underused method of economic evaluation. United Kingdom: National Institute for Health Research. Accessed 14 April 2022. Available from: <https://www.rds-london.nihr.ac.uk/wpcms/wp-content/uploads/2018/09/Cost-consequences-analysis-an-underused-method.pdf>
62. Hibbard JH, Mahoney ER, Stockard J, et al. Development and testing of a short form of the patient activation measure. *Health Serv Res*. 2005;40(6 Pt 1):1918-30. <https://doi.org/10.1111/j.1475-6773.2005.00438.x>



- 974 63. Greene J, Hibbard JH. Why does patient activation matter? An examination of the  
 975 relationships between patient activation and health-related outcomes. *J Gen Intern Med*.  
 976 2012;27(5):520–6. <https://doi.org/10.1007/s11606-011-1931-2>
- 977 64. Insignia Health. Patient activation measure (PAM) 13 TM Licence Materials  
 978 copyright. LLC: Insignia Health; 2011.
- 979 65. Remmers C, Hibbard J, Mosen DM, et al. Is patient activation associated with future  
 980 health outcomes and healthcare utilization among patients with diabetes? *J Ambul Care*  
 981 *Manage*. 2009;32(4):320-7. <https://doi.org/10.1097/JAC.0b013e3181ba6e77>
- 982 66. Australian Bureau of Statistics (ABS). 2033.0.55.001 - Socio-Economic Indexes for  
 983 Areas (SEIFA). Canberra, Australia: ABS; 2016. Accessed 14 September 2021. Available  
 984 from: [www.abs.gov.au](http://www.abs.gov.au)
- 985 67. World Health Organization (WHO). Body mass index – BMI. WHO Regional Office for  
 986 Europe; c2018. Accessed 14 September 2021. Available from:  
 987 <http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi>
- 988
- 989 68. Harris PA, Taylor R, Minor BL, et al. REDCap Consortium. The REDCap consortium:  
 990 Building an international community of software platform partners. *J Biomed Inform*.  
 991 2019;95(103208). <https://doi.org/10.1016/j.jbi.2019.103208>
- 992 69. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap) – A  
 993 metadata-driven methodology and workflow process for providing translational research  
 994 informatics support. *J Biomed Inform*. 2009;42(2):377-81.  
 995 <https://doi.org/10.1016/j.jbi.2008.08.010>


996

## 997 **References for Table 1**

- 998 1. WHO ASSIST Working Group. The Alcohol, Smoking and Substance Involvement  
 999 Screening Test (ASSIST): development, reliability and feasibility. *Addiction*.  
 1000 2002;97(9):1183-94. <https://doi.org/10.1046/j.1360-0443.2002.00185.x>

- 1001 2. Prnjak K, Mitchison D, Griffiths S, et al. Further development of the 12-item EDE-QS:  
1002 identifying a cut-off for screening purposes. *BMC Psychiatry*. 2020;20(1):146.  
1003 <https://doi.org/10.1186/s12888-020-02565-5>
- 1004 3. Gearhardt AN, Corbin WR, Brownell KD. Development of the Yale Food Addiction  
1005 Scale Version 2.0. *Psychol Addict Behav*. 2016;30(1):113-21.  
1006 <https://doi.org/10.1037/adb0000136>
- 1007 4. Collins CE, Boggess MM, Watson JF, et al. Reproducibility and comparative validity  
1008 of a food frequency questionnaire for Australian adults. *Clin Nutr*. 2014;33(5):906-14.  
1009 <https://doi.org/10.1016/j.clnu.2013.09.015>
- 1010 5. Ashton L, Williams R, Wood L, et al. Comparison of Australian Recommended Food  
1011 Score (ARFS) and Plasma Carotenoid Concentrations: A Validation Study in Adults.  
1012 *Nutrients*. 2017;9(8):888. <http://doi.org/10.3390/nu9080888>
- 1013 6. Martin A, Rief W, Klaiberg A, et al. Validity of the Brief Patient Health Questionnaire  
1014 Mood Scale (PHQ-9) in the general population. *Gen Hosp Psychiatry*. 2006;28(1):71-7.  
1015 <https://doi.org/10.1016/j.genhosppsych.2005.07.003>
- 1016 7. Spitzer RL, Kroenke K, Williams JBW, et al. A Brief Measure for Assessing  
1017 Generalized Anxiety Disorder (The GAD-7). *Arch Intern Med*. 2006;166(10):1092-7  
1018 <https://doi.org/10.1001/archinte.166.10.1092>
- 1019 8. Ingram PB 4th, Clarke E, Lichtenberg JW. Confirmatory Factor Analysis of the  
1020 Perceived Stress Scale-4 in a Community Sample. *Stress Health*. 2016;32(2):173-6.  
1021 <https://doi.org/10.1002/smi.2592>
- 1022 9. Woicik PA, Stewart SH, Pihl RO, et al. The Substance Use Risk Profile Scale: a  
1023 scale measuring traits linked to reinforcement-specific substance use profiles. *Addict Behav*.  
1024 2009;34(12):1042-55. <https://doi.org/10.1016/j.addbeh.2009.07.001>
- 1025 10. Fairburn C, Cooper Z, O'Connor M. Eating disorders examination (16.0D). In:  
1026 Fairburn C, ed. Cognitive behavior therapy and eating disorders. New York: Guilford Press  
1027 2008.

- 1028 11. Gormally J, Black S, Daston S, et al. The assessment of binge eating severity among  
1029 obese persons. *Addict Behav.* 1982;7(1):47-55. [https://doi.org/10.1016/0306-](https://doi.org/10.1016/0306-4603(82)90024-7)  
1030 [4603\(82\)90024-7](https://doi.org/10.1016/0306-4603(82)90024-7)
- 1031 12. Heriseanu AI, Hay P, Touyz S. The short inventory of grazing (SIG): development  
1032 and validation of a new brief measure of a common eating behaviour with a compulsive  
1033 dimension. *J Eat Disord.* 2019;7(4). <https://doi.org/10.1186/s40337-019-0234-6>
- 1034 13. Vainik U, Han C, Epel ES, et al. Rapidly assessing reward-related eating: The RED-  
1035 X5. *Obesity (Silver Spring).* 2019;27(2):325–31. <https://doi.org/10.1002/oby.22374>
- 1036 14. Hibbard JH, Stockard J, Mahoney ER, et al. Development of the Patient Activation  
1037 Measure (PAM): conceptualizing and measuring activation in patients and consumers.  
1038 *Health Serv Res.* 2004;39(4 Pt 1):1005–26. [https://doi.org/10.1111/j.1475-](https://doi.org/10.1111/j.1475-6773.2004.00269.x)  
1039 [6773.2004.00269.x](https://doi.org/10.1111/j.1475-6773.2004.00269.x)
- 1040 15. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group.  
1041 *Ann Med.* 2001;33(5):337-43. <https://doi.org/10.3109/07853890109002087>
- 1042 16. Australian Institute of Health and Welfare (AIHW). The Active Australia Survey: a  
1043 guide and manual for implementation, analysis and reporting. Canberra, Australia: 2003.  
1044 Accessed 22 March 2022. Available from: [https://www.aihw.gov.au/reports/physical-](https://www.aihw.gov.au/reports/physical-activity/active-australia-survey/summary)  
1045 [activity/active-australia-survey/summary](https://www.aihw.gov.au/reports/physical-activity/active-australia-survey/summary)
- 1046 17. Buysse DJ, Reynolds CF 3rd, Monk TH, et al. The Pittsburgh Sleep Quality Index: a  
1047 new instrument for psychiatric practice and research. *Psychiatry Res.* 1989;28(2):193–213.  
1048 [https://doi.org/10.1016/0165-1781\(89\)90047-4](https://doi.org/10.1016/0165-1781(89)90047-4)
- 1049 18. Beecham J, Knapp M. Costing psychiatric interventions. In: Thornicroft G, ed.  
1050 *Measuring Mental Health Needs* (2nd edition). London: Gaskell 2001: 200-24.





SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	2
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3, 6
	2b	All items from the World Health Organization Trial Registration Data Set	NA
Protocol version	3	Date and version identifier	-
Funding	4	Sources and types of financial, material, and other support	27
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1, 31
	5b	Name and contact information for the trial sponsor	1
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	7
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	NA

## Introduction

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4, 5
	6b	Explanation for choice of comparators	6
Objectives	7	Specific objectives or hypotheses	5
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	6, 7

## Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	7
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	9
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	10 - 18
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	7
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	17, 18
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	NA
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	19 - 22
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	8 (Table 1)

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including	25
2			clinical and statistical assumptions supporting any sample size calculations	
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	7
5				
6	<b>Methods: Assignment of interventions (for controlled trials)</b>			
7				
8	Allocation:			
9				
10	Sequence	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any	12
11	generation		factors for stratification. To reduce predictability of a random sequence, details of any planned restriction	
12			(eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants	
13			or assign interventions	
14				
15				
16	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered,	12
17	concealment		opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	
18	mechanism			
19				
20	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to	12
21			interventions	
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome	12, 13
25			assessors, data analysts), and how	
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's	NA
28			allocated intervention during the trial	
29				
30				
31	<b>Methods: Data collection, management, and analysis</b>			
32				
33	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related	17, 19-24, 27
34	methods		processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of	
35			study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known.	
36			Reference to where data collection forms can be found, if not in the protocol	
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be	12
40			collected for participants who discontinue or deviate from intervention protocols	
41				
42				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	26, 27
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	25, 26
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	25, 26
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	26
11				
12				
13				
14	<b>Methods: Monitoring</b>			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	NA
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	NA
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	27
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	27
29				
30				
31				
32	<b>Ethics and dissemination</b>			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	6, 29
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	NA
38				
39				
40				
41				
42				



1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	7, 10, 11
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	NA
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	26, 27
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	31
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	26, 27
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	NA
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	29
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	NA
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	NA
27				
28				
29	<b>Appendices</b>			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	NA
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	NA
35				
36				

37 \*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.  
38 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons  
39 “[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)” license.  
40  
41  
42

# BMJ Open

## Examining the efficacy of a telehealth intervention targeting addictive eating in Australian adults (the TRACE program): a randomised controlled trial protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-064151.R1
Article Type:	Protocol
Date Submitted by the Author:	09-Mar-2023
Complete List of Authors:	Skinner, Janelle; The University of Newcastle, School of Health Whatnall, Megan; The University of Newcastle, School of Health Leary, Mark; The University of Newcastle, Collins, Rebecca; The University of Newcastle, School of Health Pursey, Kirrilly; The University of Newcastle, School of Health Verdejo-García, Antonio; Monash University Hay, Phillipa ; Western Sydney University Baker, Amanda; The University of Newcastle, Hides, Leanne; University of Queensland, Paxton, Susan; La Trobe University Wood, Lisa; The University of Newcastle, Respiratory Medicine Colyvas, Kim; The University of Newcastle, School of Mathematical and Physical Sciences Collins, Clare; The University of Newcastle Burrows, Tracy; The University of Newcastle,
<b>Primary Subject Heading</b>:	Addiction
Secondary Subject Heading:	Mental health
Keywords:	NUTRITION & DIETETICS, PUBLIC HEALTH, Eating disorders < PSYCHIATRY

SCHOLARONE™  
Manuscripts

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

**Article type:** Protocol

**Title:** Examining the efficacy of a telehealth intervention targeting addictive eating in Australian adults (the TRACE program): a randomised controlled trial protocol

**Authors:** Janelle A Skinner<sup>1,2</sup>, Megan Whatnall<sup>1,2</sup>, Mark Leary<sup>1,2</sup>, Rebecca A Collins<sup>1,2</sup>, Kirrilly M Pursey<sup>1,2</sup>, Antonio Verdejo-Garcia<sup>3</sup>, Phillipa J Hay<sup>4</sup>, Amanda L Baker<sup>2,5</sup>, Leanne Hides<sup>6</sup>, Susan J Paxton<sup>7</sup>, Lisa G Wood<sup>2,8</sup>, Kim Colyvas<sup>1</sup>, Clare E Collins<sup>1,2</sup>, Tracy L Burrows<sup>1,2\*</sup>

**Institutions:**

<sup>1</sup>School of Health Sciences, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan NSW 2308, Australia

<sup>2</sup>Hunter Medical Research Institute, University of Newcastle, New Lambton Heights, NSW, 2305, Australia

<sup>3</sup>School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Clayton, VIC 3800, Australia

<sup>4</sup>Translational Health Research Institute, Western Sydney University, Campbelltown, NSW, 2751, Australia

<sup>5</sup>School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW 2308, Australia

<sup>6</sup>School of Psychology, University of Queensland, St Lucia, QLD, 4072, Australia

<sup>7</sup>Department of Psychology and Counselling, Latrobe University, Melbourne, VIC, 3086

<sup>8</sup>School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan NSW 2308, Australia

**\*Corresponding Author:** Professor Tracy Burrows. Mailing address: School of Health Sciences, University Drive, University of Newcastle, Callaghan, NSW, Australia, 2308. Ph: +610249215514. Email: [tracy.burrows@newcastle.edu.au](mailto:tracy.burrows@newcastle.edu.au)

**Word count:** 7910

**Key words:** addictive eating, food addiction, Yale Food Addiction Scale

## ARTICLE SUMMARY

**Title:** Examining the efficacy of a telehealth intervention targeting addictive eating in Australian adults (the TRACE program): a randomised controlled trial protocol

### Abstract

**Introduction** Approximately 15-20% of the adult population endorse symptoms of addictive eating and there are currently limited options for management. Motivational interviewing-based interventions, containing personalised coping skills training for addictive disorders, have been found to be effective for behaviour change. This project builds upon foundations of a feasibility study, and co-design process involving consumers. The primary aim of this three-arm randomised controlled trial is to examine the efficacy of a telehealth intervention targeting addictive eating symptoms in Australian adults compared to passive intervention and control (no intervention) groups. **Methods and analysis** Participants, aged 18-85 years, endorsing  $\geq 3$  symptoms on the Yale Food Addiction Scale 2.0, with BMI  $>18.5\text{kg/m}^2$  will be recruited. Addictive eating symptoms are assessed at baseline (pre-intervention), 3 months (post-intervention) and 6 months. Other outcomes will include dietary intake and quality, depression, anxiety, stress, quality of life, physical activity, and sleep hygiene. Using a multicomponent clinician-led approach, the active intervention consists of five telehealth sessions (15-45min each) delivered by a dietitian over 3 months. The intervention uses personalised feedback, skill-building exercises, reflective activities, and goal setting. Participants are provided with a workbook and web site access. The passive intervention group receive the intervention via a self-guided approach with access to the workbook and website (no telehealth). The control group receive personalised written dietary feedback at baseline and participants advised to follow their usual dietary pattern for six months. The control group will be offered the passive intervention after 6-months. The primary endpoint is YFAS symptom scores at 3 months. A cost consequence analysis will determine intervention costs alongside mean change outcomes. **Ethics and dissemination** The Human Research Ethics Committee of The

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

University of Newcastle Australia provided approval: H-2021-0100. Findings will be disseminated via publication in peer-reviewed journals, conference presentations, community presentations and student theses. Trial registration: Australia New Zealand Clinical Trial Registry (ANZCTR) ACTRN12621001079831.

**Strengths and Limitations of this study**

- Targeting addictive risk factors through personalised tailoring of coping strategies and use of motivational interviewing for management of symptoms of addictive eating
- Co-design approach taken, with both consumers and multidisciplinary health professionals, to inform program development
- Detailed assessment of eating behaviours, mental health and lifestyle factors with personalised feedback provided to participants during the telehealth intervention
- Fidelity outcomes will be assessed, and cost consequence analysis conducted regarding implementation
- Limitations include participants being excluded with severe mental illnesses or complex health conditions

## INTRODUCTION

Research in addictive eating has increased rapidly in recent years. Addictive eating, theorised as being on the severe end of a spectrum of overeating,[1] is a phenotype of eating behaviour marked by the chronic excessive and dysregulated consumption of food.[2, 3] Addictive eating or 'food addiction' is accepted by consumers[4] and health practitioners,[5, 6] though the construct remains contentious in the scientific community with ongoing debate regarding terms and definitions.[7] Specifically, whether the construct should be described as a behavioural disorder or as a substance-related addiction, whereby certain foods or components in foods are capable of activating an addictive-like process in susceptible individuals.[8] Addictive eating, not categorised as a distinct disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM)[9] or the International Classification of Disease[10] systems, is most commonly assessed using the Yale Food Addiction Scale (YFAS).[11] The YFAS adapts the DSM criteria for 'substance-related and addictive disorders' to specific foods.[9] Developed in 2009[2] and revised in 2016 (YFAS 2.0)[11] according to the DSM-5 criteria, this psychometric tool assesses the presence of 11 symptoms of addictive eating. Symptoms include craving, loss of control, tolerance and withdrawal associated with eating behaviours, the repeated unsuccessful attempts to reduce the consumption of specific foods and maintenance of these behaviours despite adverse physical/emotional/social/interpersonal consequences.[11] The YFAS 2.0 provides two scoring options: a continuous symptom score, reflecting the number of endorsed addiction-like symptoms; and a dichotomous diagnosis of 'food addiction'. [11] Using this self-report survey, approximately 15-20% of the adult population endorse  $\geq$  three YFAS symptoms for addictive eating. [12-14]

Higher prevalence rates of addictive eating have been reported in individuals with higher Body Mass Indexes (BMI) classified as overweight or obese compared to lower BMIs.[13, 15] Although addictive eating is not exclusive to those with higher weight status.[16] It has been suggested that addictive eating in those with underweight may be related to dietary restriction practices (e.g., consuming more than intended that breaches self-imposed dietary rules,

intense craving resulting from extreme dieting practices).[16, 17] Irrespective of weight status, results from recent research indicate that individuals with addictive eating have significantly lower diet quality and higher intakes of highly processed foods.[14, 18, 19] Poor diet is a significant contributor to early death globally[20] and addressing addictive eating may contribute to the prevention or management of adverse health outcomes.

Addictive eating is a complex issue often overlapping with other health conditions, and likely transdiagnostic.[21, 22] There is evidence that addictive eating commonly co-occurs with mental health co-morbidities, particularly depression and anxiety, as well as overlapping with eating disorders, specifically binge eating disorder (BED).[12, 19] Approximately 50% of individuals with BED meet criteria for 'food addiction' according to the YFAS.[12] The present state of the literature demonstrates there is considerable overlap between BED and addictive eating.[23, 24] Commonalities include the loss of control over consumption, continued overuse despite negative consequences, and repeated failed attempts to reduce consumption.[24] However, differences have been observed. In BED large amounts of food are consumed over discrete periods of time, and caloric intake can vary markedly from day to day depending on the number of binge episodes experienced.[25, 26] Whereas, addictive eating behaviours in some can occur over the entirety of a day.[27] Anecdotally, individuals with addictive eating often report the quantity of food consumed remains consistent from day to day. Further, individuals with addictive eating report preferences for specific foods, typically those high in added fat, and/or refined carbohydrates,[18] and not on the consumption of all foods in general as may be presented in BED. At this time, it is unclear if addictive eating will emerge as a severe subtype of BED or be regarded as a distinct form of an addiction disorder. This distinction will be important to allow for targeted treatment and prevention strategies in susceptible individuals.

Current treatment options for addictive eating largely stem from online self-help groups such as Food Addicts Anonymous[28] and Overeaters Anonymous[29] which have 10 000+

members and have been in existence for many years, demonstrating a need for services.[30]

A 2021 systematic review[31] found there is limited evidence supporting implementation of feasible and effective dietary interventions run by clinicians, for the management of addictive eating.[32] Of the nine studies reviewed, five interventional studies were found to improve symptoms of addictive eating[31] as indicated by improvements in YFAS[2, 11] outcomes. These interventions included medication (combination of naltrexone and bupropion,[33] as well as pexacerfont[34]), bariatric surgery[35, 36] and lifestyle modification.[37] Since publication of this review, a further four intervention studies (a behavioural weight loss program, [38] a brief telephone-based cognitive behavioural therapy intervention,[39] a low carbohydrate dietary program,[40] and a probiotic supplement placebo-controlled trial[41]) have been trialled. All four studies reported an improvement in YFAS addictive eating symptomatology immediately following the intervention, but two studies[38, 39] noted this improvement was not sustained over the longer-term. To date, most studies have been limited in sample size and therefore not been powered to detect a change in addictive eating symptoms.[31] Given the limited number of treatment options for addictive eating, there is a clear need for services, and development and testing of interventions. It has been suggested that interventions based on substance use addiction models may be effective at facilitating changes in eating behaviour.[42]

Motivational interviewing (MI) based interventions for addictive disorders, such as alcohol use, that contain coping skills training for traits associated with risk of addictive behaviour, have found to be effective.[43, 44] The traits that have been linked to addictive eating include impulsivity, sensation seeking, and anxiety and depression proneness.[45-49] Findings suggest that individuals with addictive eating may be highly aware of emotions, but lack the skills needed to cope with negative affect.[50] Using personalised coping skills for traits associated with personality and the risk of addictive behaviour in combination with MI, a communication approach used to identify and resolve ambivalence between desired behaviors and actual behaviors to increase motivation,[51] may be effective to facilitate



behaviour change in individuals with addictive eating. This project builds on a program of work that included an initial feasibility study for the management of addictive eating in adults (Australia New Zealand Clinical Trial Registry ACTRN12619001540101).[32] Results from the initial study indicated that the program was feasible in the target population. Feedback, received from program participants and facilitators, identified a need for a greater number of program sessions and improved strategies for increasing retention. As a result, the program was further refined with consumers using an integrated knowledge translation (iKT) framework.[52] This co-design phase included consumers with lived experience, as well as health professionals from a range of disciplines to ensure the culmination of multidisciplinary evidence-based strategies were included. This was unique as previous reports omit this co-design step or are siloed in their approach.[52] The co-design process used a series of interviews and workshops to gain input into the program overview, aims, content and materials. Subsequent changes were made to the program content, language used, and materials were created or refined to improve acceptability. The resultant behaviour change intervention, the TRACE (Targeted Research on Addictive and Compulsive Eating) program, is a complex intervention and previously described using the Medical Research Council TiDier (Template for Intervention Description and Replication) checklist for complex interventions.[53] (See [52] for the TiDier checklist of the intervention).

To the authors knowledge, the TRACE program is the first MI-based telehealth intervention involving personalised coping skills training for the management of addictive eating in adults. Telehealth has been shown to be a strategy to increase reach, with virtual sessions being comparable to face-to-face programs, and to increase access to services without compromising effectiveness.[54] Telehealth will allow participants from anywhere in Australia to participate from home, and will reduce the demands on time and cost of travel.[54] Additionally, telehealth may overcome client-centred barriers by allowing a safe atmosphere for some participants to better engage and discuss more sensitive topics that they would not normally raise.[55]

200

201 The aim of the current study is to determine the efficacy of a telehealth intervention (active

202 intervention) to reduce symptoms of addictive eating in adults, relative to passive intervention

203 and control (no intervention) groups. It is hypothesised that both the active and passive

204 intervention groups will achieve a reduction in addictive eating symptoms relative to the control

205 group. Potential moderators (e.g., participant sociodemographics) and mediators (e.g.,

206 physical activity, diet, and sleep) of intervention efficacy will also be evaluated.

## 208 METHODS

### 209 Study trial design

210 The TRACE program is a randomised controlled trial with three parallel arms (n=50 per group).

211 The primary outcome is the change in addictive eating symptoms at the 3-month post-baseline

212 assessment (primary time point). The study also includes a 6-month post-baseline follow-up

213 assessment. This project was approved by The University of Newcastle Human Research

214 Ethics Committee (H-2021-0100) and prospectively registered with the Australian New

215 Zealand Clinical Trials Registry (ACTRN12621001079831). The study protocol was

216 developed in accordance with the Standard Protocol Items: Recommendations for

217 Interventional Trials (SPIRIT) guidelines.[56] The design, conduct and reporting of the studies

218 will adhere to the CONSORT (Consolidated Standards of Reporting Trials) guidelines.[57] All

219 participants will provide informed electronic consent (see Supplementary Material 1 for a copy

220 of the consent form) to participate and can withdraw at any time for any reason. The funding

221 bodies had no role in the design, conduct or reporting of the study.

### 223 Setting

224 The active intervention will be delivered via telehealth sessions, conducted in Australia, and

225 supported by a program workbook, and website containing materials relevant to the

226 intervention.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Recruitment**

Participants will be recruited using a range of strategies including media releases, advertising via local and national newspapers, and social-media releases. Informed by our iKT process, a range of recruitment videos (tailored for gender) were also created in addition to written material which will be released via Twitter and Facebook. A non-probability sampling technique (voluntary response sampling)[58] will be used, and recruitment will continue until the desired number of participants is achieved. Recruitment commenced in August 2021 and was completed in April 2022. Recruitment materials will direct individuals to the study information sheet and eligibility survey. The eligibility survey takes approximately 15 mins to complete (Table 1). Online informed consent will be obtained prior to completing the eligibility survey.

**Eligibility**

To be eligible for inclusion in the study individuals must:

1. Be aged between 18 years and 85 years
2. Endorse  $\geq 3$  symptoms on the Yale Food Addiction Scale 2.0 (i.e. exhibiting mild to severe addictive eating)[11]
3. Have a self-reported weight and height consistent with a body mass index (BMI)  $\geq 18.5$  kg/m<sup>2</sup>
4. Be competent in the English language
5. Live in Australia
6. Have access to the internet

Individuals will be excluded from participating in the study if they:

1. Are pregnant or lactating
2. Report having a severe mental illness (including schizophrenia or bipolar disorder) or have a health condition that necessitates taking medications which affect dietary intake or weight status



3. Report purging behaviours as identified by the Eating Disorder Examination Questionnaire – Short form (EDE-QS)[59]

*Methodological considerations for eligibility criteria:* The eligibility screener excludes individuals with a BMI below 18.5kg/m<sup>2</sup>. This measure was put in place to reduce the likelihood of recruiting participants with at-risk restrictive eating practices that may be influencing a relatively low weight status. The value of <18.5 kg/m<sup>2</sup> was chosen as this is below the current healthy weight range in national guidelines for Australians[60] and The Centre of Disease Control and Prevention (CDC) in the USA.[61] Additionally, the eligibility screener includes the Eating Disorder Examination Questionnaire Short Form (EDE-QS).[59] This 12-item validated tool is commonly used to identify potential eating disorders. Based on the research team consensus, individuals who have compensatory behaviours such as bingeing/purging (specifically asked in question 7 on the EDE-QS), who may be at risk of an eating disorder and are medically compromised, will be deemed not eligible for the current study. Purging is related to higher levels of appearance dissatisfaction, anxiety and depressive symptoms and self-concept instability.[62, 63] As per the ethics protocol, participants endorsing any response to this question, indicating these compensatory behaviours will be excluded from the study. The tools for eating disorders and psychological health[59, 64–68] used in the study have been widely used in research in the areas of eating disorders, dietary interventions, substance use and mental health and are considered standard tools for their specific measures. Study information as well as at completion of surveys participants are provided with contact information if they experience or further assistance with health behaviours.

### Study procedure

Prospective participants will complete the eligibility survey. This will include demographic questions (e.g., sex, postcode, marital status, level of education, employment status); the Yale Food Addiction Scale 2.0[11] to confirm endorsement of ≥ 3 addictive eating symptoms; the EDE-QS<sup>31</sup> to confirm the absence of purging behaviours. While not necessary to determine

283 **Table 1.** Schedule of measurements

Variable	Instrument	Enrolment	Timepoint post allocation		
Primary study		Eligibility Screening	t <sub>1</sub> Baseline	t <sub>2</sub> 3- months	t <sub>3</sub> 6- months
Sample characteristics					
Demographics	Age, sex, postcode, mental health status	✓			
Socioeconomic factors	Education, income, marital status, employment status, occupation and living/accommodation status	✓			
Anthropometrics	Self-report height and weight	✓		✓	✓
Smoking and substance use	Alcohol, Smoking and Substance Involvement Screening Test - Version 3.0[64]		✓	✓	✓
Purging behaviours	Eating Disorder Examination Questionnaire Short form (EDE-QS)[59]	✓			
Primary Outcomes					
Addictive eating symptoms and severity	Yale Food Addiction Scale 2.0[11]	✓		✓	✓
Secondary Outcomes					
Dietary intake and quality	Australian Eating Survey[69, 70]		✓	✓	✓
Depression, anxiety and stress	Patient Health Questionnaire-8,[68] Generalized Anxiety Disorder 7,[65] Perceived Stress Scale[66]	✓		✓	✓
Mediators/moderators					
Trait/s associated with risk of addictive behaviour	Substance Use Risk Profile Scale[71]		✓		
Eating Behaviours	Eating Disorder Examination Questionnaire 6.0,[67] Binge Eating Scale,[72] Short Inventory of Grazing,[73] Reward-Based Eating Drive Scale[74]		✓	✓	✓
Participant activation level	Patient Activation Measure 13[75]	✓		✓	✓
Usage and engagement with program website	Google Analytics (Google LLC) to record number of site visits, visit durations, number of page views, and links accessed/resources downloaded				
Usage and engagement with Facebook group	Number of participants to join group; number of views, likes and comments per post manually recorded				
Other outcomes					
Quality of life	EQ-5D-5L[76]		✓	✓	✓
Physical activity level	Active Australia Survey[77]		✓	✓	✓
Sleep hygiene behaviours	Pittsburgh Sleep Quality Index[78]		✓	✓	✓
Health care utilisation	Consumer Services Receipt Inventory[79]		✓	✓	✓
‘Control’ and ‘Compulsion’ associated with addictive eating	Qualitative analysis of a segment of the first telehealth session		✓		

284 Eligibility Screening = assessment of inclusion/exclusion criteria, Baseline = pre-intervention, 3-months =  
 285 immediate post-intervention, 6-months = 3-months post-intervention.

eligibility, the Patient Health Questionnaire-8 (PHQ-8),[68] Generalized Anxiety Disorder-7 (GAD-7),[65] Perceived Stress Scale-4,[66] Patient Activation Measure 13,[75] and two questions relating to previous treatments sought for addictive eating, will also be completed by potential participants. These questions have been specifically added to extend our previously reported research[80] regarding the types of individuals recruited into interventions for addictive eating.

Participants deemed eligible will proceed to the online consent form (Figure 1. Overview of study schedule). Participants will be given a two-week period to consider participation. After this time, a member of the research team will contact any individuals via email who have not completed the consent form to determine their interest in participating. Following this, no other contact will be made. Participants who provide electronic written consent will complete the baseline assessment surveys measuring dietary intake and eating habits, traits associated with personality and risk of addictive behaviour, quality of life and healthcare service utilisation (Table 1. Schedule of measurements). The surveys take approximately 40 minutes to complete. On completion of baseline surveys, participants will be randomly allocated to one of three groups (Group 1: active intervention; Group 2: passive intervention; or Group 3: control; see *Intervention* description) and informed of their group allocation via email.

Figure 1. Overview of the study schedule

Following randomisation (see *Randomisation and Blinding*), a member of the research team will contact participants in Group 1 via telephone or email to arrange an appointment time for their initial telehealth session. Groups 1 and 2 will be emailed a copy of the program workbook (printable and fillable PDF versions); a hard copy is available for participants on request; and be provided with password protected access to the program website at this time. Telehealth sessions 2 – 5, for participants allocated to the active intervention group (Group 1), will be arranged during their first telehealth session.

1  
2  
3 317  
4  
5 318 Participants from all three groups will receive results from the eligibility and/or baseline surveys  
6  
7 319 by the research team via email. On survey completion, Groups 1 and 2 will receive feedback  
8  
9 320 on dominant trait/s that may be associated with increased risk for addictive behaviours (e.g.,  
10  
11 321 anxiety-proneness, impulsivity-proneness); symptoms of addictive eating; dietary, caffeine  
12  
13 322 and alcohol intake; sleep hygiene and physical activity levels. At this timepoint, Group 3 will  
14  
15 323 only receive feedback on dietary intake via email. At 6-months post study commencement,  
16  
17 324 Group 3 will be provided with feedback on trait/s associated with personality and risk of  
18  
19 325 addictive behaviour; symptoms of addictive eating; sleep hygiene and physical activity levels,  
20  
21 326 along with access to the workbook and website (the passive intervention that Group 2 received  
22  
23 327 at baseline). To ensure consistency across participants, email templates and standardised  
24  
25 328 reports will be used by the research team. Group 2 will be guided with written instructions in  
26  
27 329 their workbook on how to utilise their survey results to allow personalised goal setting  
28  
29 330 regarding their dietary intake and eating patterns.  
30  
31  
32 331  
33  
34 332 The primary and secondary outcomes will be assessed at 3-months (primary endpoint,  
35  
36 333 immediate post-active intervention period) and 6-months (follow-up) where participants will  
37  
38 334 complete post-program surveys (Table 1. Schedule of measurements). Participants will be  
39  
40 335 sent reminder emails to complete their surveys. They will be reminded a maximum of three  
41  
42 336 times at each time point. If no contact is received after such time, no further contact will be  
43  
44 337 made. Participants will be remunerated with a gift voucher to the value of AUD20 at the  
45  
46 338 completion of baseline, 3-month and 6-month surveys, corresponding to a maximum of AUD60  
47  
48 339 per participant over the course of the study.  
49  
50  
51  
52 340

53  
54 341 **Randomisation and Blinding**

55  
56 342 Following completion of baseline assessments, participants will be stratified into 4 groups by  
57  
58 343 sex and mental health status (presence or absence, based on either depression, scale PHQ-  
59  
60 344 8 scores  $\geq 15$  or below 15, or anxiety scale GAD-7 scores  $\geq 11$  or below 11). Participants within



each of these four groups will be randomised to one of the three study groups in equal ratios using permuted block randomisation, with block sizes of six. Randomisation will promote group balance on these variables shown to be important in past cross-sectional research (for example, [12, 13, 15, 80]). The randomisation sequence will be generated by an independent statistician and implemented by a designated study co-ordinator. The allocation list will be stored in a password protected computer file and accessed only by the study co-ordinator.

Due to the telehealth nature of the active intervention, blinding of participants and dietitians to intervention group allocation in this study will not be possible. However, several strategies will be employed to reduce the risk of bias. First, participants will only be provided with partial information on the study hypotheses. Second, all communication between participants and research staff during the period of intervention (i.e., scheduling concerns, questions regarding the intervention) will be done directly between participants and the 'study co-ordinator' or their respective 'telehealth clinician'. Lastly, statistical analyses will be conducted by researchers who are blind to group allocation prior to analysis.

## Intervention

The intervention study arms are:

Group 1. Active intervention: targeting change in addictive eating behaviours using a multicomponent clinician led approach (telehealth sessions, program workbook and program website)

Group 2. Passive intervention: targeting change in addictive eating behaviours using a multicomponent self-guided approach (program workbook and program website)

Group 3. Control: dietary feedback, via paper-based report, provided at baseline and participants follow their usual dietary pattern for six months.

The comparator groups were chosen to provide a passive delivery option of the program which would be consistent with a self-guided Cognitive Behaviour Therapy approach (Group 2), and



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

373 a control group consistent with a standard version of dietary feedback (Group 3). The control  
374 group is not a wait list control, however participants in this group will be offered access to the  
375 passive intervention (i.e., program workbook and program website) after the completion of the  
376 6-month assessment.

**TRACE Active Intervention (Group 1):** Participants will receive five standardised one-on-  
one telehealth/phone sessions with an Accredited Practising Dietitian, with training in  
behaviour change and eating disorders, over a 3-month period (i.e., weeks 1, 2, 4, 8 and 12).  
Additionally, dietitians leading the intervention delivery will have extensive experience in  
private practice work and working with clients including those with disordered eating and those  
with mental health conditions. Sessions will range from 15-45 mins. Telehealth sessions will  
be provided via the VSee platform ([www.vsee.com](http://www.vsee.com)). The active intervention uses personalised  
feedback, skill-building exercises, and goal setting to help individuals reduce their symptoms  
of addictive eating and improve their dietary intake, and relationship with food (see Table 2 for  
*Overview of intervention sessions*). The intervention is personalised based on an individual's  
dominant trait/s associated with personality and risk of addictive behaviour (i.e., the traits:  
depression proneness, anxiety proneness, sensation proneness and/or impulsivity proneness;  
measured via The Substance Use Risk Profile Scale<sup>37</sup> which the individual scores the most  
highly for) and addresses a range of factors that influence behaviour, both internal and  
external. Further, dominant trait/s associated with personality and risk of addictive behaviour  
are mapped to specific coping skill strategies which are in turn incorporated into the goal  
setting process. As part of session 1, the first 15 mins of the consultation will be audio recorded  
to enable qualitative analysis of responses to standardised questions regarding two elements  
of 'control' and 'compulsion' around the participant's food intake. These two themes were  
previously identified, through thematic analysis of the feasibility study data,[81] as having an  
influential relationship with addictive eating behaviours. On completion of the five telehealth  
sessions, participants will be invited to join a closed Facebook group from 3-months post

commencement of the intervention until the 6-month outcome survey measures are conducted. Joining the Facebook group is voluntary.

**Table 2.** Overview of intervention sessions

Session	Session aims
<b>1) Personality (Week 1: 45 mins)</b>	<ul style="list-style-type: none"> <li>• Introduce the intervention</li> <li>• Determine participant's main concerns with their food intake</li> <li>• Provide feedback on baseline scores of addictive eating</li> <li>• Discuss what this means when attempting and preparing to make changes</li> <li>• Provide feedback on traits associated with personality and risk of addictive behaviour</li> <li>• Discuss how personality traits may relate to food intake and addictive eating, and what this means for the individual</li> <li>• Discuss coping strategies based on personality traits and complete 'Urge Surfing' activity</li> <li>• Introduce 'Distraction List'</li> <li>• Set homework task: choose and practice 2 coping strategy exercises</li> <li>• Provide session summary</li> </ul>
<b>2) Food (Week 2: 45 min)</b>	<ul style="list-style-type: none"> <li>• Review session 1</li> <li>• Check in for episodes of overeating</li> <li>• Discuss progress with homework task - coping strategies</li> <li>• Provide feedback on dietary intake</li> <li>• Discuss core vs non-core food intake (Optional: discuss alcohol intake)</li> <li>• Develop 3 nutrition goals using <i>SMARTER Goal Checklist</i> <ol style="list-style-type: none"> <li>1) Positive – increase core foods</li> <li>2) Reduction – decrease non-core foods</li> <li>3) 'Eating awareness' – using strategies to delay or halt overeating</li> </ol> </li> <li>• Discuss enablers/barriers when making changes to eating habits</li> <li>• Discuss 'No Money No Time' website (<a href="http://www.nomoneynotime.com.au">www.nomoneynotime.com.au</a>)</li> <li>• Discuss 'Practical Strategies to Achieve Goals'</li> <li>• Set homework task: complete 'Triggers for Overeating Checklist'</li> </ul>

Session	Session aims
<b>3) Skills (Week 4: 30 min)</b>	<ul style="list-style-type: none"> <li>• Provide session summary</li> <li>• Review session 2</li> <li>• Assess progress with SMARTER goals</li> <li>• Check in for episodes of overeating</li> <li>• Discuss homework task - '<i>Triggers for Overeating</i>'</li> <li>• Explore strategies to overcome triggers, building on previous coping strategies and '<i>Practical Strategies to Achieve Goals</i>'</li> <li>• Discuss and determine a '<i>food line</i>' to identify when eating is no longer enjoyable or not tasting food</li> <li>• Discuss strategies to stay below the '<i>food line</i>'</li> <li>• Set homework task: complete '<i>Mood Monitor</i>' worksheet</li> <li>• Provide session summary</li> </ul>
<b>4) Confidence (Week 8: 30 min)</b>	<ul style="list-style-type: none"> <li>• Review session 3</li> <li>• Discuss progress with plan to stay below '<i>food line</i>' and for episodes of overeating</li> <li>• Explore enablers/barriers to achieving goals</li> <li>• Discuss homework task - '<i>Mood Monitor</i>', and explore emotions that participant has difficulty coping with</li> <li>• Discuss seeing emotions differently</li> <li>• Explore coping strategies for difficult emotions</li> <li>• Discuss importance of sleep, physical activity, and responsible intake of alcohol for emotional health</li> <li>• Discuss implementing coping skills plan to achieve SMARTER goals (i.e. consolidate information from sessions 1 – 4)</li> <li>• Set homework task: practice implementation of coping skills plan to achieve goals</li> <li>• Provide session summary</li> </ul>
<b>5) Moving forward (Week 12: 20 mins)</b>	<ul style="list-style-type: none"> <li>• Review session 4</li> <li>• Check in/briefly problem solve and encourage participant to continue with goals and strategies</li> <li>• Discuss topics from previous sessions (participant led)</li> <li>• Reassess confidence to achieve goals</li> <li>• Provide final <i>Addictive Eating Action Plan</i></li> <li>• Discuss how support group on Facebook works and encourage sign up</li> </ul>

1  
2  
3 405 *Participant Workbook and Program Website:* Participants will have access to a participant  
4  
5 406 workbook and password protected access to a study specific website, both built for the study  
6  
7 407 to support the materials discussed in the intervention sessions. To further facilitate the co-  
8  
9 408 design process, the workbook and website content was piloted with end users (n=2) with lived  
10  
11 409 experience of addictive eating, who participated in the iKT interviews/workshops. The end  
12  
13 410 users reported the workbook and website to be highly usable in terms of the content, and the  
14  
15 411 language used throughout as appropriate with only minor modifications made. Additionally,  
16  
17 412 the piloting process allowed the estimated time to complete each workbook module to be  
18  
19 413 calculated.  
20  
21  
22 414

23  
24 415 *Program Workbook:* The workbook consists of five modules: 1) Personality; 2) Food; 3) Skills;  
25  
26 416 4) Confidence; and 5) Moving forward. The content of the five modules mirrors that of the  
27  
28 417 telehealth sessions. The workbook also contains reflective activities/worksheets, discussed  
29  
30 418 during the telehealth sessions, for the participants to complete. These elements were deemed  
31  
32 419 important during the iKT process. The amount of time spent completing activities in the  
33  
34 420 workbook each week, between telehealth sessions, will take approximately 30 - 60 minutes.  
35  
36 421 However, the time to complete each module may vary from person to person, and participants  
37  
38 422 are advised to work through the workbook at a pace that is right for them.  
39  
40  
41 423

42  
43 424 *Program Website:* The website includes the following pages: 1) Home/Landing page: brief  
44  
45 425 information about the program and login; 2) Dashboard: navigation page to access each of  
46  
47 426 the program's module pages; 3) Module pages: each of the five modules within the  
48  
49 427 intervention has a separate page on the website. This includes additional resources to  
50  
51 428 complement the telehealth sessions and workbook; and 4) About us: brief information about  
52  
53 429 the research/clinician team behind the program, including contact information (email). The  
54  
55 430 website will be available for a period of 12 months from study commencement. All data  
56  
57 431 captured from the website will be encrypted and stored securely on a server.  
58  
59  
60

1  
2  
3 432 *Program Facebook Group:* This is a voluntary part of the study which aims to further support  
4  
5 433 participants with behaviour change. The Facebook forum is set up as a private Facebook  
6  
7 434 group. Participants can use their standard Facebook login, or alternatively, create a new login  
8  
9 435 (a pseudo account) that does not identify them if they wish to remain anonymous. Participants  
10  
11 436 will be prompted with information related to the intervention for the 3-month duration in the  
12  
13 437 form of short posts, blogs, and polls. The Facebook group will allow participants to engage  
14  
15 438 with other participants from the program, as well as serve as a communication method to  
16  
17 439 remind participants about assessments for the study.  
18  
19  
20 440  
21  
22 441 The Facebook forum has the following restrictions: 1) Membership will be by invitation only;  
23  
24 442 2) The group will not appear in search results or the participants Facebook profile; and 3) Only  
25  
26 443 group members will be able to see the group information and group posts. Participants will be  
27  
28 444 advised of the appropriate use of language and etiquette for using the social media/discussion  
29  
30 445 forum in the workbook and reminded at the final telehealth session. The Facebook group will  
31  
32 446 be moderated by a member of the research team via the TRACE research Facebook account.  
33  
34  
35 447  
36  
37 448 *Intervention fidelity:* A detailed clinician manual will be used by the dietitian for all telehealth  
38  
39 449 sessions to maintain treatment fidelity. Dietitians administering the intervention will be trained  
40  
41 450 by the principal investigator prior to study implementation. Dietitians will also follow each  
42  
43 451 session as outlined in the manual and keep a dietitian log of participants telehealth sessions.  
44  
45 452 Further, five participants allocated to Group 1, with their consent, will have all their telehealth  
46  
47 453 sessions audio recorded. The dietitian log and audio recordings will be reviewed by an  
48  
49 454 independent researcher to ensure the intervention was delivered as intended. Regular  
50  
51 455 supervisory meetings will be conducted with the dietitians and program coordinator led by the  
52  
53 456 principal investigator. Participant adherence to the intervention will be assessed by a session  
54  
55 457 attendance checklist completed by a member of the research team. Dietitians administering  
56  
57 458 the telehealth sessions will monitor completion of homework tasks and workbook activities at  
58  
59 459 the start of telehealth sessions 2 to 5. Assistance will be provided by the dietitian at this time  
60

if participants experienced any difficulties completing the homework tasks/activities. Additionally, to assist with adherence, on completion of each telehealth session the dietitian will email a personalised 'Addictive Eating Action Plan', completed on a standardised template, to the participant.

**TRACE Passive Intervention (Group 2):** Participants will receive the intervention via self-guided approach, with access to the five-module workbook and website (as described above), but without the telehealth consults. The content of the workbook modules mirrors the content of the five telehealth sessions. In addition to the written materials provided, the workbook contains spaces for reflective activities, documenting goals and monitoring progress. Participants will be asked, on receipt of the workbook, to complete the workbook within a 3-month period. The proportion of the workbook completed by participants in the passive intervention arm will not be monitored. Following the 3-month self-guided learning period, participants will be invited to join the closed Facebook group as described above.

**Control (Group 3):** Participants will receive personalised dietary feedback on baseline surveys, provided by an automated report, generated from the Australian Eating Survey. This is consistent with standard dietary feedback from a dietitian. Participants in the control group will be offered access to the participant workbook and study website after the completion of the 6-month assessment.

### **Patient and public involvement**

Consumer (i.e., individuals with lived experience of addictive eating who participated in the pilot study) input was received on the pilot version of the intervention (FoodFix process evaluation[32]) that directly guided the enhancement of the TRACE telehealth sessions. The TRACE program workbook and website for the current study was developed following the pilot study. A sample of consumer representatives (individuals with lived experience of addictive eating and healthcare experts including clinicians and managers), independent of those

1  
2  
3 488 involved in the pilot study, were involved in the review of the program and program  
4  
5 489 materials.[52]  
6  
7 490

9 491 Consumer representatives were interviewed to:

- 11 492 • Identify what individuals with addictive eating need and want more accurately
- 13 493 • Gather information about what works well and what needs improving, first-hand from  
15 494 consumers who may use them
- 17 495 • Openly consider different or opposing views about aspects of the research project
- 19 496 • Test resources during development and refine resources making sure they will work  
21 497 well in practice
- 23 498 • Detect any unforeseen consequences of a particular decision or direction that has  
25 499 been made regarding the project
- 27 500 • Gain support of consumers to implement changes to the research project

30 501  
31  
32 502 The opinion of consumers has been considered to create a program that:

- 33 503 • Aligns to the needs of the people it is trying to help i.e., individuals with addictive eating
- 35 504 • Is beneficial in terms of delivering meaningful outcomes for individuals with addictive  
37 505 eating
- 39 506 • Is conducted in a way that is sensitive to peoples' needs

41 507  
42  
43 508 Consumers were not involved in the design of the current study, the selection of outcome  
45 509 measurements, research questions or the recruitment of additional participants. However,  
47 510 consumers were involved in the overall concepts employed in the study and may be called  
49 511 upon at the dissemination stage. For example, to review plain language summaries of the  
51 512 results, provide advice on ways to communicate/translate our findings, or present our findings  
53 513 to the community. Participants of the current study can request a plain English summary of  
55 514 the study outcomes on its completion.

## Outcome measures

All outcome measures are completed at baseline, 3 months (immediate post-active intervention period) and 6 months (follow-up) via online surveys. The same survey tools will be used at each time point. Participants will receive assessment reminders by email. (Reference to where data collection forms can be found is included in Supplementary Material 2)

## Primary outcomes

**Addictive eating symptoms and severity:** The Yale Food Addiction Scale (YFAS 2.0)[11] will be used to assess the change in addictive eating symptomatology and severity. The YFAS 2.0 is a validated self-report 35-item questionnaire. The YFAS 2.0 asks participants to think of specific foods they have had difficulty controlling the consumption of within the past 3 months (e.g., ice cream, chocolate, chips, hamburgers). The YFAS 2.0 provides an addictive eating symptom score ranging from zero to 11. Additionally, two items assess clinically significant impairment or distress from eating. A ‘food addiction diagnosis’ can be given when  $\geq 2$  symptoms are endorsed, and clinically significant impairment or distress is present. However, for the purpose of this study a ‘food addiction diagnosis’ will not be given, and severity of addictive eating will be classified in accordance with YFAS scoring instructions as follows: “mild” = 3 symptoms, “moderate” = 4-5 symptoms or “severe”  $\geq 6$  symptoms. The YFAS 2.0 has been found to be a robust and psychometrically sound measure of addictive eating symptomatology in non-clinical[2, 82] and clinical populations with good test/retest validity.[83] Preliminary evidence[31, 32] suggests that YFAS scores are sensitive to change and are decreased after intervention.

## Secondary outcomes

**Dietary intake and quality:** Changes in dietary intake and quality will be measured using the Australian Eating Survey (AES).[69] The following dietary outcomes will be measured: (1) core foods and non-core foods percentage contribution to total energy intake; (2) average daily



energy intake, proportion of total energy intake contributed by macronutrients, micronutrient intakes; and (3) overall diet quality. The AES is a validated 120-item semi-quantitative Food Frequency Questionnaire that assesses usual food and nutrient intakes over the previous 3-6 months. The AES includes a comprehensive list of foods, including drinks, milk and dairy foods, breads and cereals, sweet and savoury snacks, main meals, other foods, vegetables and fruit. Frequency response options for each food, or food type, range from 'never' to '≥7 times per day'. The AES has been assessed for comparative validity relative to weighed food records and for fruit and vegetable intakes using plasma carotenoids.[69, 70] Standard portion sizes for adult men and women have been determined for each AES item in the survey, using data from the most recent Australian National Nutrition Survey. The food and beverage weight per serving, used in the calculation of food group servings (as serves per day) is consistent with sizes specified in the Australian Guide to Healthy Eating.[69, 70, 84] Nutrient intakes from the AES Food Frequency Questionnaire were computed using data in the AUSNUT 2011–13 database.[85] The AES also provides an Australian Recommended Food Score (ARFS), derived from a subset of 70 AES questions, as a measure of diet quality that reflects the overall healthiness and nutritional quality of an individual's usual eating pattern.[70] The ARFS is based on the frequency of consumption of core foods, recommended in the Australian Dietary Guidelines,[86] with foods awarded one point for a consumption frequency of ≥once per week. The total score is calculated by summing the points for each item and scores can range from zero to 73, with higher scores awarded for greater dietary variety.[70]

563

**Depression, anxiety and stress:** Changes in symptom scores for depression, anxiety and stress will be measured using the Patient Health Questionnaire (PHQ-8),[68] the Generalized Anxiety Disorder 7 (GAD-7)[65] and the Perceived Stress Scale (PSS-4),[66] respectively. The PHQ-8 is a validated self-report 8-item tool that asks the individual to rate the severity of depressive symptoms over the past two weeks from 0 ('not at all') to 3 ('nearly every day'). Total scores for the 8 items range from 0 to 24, and severity will be determined using the following cut-offs: 0-4 = minimal, 5-9 = mild, 10-14 = moderate, 15-19 = moderately severe,

and 20-24 = severe.[68] The GAD-7 is a validated self-report 7-item tool that asks the individual to rate the severity of symptoms over the past two weeks from 0 ('not at all sure') to 3 ('nearly every day'). GAD-7 total scores range from 0 to 21, and severity is determined using the following cut-offs: 0-5 = mild, 6-10 = moderate, 11-15 = moderately severe, and 15-21 = severe.[65] The PSS-4 is a validated self-report 4-item tool that assesses the degree to which a person perceives life as stressful.[66] The questions have been designed to assess how unpredictable, uncontrollable, and overloaded a person feels their life to be. Frequency over the previous month is rated on a five-point Likert scale ranging from 'Never' to 'Very often'. PSS-4 total scores range from 0 to 16, and higher scores indicate greater stress.[66] Currently, there is no established cut-off for the PSS-4 score to indicate adverse levels of stress.

#### **Other outcomes**

A selection of other outcomes was chosen based on co-occurring health conditions (see Table 1 for schedule of measurements).

**Quality of Life:** Changes in subjective quality of life will be measured using the EQ-5D-5L.[76] The EQ5D-5L is a validated self-report 5-item tool to assess health-related quality of life. A descriptive system comprising five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems (labelled 1–3). Participants are asked to indicate their health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results into a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes respondent's health state. The EQ-5D-5 L will be analysed to produce an index score between 0 (state of death) and 1 (perfect health).

**Physical activity level:** Changes in physical activity level will be measured using the Active Australia Survey (AAS).[77] The AAS is a validated self-report tool containing eight core

1  
2  
3 599 questions to assess participation (hours/mins per week) in moderate and vigorous intensity  
4  
5 600 physical activity and walking for recreation, over the previous week.  
6  
7 601  
8  
9 602 **Sleep hygiene behaviours:** Changes in sleep hygiene behaviours will be measured using  
10  
11 603 the Pittsburgh Sleep Quality Index (PSQI).[78] The PSQI is a validated self-report survey with  
12  
13 604 19 self-rated items and 5 items rated by the bed partner or roommate (if applicable). The tool  
14  
15 605 assesses seven components of sleep to provide one global score. Components measured  
16  
17 606 include 1) Subjective sleep quality, 2) Sleep latency, 3) Sleep duration, 4) Habitual sleep, 5)  
18  
19 607 Sleep disturbances, 6) Use of sleeping medication, and 7) Daytime dysfunction. The overall  
20  
21 608 global score of sleep quality will be calculated, and the subcomponents reported.  
22  
23  
24 609  
25  
26 610 **Health care utilisation:** For the purpose of conducting a cost analysis the Consumer Services  
27  
28 611 Receipt Inventory (CSRI)[79] will be completed by participants at each time point. The CSRI  
29  
30 612 is an adaptable tool that ensures the format, language, scope and content is compatible with  
31  
32 613 the research aims, context, participants' likely circumstances, and the quantity and precision  
33  
34 614 of information required.[87] Health care utilisation is captured through self-report and includes  
35  
36 615 information on the number of appointments and type of health care services used in the  
37  
38 616 preceding 3 months.  
39  
40  
41 617  
42  
43 618 **Cost analysis:** A cost-consequence analysis will be conducted including calculating the cost  
44  
45 619 of each intervention (i.e., active, passive and control) and reporting intervention costs  
46  
47 620 alongside mean change outcomes. Intervention costs will be recorded in terms of cost of  
48  
49 621 intervention development, intervention delivery and the operating costs of the RCT. Outcomes  
50  
51 622 to be reported as part of the cost analysis will include mean change in addictive eating  
52  
53 623 symptom scores assessed using the YFAS (i.e. the primary outcome), as well as mean change  
54  
55 624 in the number of health care appointments in the past 3-months assessed using the CSRI,  
56  
57 625 and mean change in Quality Adjusted Life Years (QALYs) assessed using the EQ-5D-5L. This  
58  
59  
60

approach was selected to provide a comprehensive and transparent overview of intervention costs, given the lack of cost analysis data in this area of research.[88, 89]

628

### 629 **Mediators/Moderators**

630 The following potential mediators and moderators of intervention efficacy will be examined:

631

632 **Trait/s associated with personality and risk of addictive behaviour:** Participant's will  
633 complete the Substance Use Risk Profile Scale (SURPS)[71] at baseline to determine their  
634 dominant trait/s. The SURPS is a validated self-report 23-item survey that assess four traits  
635 associated with increased risk for addictive behaviours (Impulsivity proneness, Sensation  
636 proneness, Depression proneness, and Anxiety proneness).

637

638 **Eating behaviours:** Eating behaviours that have been shown to have overlap with addictive  
639 eating will be measured. This includes eating disorders, binge eating, grazing behaviours and  
640 reward driven eating. Eating disorders will be measured using the Eating Disorder  
641 Examination Questionnaire 6.0 (EDEQ-6.0)[67] The EDEQ-6.0 is a validated self-report 28-  
642 item questionnaire that assesses the occurrence and frequencies of key eating disorder  
643 behaviours with cognitive subscales related to eating disorders (restraint, eating concern,  
644 shape concern, and weight concern) and behavioural symptoms related to these concerns  
645 (e.g. frequency of binge eating, vomiting, use of laxatives or diuretics, and overexercise).  
646 Subscale and global scores reflect the severity of eating disorder psychopathology. Binge  
647 eating will be measured using the Binge Eating Scale (BES).[72] The BES is a validated self-  
648 report 16-item questionnaire to assess the presence of certain binge eating behaviours, over  
649 the past 28 days, which may be indicative of an eating disorder. Each item contains 3-4  
650 statements about behaviours, thoughts, and emotional states. Grazing behaviours will be  
651 measured using the Short Inventory of Grazing (SIG).[73] The SIG is a validated self-report 2-  
652 item measure to assess 1) the presence and frequency of grazing in general, and 2) the  
653 presence and frequency of grazing accompanied by a sense of loss of control. Reward driven

1  
2  
3 654 eating will be measured using the Reward-Based Eating Drive Scale (REDX-5).[74] The  
4  
5 655 REDX-5 is a validated self-report 5-item questionnaire, in 5-point Likert scale format from 1  
6  
7 656 (strongly disagree) to 5 (strongly agree), that assesses reward-driven eating (loss of control  
8  
9 657 over eating, lack of satiety, and preoccupation with food).  
10

11 658  
12  
13  
14 659 **Participant Activation Level:** Participant’s underlying knowledge, skills and confidence in  
15  
16 660 managing their addictive eating behaviours and overall health will be measured using the  
17  
18 661 Patient Activation Measure (PAM-13).[90] The PAM-13 is a validated self-report 13-item scale  
19  
20 662 that draws on concepts such as health locus of control, self-efficacy in managing health  
21  
22 663 behaviours and readiness to change health behaviours.[75, 91] Higher PAM-13 scores  
23  
24 664 indicate that individuals have higher levels of activation, and understand their role in the self-  
25  
26 665 management process and feel capable of fulfilling that role.[92] Research has demonstrated  
27  
28 666 that a single point change in PAM score is meaningful.[93]  
29

30 667  
31  
32  
33 668 **Engagement and use of the program website and Facebook group:** Interaction with the  
34  
35 669 website will be objectively tracked throughout the study (baseline to 6 months i.e., timepoints  
36  
37 670 1 to 3) using Google Analytics (Google LLC). Measures of engagement and usage will include  
38  
39 671 number of website visits, website visit duration, number of page views and links  
40  
41 672 accessed/resources downloaded.  
42

43 673  
44  
45 674 Interaction with the Facebook group will be measured throughout the post-intervention period  
46  
47 675 (3 to 6 months from baseline i.e., timepoints 2 to 3). Measures of engagement and usage will  
48  
49 676 include number of participants to join the Facebook group, and number of views, likes and  
50  
51 677 comments per post.  
52

53 678  
54  
55  
56 679 **Study sample characteristics**  
57  
58 680 Sociodemographic data will be collected by online questionnaire at baseline. Participants will  
59  
60 681 provide information on their age, sex, marital status, postal code, years of education,

employment status and current living situation. Index of Relative Socio-Economic Disadvantage (IRSD) score,[94] based on the Australian Bureau of Statistics census data and reflecting a proxy index of socioeconomic status, will be determined by postal code of residence. Current smoking and substance use will be measured using the Alcohol, Smoking and Substance Involvement Screening Test - Version 3.0.[64] Additionally, previous treatment sought for overeating from health professionals or products used to treat overeating will be collected.

Anthropometric data (self-reported height and weight) will be collected by online questionnaire at baseline. BMI will be calculated using standardised techniques and categorised according to the World Health Organization adult cut-off points.[95]

### **Sample size**

The sample size for the study was calculated based on data from the feasibility study,[32] given the absence of other intervention studies. Through guidance with statisticians, a large effect size was chosen and needed to enable the possibility of a clinically meaningful result. A clinically meaningful difference in symptoms of addictive eating was selected as a decrease of 2 symptoms, given this would correspond to a change in severity classification on the YFAS 2.0 tool. To detect a mean 2-unit difference ( $SD = 2.2$ ) in the YFAS symptoms between the active intervention group and the passive intervention group or control group and using a standardised effect size of  $d=0.91$ , a sample size of 32 individuals per group (total sample size  $n=96$ ) is required to detect this change with a power of 0.90 and a type 1 error rate set at 0.025 to account for multiple testing. However, allowing for a 30% dropout rate from the pilot, a sample size of 46 individuals per group (total sample size  $n=138$ ) would be required. Therefore, a total sample size of 150 individuals, with 50 per group, was chosen to remain conservative.

1  
2  
3 710 **Statistical analysis plan**  
4

5 711 Data analysis will be conducted by a researcher blinded to the intervention conditions.  
6  
7 712 Descriptive statistics of sample characteristics will be presented. For the primary YFAS  
8  
9 713 outcome a Linear Mixed Model (LMM) will be based on a model with main effects for group  
10  
11 714 (active intervention, passive intervention, control) and time (treated as categorical at levels  
12  
13 715 baseline, 3 and 6 months), and the group-by-time interaction. An unstructured residual  
14  
15 716 covariance structure will be used to allow for correlation between the repeated measurements  
16  
17 717 for a subject. The primary outcome effect will be reported as the difference between means at  
18  
19 718 baseline and 3 months, with a 95% CI for the difference. Mental health condition and BMI will  
20  
21 719 be examined for possible moderating effects on the effect size, and if so adjustment for them  
22  
23 720 will be carried out. Secondary descriptive analysis will be carried out to identify whether  
24  
25 721 specific symptoms were predominantly associated with reductions in YFAS score.  
26  
27  
28 722  
29

30 723 A secondary outcome will be a categorical variable, clinically significant change from baseline  
31  
32 724 to 3 months, where significant requires a reduction of 2 or more symptoms in the YFAS. This  
33  
34 725 will be analysed using logistic regression with group being the only factor. Additional  
35  
36 726 secondary outcomes will include dietary outcomes (average daily energy intake, proportion of  
37  
38 727 total energy intake contributed by core foods and non-core foods intakes, macronutrients  
39  
40 728 intakes, micronutrient intakes; and overall diet quality) and mental health status (depression,  
41  
42 729 anxiety and stress scores). These will also be analysed using LMMs as per the approach  
43  
44 730 above. All available data will be used with no imputation of missing values at 3 and 6 months,  
45  
46 731 however baseline scores will be kept. The participants will be analysed according to their  
47  
48 732 allocated randomisation group consistent with an intention-to-treat analysis. Statistical  
49  
50 733 significance will be set at 0.05.  
51  
52  
53 734  
54

55  
56 735 **Data management and monitoring**  
57

58 736 Online survey data will be managed using REDCap electronic data capture tools[96, 97]  
59  
60 737 hosted at the University of Newcastle. REDCap (Research Electronic Data Capture) is a



secure, web-based software platform designed to support data capture for research studies, providing 1) an intuitive interface for validated data capture; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless data downloads to common statistical packages; and 4) procedures for data integration and interoperability with external sources.

All data captured from the study website will be encrypted and stored securely on the server. All other data collected will be entered into a password protected central database which is hosted on secure university-based servers, which comply with robust security standards for clinical data and are subject to daily backups and regular offsite backups. Only authorised members of the research team will have access to the database. Research staff handling study data are trained in procedures for handling sensitive information, accurate data entry, surveillance and intervention-specific data storage and data archive. Facilitators of the telehealth sessions are responsible for the electronic storage of study forms on the central database. All completed forms will be checked for completeness and accuracy, first by data collectors and later by a member of the research team responsible for data management. Throughout the study period (at 25% and 50% of required participants) approximately 5% of records will be randomly selected for data quality checks of accuracy and completeness by an independent reviewer.

A Data Safety Monitoring Board will not be established for this study as all elements of the intervention have been previously explored and used in interventions. To monitor for potential risks, the study co-ordinator managing the day-to-day conduct of the trial, and facilitators of the telehealth sessions, will report weekly to the Chief Investigator. Oversight concerning the overall conduct of the trial will be provided by our multi-disciplinary research team. This will include regular meetings to review protocol adherence, participant retention rates and safety reports. For the entire study period, any adverse events, of any kind, that might be related to either the trial intervention or trial procedures will be logged in an adverse event log and



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

766 reported to the Human Research Ethics Committee by the Chief Investigator. To maintain the  
767 welfare of participants, with their consent, relevant survey results from the GAD-7[65] and  
768 PHQ-8[68] will be sent to the participant's nominated General Practitioner/ health professional  
769 if they score in the severe category for either anxiety (GAD-7 scores  $\geq 16$ ) or depression (PHQ-  
770 8 scores  $\geq 20$ ) if participants consent to this disclosure.

771  
**772 Study sponsorship and organisation**

773 The sponsor of the trial is the University of Newcastle, and funding was provided by the  
774 National Health and Medical Research Council (NHMRC). The trial will be conducted and  
775 evaluated independent of the study sponsor and funder. The study is coordinated  
776 independently of the study sponsor and funder, by researchers at the University of Newcastle,  
777 Australia with the study overseen by the trial management committee comprising the chief  
778 investigators.

779  
**780 Ethics and dissemination**

781 The trial will be undertaken in compliance with the Declaration of Helsinki and approval to  
782 conduct the study was received from the University of Newcastle Human Research Ethics  
783 Committee (H-2021-0100). This trial adheres to the SPIRIT guidelines for randomised trials  
784 protocols[56] and the results will be reported in accordance with CONSORT guidelines  
785 (TIDieR checklist and guide[53]). Protocol modifications will be registered with the Ethics  
786 Committee and trial register. All participants will provide electronic consent to participate prior  
787 to completing the eligibility and baseline surveys. Results of the study will be disseminated via  
788 peer-reviewed publications and presentations at national and international conferences and  
789 will also form part of student dissertations. Data from the TRACE study may be made available  
790 in the future for collaborative research questions. Such requests must be authorised by the  
791 principal investigators and the appropriate Human Research Ethics Committees.

792  
793

## 794 **Limitations**

795 Limitations of the study include the level of experience required of the dietitians administering  
796 the telehealth sessions, which may impact the scalability of the intervention. However,  
797 dietitians are highly trained professionals in behaviour change and extra care was taken given  
798 the uniqueness of the intervention. The fidelity outcomes assessed as part of the trial will  
799 provide important information regarding future implementation. Additional limitations include  
800 the exclusion of individuals with severe mental illnesses or complex health conditions. The  
801 current intervention is not designed for complex co-morbidities. It is envisaged that for these  
802 individuals a more complex care model is required where the TRACE program could be  
803 implemented alongside other approaches or treatments.

804  
805 The TRACE program is designed to raise awareness, and support behaviour change, of  
806 addictive eating. If successful, our study will provide essential evidence regarding the efficacy  
807 of behavioural and dietary improvement in the management of addictive eating, thus allowing  
808 for the implementation of management strategies for addictive eating into community and  
809 clinical healthcare services. Further, if both the active and passive interventions are found to  
810 be effective it will provide evidence of different levels of care that could be utilised within these  
811 services.

812  
813 **Author Contributions:** TLB conceptualised the study, and TLB, JAS, MW, ML, RC, KMP,  
814 AVG, PJH, ALB, LH, SJP, LGW, KC and CEC contributed to the study protocol. TLB, JAS,  
815 MW, ML, RC, KMP, AVG, PJH, ALB, LH, SJP, and CEC contributed to the intervention  
816 development and design, intervention resources and assessment methodology. JAS wrote  
817 the initial manuscript draft. TLB, JAS, MW, ML, RC, KMP, AVG, PJH, ALB, LH, SJP, LGW,  
818 KC and CEC contributed to the writing of the final manuscript and/or provided critical  
819 comments during revisions. All authors approved the final version prior to submission. TLB,  
820 JAS, MW, ML and RC will be responsible for recruitment, data collection and intervention  
821 delivery.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Competing interests:** None declared.

**Funding:** This work was supported by the National Health and Medical Research Council (NHMRC) grant number [G1801414].

**References**

1. Davis C. From Passive Overeating to “Food Addiction”: A Spectrum of Compulsion and Severity. *International Scholarly Research Notices Obesity*. 2013; 435027: 1-20. <http://dx.doi.org/10.1155/2013/435027>.
2. Gearhardt AN, Corbin WR, and Brownell KD. Preliminary validation of the Yale Food Addiction Scale. *Appetite*. 2009; 52(2): 430-436. <https://doi.org/10.1016/j.appet.2008.12.003>.
3. Gearhardt AN, Davis C, Kuschner R, et al. The Addiction Potential of Hyperpalatable Foods. *Current Drug Abuse Reviews*. 2011; 4: 140-145. doi: 10.2174/1874473711104030140.
4. Ruddock HK, Christiansen P, Halford JCG, et al. The development and validation of the Addiction-like Eating Behaviour Scale. *International Journal of Obesity (London)*. 2017; 41(11): 1710-1717. <https://doi.org/10.1038/ijo.2017.158>.
5. Burrows T, Verdejo-Garcia A, Carter A, et al. Health Professionals’ and Health Professional Trainees’ Views on Addictive Eating Behaviours: A Cross-Sectional Survey. *Nutrients*. 2020; 12(9): E2860. <https://doi.org/10.3390/nu12092860>.
6. Whatnall M, Skinner J, Verdejo-Garcia A, et al. Symptoms of Addictive Eating: What Do Different Health Professions Think? *Behavioral Sciences*. 2021; 11(5): 60. <https://doi.org/10.3390/bs11050060>.
7. Gearhardt AN and Hebebrand J. The concept of “food addiction” helps inform the understanding of overeating and obesity: Debate Consensus. *The American Journal of Clinical Nutrition*. 2021; 113(2): 274–276. <https://doi.org/10.1093/ajcn/nqaa345>.

- 849 8. Hauck C, Cook B, and Ellrott T. Food addiction, eating addiction and eating  
850 disorders. *The Proceedings of the Nutrition Society*. 2020; 79(1): 103–112.  
851 <https://doi.org/10.1017/S0029665119001162>.
- 852 9. American Psychiatric Association, *Diagnostic and statistical manual of mental*  
853 *disorders*. 5th ed. 2013, Arlington: VA American Psychiatric Publishing.
- 854 10. World Health Organization. International statistical classification of diseases and  
855 related health problems (11th ed.). 2019. <https://icd.who.int/>.
- 856 11. Gearhardt AN, Corbin WR, and Brownell KD. Development of the Yale Food  
857 Addiction Scale Version 2.0. *Psychology of Addictive Behaviors*. 2016; 30(1): 113-  
858 121. <https://doi.org/10.1037/adb0000136>.
- 859 12. Burrows T, Kay-Lambkin F, Pursey K, et al. Food addiction and associations with  
860 mental health symptoms: a systematic review with meta-analysis. *Journal of Human*  
861 *Nutrition and Dietetics*. 2018; 31(4): 544-572. <https://doi.org/10.1111/jhn.12532>.
- 862 13. Pursey K, Stanwell P, Gearhardt A, et al. The prevalence of food addiction as  
863 assessed by the Yale Food Addiction Scale: a systematic review. *Nutrients* 2014;  
864 6(10): 4552–4590. <https://doi.org/10.3390/nu6104552>.
- 865 14. Pursey KM, Collins CE, Stanwell P, et al. Foods and dietary profiles associated with  
866 'food addiction' in young adults. *Addictive Behaviors Reports* 2015; 2: 41–48.  
867 <http://dx.doi.org/10.1016/j.abrep.2015.05.007>.
- 868 15. Skinner J, Jebeile H, and Burrows T. Food addiction and mental health in  
869 adolescents: a systematic review. *The Lancet. Child and adolescent health*. . 2021;  
870 5(10): 751-766. [https://doi.org/10.1016/S2352-4642\(21\)00126-7](https://doi.org/10.1016/S2352-4642(21)00126-7).
- 871 16. Sanchez I, Lucas I, Munguía I, et al. Food addiction in anorexia nervosa: Implications  
872 for the understanding of crossover diagnosis. *European Eating Disorders Review*.  
873 2022; 30(3): 278–288. <https://doi.org/10.1002/erv.2897>.
- 874 17. Schulte EM and Gearhardt AN. Associations of Food Addiction in a Sample  
875 Recruited to Be Nationally Representative of the United States. *European Eating*  
876 *Disorders Review*. 2018; 26(2): 112–119. <https://doi.org/10.1002/erv.2575>.

- 1  
2  
3 877 18. Pursey KM, Skinner J, Leary M, et al. The Relationship between Addictive Eating and  
4  
5 878 Dietary Intake: A Systematic Review. *Nutrients*. 2021(1): 164.  
6  
7 879 <https://doi.org/10.3390/nu14010164>.  
8  
9 880 19. Burrows T, Hides L, Brown R, et al. Differences in Dietary Preferences, Personality  
10  
11 881 and Mental Health in Australian Adults with and without Food Addiction. *Nutrients*  
12  
13 882 2017; 9 (3): E285. <https://doi.org/10.3390/nu9030285>.  
14  
15 883 20. GBD 2017 Diet Collaborators. Health effects of dietary risks in 195 countries, 1990-  
16  
17 884 2017: a systematic analysis for the Global Burden of Disease Study 2017. . *Lancet*  
18  
19 885 (*London, England*),. 2019; 393(10184): 1958–1972. <https://doi.org/10.1016/S0140->  
20  
21 886 6736(19)30041-8.  
22  
23 887 21. Treasure J, Leslie M, Chami R, et al. Are trans diagnostic models of eating disorders  
24  
25 888 fit for purpose? A consideration of the evidence for food addiction. *European Eating*  
26  
27 889 *Disorder Review*. 2018; 26(2): 83-91. doi: 10.1002/erv.2578.  
28  
29 890 22. Wiss DA and Brewerton TD. Incorporating food addiction into disordered eating: the  
30  
31 891 disordered eating food addiction nutrition guide (DEFANG). *Eating and Weight*  
32  
33 892 *Disorders*. 2017; 22(1): 49-59. doi: 10.1007/s40519-016-0344-y.  
34  
35 893 23. Burrows T, Skinner J, McKenna R, et al. Food Addiction, Binge Eating Disorder, and  
36  
37 894 Obesity: Is There a Relationship? *Behavioral Sciences*. 2017; 7(3): pii: E54.  
38  
39 895 <https://doi.org/10.3390/bs7030054>.  
40  
41 896 24. Bao K, French EN, Schleyer B, et al. Food addiction is associated with greater  
42  
43 897 objective binge eating and eating disorder psychopathology, and higher body mass  
44  
45 898 index in youth, a meta-analysis. *Psychiatry Research Communications*. 2022; 2(3):  
46  
47 899 100067. <https://doi.org/10.1016/j.psychom.2022.100067>.  
48  
49 900 25. Saunders R. "Grazing": A High-Risk Behavior. *Obesity Surgery*. 2004; 14(1): 98-102.  
50  
51 901 doi: 10.1381/096089204772787374.  
52  
53 902 26. Dingemans A, Bruna M, and van Furth E. Binge eating disorder: a review.  
54  
55 903 *International Journal of Obesity*. 2002; 26: 299–307.  
56  
57 904 <https://doi.org/10.1038/sj.ijo.0801949>.  
58  
59  
60

- 905 27. Gearhardt A, White M, and Potenza M. Binge Eating Disorder and Food Addiction.  
906 *Current drug abuse reviews*. 2011; 4(3): 210-207. doi:  
907 10.2174/1874473711104030201.
- 908 28. Food Addicts Anonymous. [Homepage]. [cited 2022 24 March]; Available from:  
909 <https://faacanhelp.org/>.
- 910 29. Overeaters Anonymous. [Homepage]. [cited 2022 24 March]; Available from:  
911 <https://oa.org/>.
- 912 30. McKenna RA, Rollo ME, Skinner JA, et al. Food Addiction Support: Website Content  
913 Analysis. *JMIR Cardio*. 2018; 2(1): e10. <https://doi.org/10.2196/cardio.8718>.
- 914 31. Leary M, Pursey KM, Verdejo-Garcia A, et al. Current Intervention Treatments for  
915 Food Addiction: A Systematic Review. *Behavioral Sciences* 2021; 11(6): 80.  
916 <https://doi.org/10.3390/bs11060080>.
- 917 32. Burrows T, Collins R, Rollo M, et al. The feasibility of a personality targeted  
918 intervention for addictive overeating: FoodFix. *Appetite*. 2021; 156(104974).  
919 <https://doi.org/10.1016/j.appet.2020.104974>.
- 920 33. Carbone EA, Caroleo M, Rania M, et al. An open-label trial on the efficacy and  
921 tolerability of naltrexone/bupropion SR for treating altered eating behaviours and  
922 weight loss in binge eating disorder. *Eating and Weight Disorders*. 2021; 26(3): 779–  
923 788. <https://doi.org/10.1007/s40519-020-00910-x>.
- 924 34. Epstein DH, Kennedy AP, Furnari M, et al. Effect of the CRF1-receptor antagonist  
925 pexacerfont on stress-induced eating and food craving. *Psychopharmacology*. 2016;  
926 233(23-24): 3921–3932. <https://doi.org/10.1007/s00213-016-4424-5>.
- 927 35. Sevinçer GM, Konuk N, Bozkurt S, et al. Food addiction and the outcome of bariatric  
928 surgery at 1-year: Prospective observational study. *Psychiatry Research*. 2016; 244  
929 159–164. <https://doi.org/10.1016/j.psychres.2016.07.022>.
- 930 36. Murray SM, Tweardy S, Geliebter A, et al. A Longitudinal Preliminary Study of  
931 Addiction-Like Responses to Food and Alcohol Consumption Among Individuals



- 932 Undergoing Weight Loss Surgery. *Obesity Surgery*. 2019; 29(8): 2700–2703.
- 933 <https://doi.org/10.1007/s11695-019-03915-3>.
- 934 37. Chao AM, Wadden TA, Tronieri JS, et al. Effects of addictive-like eating behaviors on
- 935 weight loss with behavioral obesity treatment. *Journal of Behavioral Medicine*. 2019;
- 936 42(2): 246–255. <https://doi.org/10.1007/s10865-018-9958-z>.
- 937 38. Gordon EL, Merlo LJ, Durning PE, et al. Longitudinal Changes in Food Addiction
- 938 Symptoms and Body Weight among Adults in a Behavioral Weight-Loss Program.
- 939 *Nutrients*. 2020; 12(12): 3687. <https://doi.org/10.3390/nu12123687>.
- 940 39. Cassin S, Leung S, Hawa R, et al. Food Addiction Is Associated with Binge Eating
- 941 and Psychiatric Distress among Post-Operative Bariatric Surgery Patients and May
- 942 Improve in Response to Cognitive Behavioural Therapy. *Nutrients*. 2020; 12(10):
- 943 2905. <https://doi.org/10.3390/nu12102905>.
- 944 40. Unwin J, Delon C, Giæver H, et al. Low carbohydrate and psychoeducational
- 945 programs show promise for the treatment of ultra-processed food addiction. *Frontiers*
- 946 *in Psychiatry*. 2022; 13: 1005523. <https://doi.org/10.3389/fpsyt.2022.1005523>.
- 947 41. Carlos LO, Ramos MRZ, Wagner NRF, et al. Probiotic Supplementation attenuates
- 948 binge eating and food addiction 1 year after roux-en-y gastric bypass: a randomized,
- 949 double-blind, placebo controlled trial. *Arquivos brasileiros de cirurgia digestiva*. 35:
- 950 e1659. <https://doi.org/10.1590/0102-672020210002e1659>.
- 951 42. Cassin SE, Sijercic I, and Montemarano V. Psychosocial Interventions for Food
- 952 Addiction: A Systematic Review *Current Addiction Reports*. 2020; 7: 9–19.
- 953 <https://doi.org/10.1007/s40429-020-00295-y>.
- 954 43. Hides L, Kavanagh DJ, Daglish M, et al. The Quik Fix study: a randomised controlled
- 955 trial of brief interventions for young people with alcohol-related injuries and illnesses
- 956 accessing emergency department and crisis support care. *BMC Emergency*
- 957 *Medicine*. 2014; 14(19). <https://doi.org/10.1186/1471-227X-14-19>.

- 1  
2  
3 958 44. Hides L, Wilson H, Quinn C, et al. QuikFix: enhanced motivational interviewing  
4  
5 959 interventions for youth substance use. *Advances in Dual Diagnosis*. 2016; 9(2/3):  
6  
7 960 53-65. <https://doi.org/10.1108/ADD-03-2016-0008>.  
8  
9 961 45. Murphy CM, Stojek MK, and MacKillop J. Interrelationships among impulsive  
10  
11 962 personality traits, food addiction, and body mass index. *Appetite*. 2014; 73: 45–50.  
12  
13 963 <https://doi.org/10.1016/j.appet.2013.10.008>.  
14  
15 964 46. Davis C. A narrative review of binge eating and addictive behaviors: shared  
16  
17 965 associations with seasonality and personality factors. *Frontiers in Psychiatry*. 2013;  
18  
19 966 4: 183. <https://doi.org/10.3389/fpsy.2013.00183>.  
20  
21 967 47. Brunault P, Ducluzeau PH, Courtois R, et al. Food Addiction is Associated with  
22  
23 968 Higher Neuroticism, Lower Conscientiousness, Higher Impulsivity, but Lower  
24  
25 969 Extraversion in Obese Patient Candidates for Bariatric Surgery. *Substance Use and*  
26  
27 970 *Misuse*. 2018; 53(11): 1919–1923. <https://doi.org/10.1080/10826084.2018.1433212>.  
28  
29 971 48. Ouellette AS, Rodrigue C, Lemieux S, et al. An examination of the mechanisms and  
30  
31 972 personality traits underlying food addiction among individuals with severe obesity  
32  
33 973 awaiting bariatric surgery. *Eating and Weight Disorders*. 22(4): 633–640.  
34  
35 974 <https://doi.org/10.1007/s40519-017-0440-7>.  
36  
37 975 49. Jiménez-Murcia S, Agüera Z, Paslakis G, et al. Food Addiction in Eating Disorders  
38  
39 976 and Obesity: Analysis of Clusters and Implications for Treatment. *Nutrients*. 2019;  
40  
41 977 11(11): 2633. <https://doi.org/10.3390/nu11112633>.  
42  
43 978 50. Bunio LK, Battles JA, and Loverich TM. The nuances of emotion regulation difficulties  
44  
45 979 and mindfulness in food addiction. *Addiction Research and Theory*. 2021; 29(1): 11-  
46  
47 980 17. <https://doi.org/10.1080/16066359.2020.1714038>.  
48  
49 981 51. Miller W and Rollnick S. Motivational Interviewing. 3rd ed. New York, NY: Guilford  
50  
51 982 Press. 2013.  
52  
53 983 52. Leary M, Pursey KM, Verdejo-Garcia A, et al. Designing an online intervention for  
54  
55 984 adults with addictive eating: A qualitative Integrated Knowledge Translation  
56  
57  
58  
59  
60



1  
2  
3 985 approach. *BMJ Open*. 2022; 12(6): e060196. <https://doi.org/10.1136/bmjopen-2021->  
4  
5 986 060196.  
6  
7 987 53. Hoffmann T, Glasziou P, Boutron I, et al. Better reporting of interventions: template  
8  
9 988 for intervention description and replication (TIDieR) checklist and guide. *BMJ*. 2014;  
10  
11 989 348: g1687. <https://doi.org/10.1136/bmj.g1687>.  
12  
13 990 54. Kelly JT, Allman-Farinelli M, Chen J, et al. Dietitians Australia position statement on  
14  
15 991 telehealth. *Nutrition and Dietetics: the journal of the Dietitians Association of*  
16  
17 992 *Australia*. 2020; 77(4): 406-415. <https://doi.org/10.1111/1747-0080.12619>.  
18  
19 993 55. Reynolds DJ Jr, Stiles WB, Bailer AJ, et al. Impact of exchanges and client-therapist  
20  
21 994 alliance in online-text psychotherapy. *Cyberpsychology, Behavior and Social*  
22  
23 995 *Networking*. 2013; 16(5): 370–377. <https://doi.org/10.1089/cyber.2012.0195>.  
24  
25 996 56. Chan A-W, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 Statement: Defining standard  
26  
27 997 protocol items for clinical trials. *Annals of Internal Medicine*. 2013; 158(3): 200-207.  
28  
29 998 <https://doi.org/10.7326/0003-4819-158-3-201302050-00583>.  
30  
31 999 57. Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 statement: updated  
32  
33 1000 guidelines for reporting parallel group randomised trials. *BMJ*. 2010; 340(c332).  
34  
35 1001 <https://doi.org/10.1136/bmj.c332>.  
36  
37 1002 58. Purna Singh A, Vadakedath S, and Kandi V. Clinical Research: A Review of Study  
38  
39 1003 Designs, Hypotheses, Errors, Sampling Types, Ethics, and Informed Consent.  
40  
41 1004 *Cureus*. 2023; 5(1): e33374. <https://doi.org/10.7759/cureus.33374>.  
42  
43 1005 59. Prnjak K, Mitchison D, Griffiths S, et al. Further development of the 12-item EDE-QS:  
44  
45 1006 identifying a cut-off for screening purposes. *BMC Psychiatry*. 2020; 20(1): 146.  
46  
47 1007 <https://doi.org/10.1186/s12888-020-02565-5>.  
48  
49 1008 60. Australian Government Department of Health. Body mass index (BMI) and waist  
50  
51 1009 measurement. 2021 [cited 2022 8 March]; Available from:  
52  
53 1010 <https://www.health.gov.au/health-topics/overweight-and-obesity/bmi-and-waist>.  
54  
55  
56  
57  
58  
59  
60


- 1011 61. Centers for Disease Control and Prevention (CDC). Healthy Weight, Nutrition, and  
1012 Physical Activity: Assessing Your Weight. 2021 [cited 2022 8 March]; Available from:  
1013 <https://www.cdc.gov/healthyweight/assessing/index.html>.
- 1014 62. Mond J, Hay P, Rodgers B, et al. Use of extreme weight control behaviors with and  
1015 without binge eating in a community sample: implications for the classification of  
1016 bulimic-type eating disorders. *International Journal of Eating Disorders*. 2006; 39(4):  
1017 294-302. <https://doi.org/10.1002/eat.20265>.
- 1018 63. Mond JJ, Hay PJ, Rodgers B, et al. Correlates of the use of purging and non-purging  
1019 methods of weight control in a community sample of women. *The Australian and New*  
1020 *Zealand Journal of Psychiatry*. 2006; 40(2): 136-142. [https://doi.org/10.1080/j.1440-](https://doi.org/10.1080/j.1440-1614.2006.01760.x)  
1021 [1614.2006.01760.x](https://doi.org/10.1080/j.1440-1614.2006.01760.x).
- 1022 64. WHO ASSIST Working Group. The Alcohol, Smoking and Substance Involvement  
1023 Screening Test (ASSIST): development, reliability and feasibility. *Addiction*. 2002;  
1024 97(9): 1183-1194. <https://doi.org/10.1046/j.1360-0443.2002.00185.x>.
- 1025 65. Spitzer RL, Kroenke K, Williams JBW, et al. A Brief Measure for Assessing  
1026 Generalized Anxiety Disorder (The GAD-7). *Archives of Internal Medicine*. 2006;  
1027 166(10): 1092–1097 <https://doi.org/10.1001/archinte.166.10.1092>.
- 1028 66. Ingram PB 4th, Clarke E, and Lichtenberg JW. Confirmatory Factor Analysis of the  
1029 Perceived Stress Scale-4 in a Community Sample. *Stress Health*. 2016; 32(2): 173–  
1030 176. <https://doi.org/10.1002/smi.2592>.
- 1031 67. Fairburn C, Cooper Z, and O'Connor M, *Eating disorders examination (16.0D)* in *In:*  
1032 *Cognitive behavior therapy and eating disorders*, Fairburn C (Ed.), Editor. 2008,  
1033 Guilford Press: New York.
- 1034 68. Kroenke K, Strine TW, Spitzer RL, et al. The PHQ-8 as a measure of current  
1035 depression in the general population. *Journal of affective disorders*. 2009; 114(1-3):  
1036 163-173. <https://doi.org/10.1016/j.jad.2008.06.026>.

- 1037 69. Collins CE, Boggess MM, Watson JF, et al. Reproducibility and comparative validity  
1038 of a food frequency questionnaire for Australian adults. *Clinical Nutrition*. 2014; 33(5):  
1039 906-914. <https://doi.org/10.1016/j.clnu.2013.09.015>.
- 1040 70. Ashton L, Williams R, Wood L, et al. Comparison of Australian Recommended Food  
1041 Score (ARFS) and Plasma Carotenoid Concentrations: A Validation Study in Adults.  
1042 *Nutrients*. 2017; 9(8): 888. <http://doi.org/10.3390/nu9080888>.
- 1043 71. Woicik PA, Stewart SH, Pihl RO, et al. The Substance Use Risk Profile Scale: a  
1044 scale measuring traits linked to reinforcement-specific substance use profiles.  
1045 *Addictive Behaviors*. 2009; 34(12): 1042-1055.  
1046 <https://doi.org/10.1016/j.addbeh.2009.07.001>.
- 1047 72. Gormally J, Black S, Daston S, et al. The assessment of binge eating severity among  
1048 obese persons. *Addictive Behaviors*. 1982; 7(1): 47-55. [https://doi.org/10.1016/0306-](https://doi.org/10.1016/0306-4603(82)90024-7)  
1049 [4603\(82\)90024-7](https://doi.org/10.1016/0306-4603(82)90024-7).
- 1050 73. Heriseanu AI, Hay P, and Touyz S. The short inventory of grazing (SIG):  
1051 development and validation of a new brief measure of a common eating behaviour  
1052 with a compulsive dimension. *Journal of Eating Disorders*. 2019; 7(4).  
1053 <https://doi.org/10.1186/s40337-019-0234-6>.
- 1054 74. Vainik U, Han C, Epel ES, et al. Rapidly assessing reward-related eating: The RED-  
1055 X5. *Obesity*. 2019; 27(2): 325–331. <https://doi.org/10.1002/oby.22374>.
- 1056 75. Hibbard JH, Stockard J, Mahoney ER, et al. Development of the Patient Activation  
1057 Measure (PAM): conceptualizing and measuring activation in patients and  
1058 consumers. *Health Services Research*. 2004; 39(4 Pt 1): 1005–1026.  
1059 <https://doi.org/10.1111/j.1475-6773.2004.00269.x>.
- 1060 76. Rabin R and de Charro F. EQ-5D: a measure of health status from the EuroQol  
1061 Group. *Annals of Medicine*. 2001; 33(5): 337-343.  
1062 <https://doi.org/10.3109/07853890109002087>.

- 1063 77. Australian Institute of Health and Welfare (AIHW). The Active Australia Survey: a  
1064 guide and manual for implementation, analysis and reporting. 2003; Available from:  
1065 <https://www.aihw.gov.au/reports/physical-activity/active-australia-survey/summary>.  
1066 78. Buysse DJ, Reynolds CF 3rd, Monk TH, et al. The Pittsburgh Sleep Quality Index: a  
1067 new instrument for psychiatric practice and research. *Psychiatry Research*. 1989;  
1068 28(2): 193–213. [https://doi.org/10.1016/0165-1781\(89\)90047-4](https://doi.org/10.1016/0165-1781(89)90047-4).  
1069 79. Beecham J and Knapp M, *Costing psychiatric interventions*, in *Measuring Mental*  
1070 *Health Needs (2nd edition)*, Thornicroft G, Editor. 2001, Gaskell: London. p. 200-224.  
1071 80. Pursey KM, Collins R, Skinner J, et al. Characteristics of individuals seeking  
1072 addictive eating treatment. *Eating and Weight Disorders*. 2021; 26(8): 2779-2786.  
1073 <https://doi.org/10.1007/s40519-021-01147-y>.  
1074 81. Collins R, Haracz K, Leary M, et al. No control and overwhelming cravings:  
1075 Australian adults' perspectives on the experience of food addiction. *Appetite*. 2021;  
1076 59(105054). <https://doi.org/10.1016/j.appet.2020.105054>.  
1077 82. Pedram P, Wadden D, Amini P, et al. Food addiction: its prevalence and significant  
1078 association with obesity in the general population. *PLOS One*. 2013; 8(9): e74832.  
1079 <https://doi.org/10.1371/journal.pone.0074832>.  
1080 83. Lemeshow AR, Gearhardt AN, Genkinger JM, et al. Assessing the psychometric  
1081 properties of two food addiction scales *Eating Behaviors*. 2016; 23: 110–114.  
1082 <https://doi.org/10.1016/j.eatbeh.2016.08.005>.  
1083 84. National Health and Medical Research Council (NHMRC). Australian Guide to  
1084 Healthy Eating. 2017; Available from:  
1085 <https://www.eatforhealth.gov.au/guidelines/australian-guide-healthy-eating>.  
1086 85. Food Standards Australia New Zealand (FSANZ). AUSNUT 2011–13–Australian  
1087 Food Composition Database. 2014 [cited 2021 31 May]; Available from:  
1088 <http://foodstandards.gov.au/>.  
1089 86. National Health and Medical Research Council. Australian Dietary Guidelines.  
1090 Canberra. 2013; Available from: [www.nhmrc.gov.au/guidelines-publications/n55](http://www.nhmrc.gov.au/guidelines-publications/n55).

- 1091 87. Personal Social Services Research Unit (PSSRU). 2022 [cited 2022 14 April];
- 1092 Available from: <https://www.pssru.ac.uk/csri/client-service-receipt-inventory/>.
- 1093 88. Mauskopf JA, Paul JE, Grant DM, et al. The role of cost-consequence analysis in
- 1094 healthcare decision-making. *Pharmacoeconomics*. 1998; 13(3): 277-288.
- 1095 <https://doi.org/10.2165/00019053-199813030-00002>.
- 1096 89. Hunter R and Shearer J. Cost-consequences analysis - an underused method of
- 1097 economic evaluation. [cited 2022 8 March]; Available from: [https://www.rds-](https://www.rds-london.nihr.ac.uk/wpcms/wp-content/uploads/2018/09/Cost-consequences-analysis-an-underused-method.pdf)
- 1098 [london.nihr.ac.uk/wpcms/wp-content/uploads/2018/09/Cost-consequences-analysis-](https://www.rds-london.nihr.ac.uk/wpcms/wp-content/uploads/2018/09/Cost-consequences-analysis-an-underused-method.pdf)
- 1099 [an-underused-method.pdf](https://www.rds-london.nihr.ac.uk/wpcms/wp-content/uploads/2018/09/Cost-consequences-analysis-an-underused-method.pdf).
- 1100 90. Hibbard JH, Mahoney ER, Stockard J, et al. Development and testing of a short form
- 1101 of the patient activation measure. *Health Services Research*. 2005; 40(6 Pt 1): 1918-
- 1102 1930. <https://doi.org/10.1111/j.1475-6773.2005.00438.x>.
- 1103 91. Greene J and Hibbard JH. Why does patient activation matter? An examination of the
- 1104 relationships between patient activation and health-related outcomes. *Journal of*
- 1105 *General Internal Medicine*. 2012; 27(5): 520–526. [https://doi.org/10.1007/s11606-](https://doi.org/10.1007/s11606-011-1931-2)
- 1106 [011-1931-2](https://doi.org/10.1007/s11606-011-1931-2).
- 1107 92. Insignia Health, *Patient activation measure (PAM) 13 TM Licence Materials*
- 1108 *copyright*. 2011, LLC: Insignia Health.
- 1109 93. Remmers C, Hibbard J, Mosen DM, et al. Is patient activation associated with future
- 1110 health outcomes and healthcare utilization among patients with diabetes? *The*
- 1111 *Journal of Ambulatory Care Management*. 2009; 32(4): 320-327.
- 1112 <https://doi.org/10.1097/JAC.0b013e3181ba6e77>.
- 1113 94. Australian Bureau of Statistics (ABS). 2033.0.55.001 - Socio-Economic Indexes for
- 1114 Areas (SEIFA). 2016 [cited 2021 14 September]; Available from: [www.abs.gov.au](http://www.abs.gov.au).
- 1115 95. World Health Organization (WHO). Body mass index - BMI. c2018 [cited 2021
- 1116 September 1]; Available from: [http://www.euro.who.int/en/health-topics/disease-](http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi)
- 1117 [prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi](http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi).

- 1  
2  
3 1118 96. Harris PA, Taylor R, Minor BL, et al. REDCap Consortium. The REDCap consortium:  
4  
5 1119 Building an international community of software platform partners. *Journal of*  
6  
7 1120 *Biomedical Informatics*. 2019; 95(103208). <https://doi.org/10.1016/j.jbi.2019.103208>.  
8  
9 1121 97. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap) – A  
10  
11 1122 metadata-driven methodology and workflow process for providing translational  
12  
13 1123 research informatics support. *Journal of Biomedical Informatics*. 2009; 42(2): 377-  
14  
15 1124 381. <https://doi.org/10.1016/j.jbi.2008.08.010>.  
16  
17  
18 1125  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60





WELCOME BACK! As you have been found eligible to participate in the personality based intervention for addictive eating, it is important that you carefully read the following information and give consent at the bottom if you wish to continue to the baseline surveys.

I have read the previous Participant Information Statement and give my consent to participate in this study? ☐ Yes ☐ No

I understand that it is possible that some questionnaires may identify potential health issues that may require follow-up with my GP. I give consent for a copy of the relevant results to be sent to my local doctor/GP or other Health Professional ☐ Yes ☐ No

Please provide Health Professional details (e.g Name, Phone number)

I agree to participate in the Personality based intervention for Addictive Eating Behaviours study and give my consent freely.

I understand that the project will be conducted as described in the previous Participant Information Statement, a copy of which I have had the opportunity to download.

I understand I can withdraw from the project at any time and do not have to give any reason for withdrawing. I am aware I have an equal chance of being allocated into one of three intervention groups. If allocated to:

- Group 1, I consent to completing online questionnaires at the beginning of the study and after 3 and 6 months, and to participating in five telehealth/phone consultations of 30-45mins with an Accredited Practising Dietitian.

- Group 2, I consent to completing online questionnaires at the beginning of the study and after 3 and 6 months, and to complete the self-guided workbook and access the study website.

- Group 3, I consent to completing online questionnaires at the beginning of the study and after 3 and 6 months, and to follow my usual dietary intake for the study duration. I understand that after 6 months I will have access to complete the self-guided workbook and access to the study website.

If allocated to group 1, I consent for my five sessions with the dietitian to be recorded for quality and training purposes. ☐ Yes ☐ No

Please provide your First Name:

Please provide your Last Name:

Please sign:

Do you wish to continue to the Baseline Surveys? ☐ Yes ☐ No



**Title:** Examining the efficacy of a telehealth intervention targeting addictive eating in Australian adults (the TRACE program): a randomised controlled trial protocol

**Reference to where data collection forms can be found**

Survey	Assessment tool	Reference	Available from
AAS	Active Australia Survey	Australian Institute of Health and Welfare (AIHW) 2003. The Active Australia Survey: a guide and manual for implementation, analysis and reporting. Canberra: AIHW.	<a href="https://www.aihw.gov.au/reports/physical-activity/active-australia-survey/summary">https://www.aihw.gov.au/reports/physical-activity/active-australia-survey/summary</a>
AES	Australian Eating Survey	Ashton L, Williams R, Wood L, Schumacher T, Burrows T, Rollo M, et al. Comparison of Australian Recommended Food Score (ARFS) and Plasma Carotenoid Concentrations: A Validation Study in Adults. <i>Nutrients</i> . 2017;9(8):888. <a href="http://doi.org/10.3390/nu9080888">http://doi.org/10.3390/nu9080888</a>  Collins CE, Boggess MM, Watson JF, Guest M, Duncanson K, Pezdirc K, et al. Reproducibility and comparative validity of a food frequency questionnaire for Australian adults. <i>Clinical Nutrition</i> . 2014;33(5):906-14. doi: 10.1016/j.clnu.2013.09.015	<a href="https://australianeatingsurvey.com.au/">https://australianeatingsurvey.com.au/</a>
ASSIST	Alcohol, Smoking and Substance Involvement Screening Test - Version 3.0	WHO ASSIST Working Group (2002) The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. <i>Addiction</i> , 97:1183-1194. doi: 10.1046/j.1360-0443.2002.00185.x	<a href="https://www.who.int/publications/i/item/978924159938-2">https://www.who.int/publications/i/item/978924159938-2</a>
BES	Binge Eating Scale	Gormally J, Black S, Daston S, Rardin D. The assessment of binge eating severity among obese persons. <i>Addictive Behaviors</i> . 1982;7(1):47-55. <a href="https://doi.org/10.1016/0306-4603(82)90024-7">https://doi.org/10.1016/0306-4603(82)90024-7</a>	Available in the publication
CSRI	Consumer Services Receipt Inventory	Beecham J and Knapp M. (2001) Costing psychiatric interventions, in G. Thornicroft (ed.) <i>Measuring Mental Health Needs</i> , Gaskell, 2nd edition, 200-224.	<a href="https://www.pssru.ac.uk/csri/what-is-the-csri/">https://www.pssru.ac.uk/csri/what-is-the-csri/</a>
EDE-Q 6.0	Eating Disorder	Fairburn C, Cooper Z, O'Connor M. Eating disorders examination (16.0D) In: Fairburn C (Ed.), editor. In:	<a href="https://nedc.com.au/assets/Medicare-related-forms/Eating-Disorder-Examination-Questionnaire-Smart-PDF.pdf">https://nedc.com.au/assets/Medicare-related-forms/Eating-Disorder-Examination-Questionnaire-Smart-PDF.pdf</a>

	<b>Examination Questionnaire 6.0</b>	Cognitive behavior therapy and eating disorders. New York: Guilford Press; 2008.	
<b>EDE-QS</b>	<b>Eating Disorder Examination Questionnaire Short Form</b>	Prnjak K, Mitchison D, Griffiths S, Mond J, Gideon N, Serpell L, Hay P. Further development of the 12-item EDE-QS: identifying a cut-off for screening purposes. BMC Psychiatry. 2020;20:146. <a href="https://doi.org/10.1186/s12888-020-02565-5">https://doi.org/10.1186/s12888-020-02565-5</a>	Available as Supporting Information accompanying the publication
<b>EQ5D-5L</b>	<b>EQ5D-5L</b>	Brazier J, Ratcliffe J, Tsuchiya A, Salomon J. Measuring and Valuing Health Benefits for Economic Evaluation. 2nd ed. Oxford: Oxford University Press; 2016. doi: 10.1093/med/9780198725923.001.0001.	<a href="https://aci.health.nsw.gov.au/_data/assets/pdf_file/0003/632847/EuroQol-5-Dimension.pdf">https://aci.health.nsw.gov.au/_data/assets/pdf_file/0003/632847/EuroQol-5-Dimension.pdf</a>
<b>GAD-7</b>	<b>Generalized Anxiety Disorder 7</b>	Spitzer RL, Kroenke K, Williams JBW, Löwe B. A Brief Measure for Assessing Generalized Anxiety Disorder (The GAD-7). Archives of Internal Medicine. 2006;166(10):1092–7 <a href="https://doi.org/10.1001/archinte.166.10.1092">https://doi.org/10.1001/archinte.166.10.1092</a>	<a href="https://adaa.org/sites/default/files/GAD-7_Anxiety-updated_0.pdf">https://adaa.org/sites/default/files/GAD-7_Anxiety-updated_0.pdf</a>
<b>PAM-13</b>	<b>Patient Activation Measure 13-item</b>	Hibbard JH, Stockard J, Mahoney ER, Tusler M. (2004). Development of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers. Health services research. 2004;39(4 Pt 1): 1005–1026. <a href="https://doi.org/10.1111/j.1475-6773.2004.00269.x">https://doi.org/10.1111/j.1475-6773.2004.00269.x</a>	<a href="https://www.insigniahealth.com/products/pam">https://www.insigniahealth.com/products/pam</a>
<b>PQH-8</b>	<b>Patient Health Questionnaire</b>	Kroenke K, et al., The PHQ-8 as a measure of current depression in the general population. Journal of affective disorders, 2009. 114(1-3): p. 163-173 <a href="https://doi.org/10.1016/j.jad.2008.06.026">https://doi.org/10.1016/j.jad.2008.06.026</a>	<a href="https://www.psychologywizard.net/uploads/2/6/6/4/26640833/kroenke_phq8.pdf">https://www.psychologywizard.net/uploads/2/6/6/4/26640833/kroenke_phq8.pdf</a>
<b>PSQI</b>	<b>Pittsburgh Sleep Quality Index</b>	Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Research. 1989;28(2): 193–213. <a href="https://doi.org/10.1016/0165-1781(89)90047-4">https://doi.org/10.1016/0165-1781(89)90047-4</a>	<a href="https://www.med.upenn.edu/cbti/assets/user-content/documents/Pittsburgh%20Sleep%20Quality%20Index%20(PSQI).pdf">https://www.med.upenn.edu/cbti/assets/user-content/documents/Pittsburgh%20Sleep%20Quality%20Index%20(PSQI).pdf</a>
<b>PSS-4</b>	<b>Perceived Stress Scale</b>	Ingram PB 4th, Clarke E, Lichtenberg JW. Confirmatory Factor Analysis of the Perceived Stress Scale-4 in a Community Sample. Stress Health. 2016; 32(2): 173–176. <a href="https://doi.org/10.1002/smi.2592">https://doi.org/10.1002/smi.2592</a>	<a href="https://scholar.harvard.edu/files/bettina.hoeppner/files/pss-4.pdf">https://scholar.harvard.edu/files/bettina.hoeppner/files/pss-4.pdf</a>

<b>REDX-5</b>	<b>Reward-Based Eating Drive Scale</b>	Vainik U, Han C, Epel ES, Dagher A, Mason AE. Rapid assessment of reward-related eating: The RED-X5. Obesity. 2019;27(2):325–31. doi:10.1002/oby.22374	<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352904/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352904/</a>
<b>SURPS</b>	<b>Substance Use Risk Profile Scale</b>	Woicik PA, Stewart SH, Pihl RO, Conrod PJ. The Substance Use Risk Profile Scale: a scale measuring traits linked to reinforcement-specific substance use profiles. Addictive Behaviors. 2009;34(12): 1042-55. doi: 10.1016/j.addbeh.2009.07.001	Available on request from the corresponding author: Woicik can be contacted at Neuropsychomaging Group, Brookhaven National Laboratory, Medical Department, Building 490, Upton, New York, 11973, United States. Tel.: +1 631 344 4472. Conrod, NIHR Biomedical Research Centre, Section of Addiction, Department of Psychological Medicine and Psychiatry, King's College London, 4 Windsor Walk, Denmark Hill, London, SE5 8BB, United Kingdom. Tel.: +44 207 848 0836; fax: +44 207 701 8584. <a href="mailto:p.conrod@iop.kcl.ac.uk">p.conrod@iop.kcl.ac.uk</a>
<b>YFAS 2.0</b>	<b>Yale Food Addiction Scale 2.0</b>	Gearhardt AN, Corbin WR, Brownell KD. Development of the Yale Food Addiction Scale Version 2.0. Psychology of Addictive Behaviors. 2016;30(1):113-21. doi: 10.1037/adb0000136	<a href="https://sites.lsa.umich.edu/fastlab/yale-food-addiction-scale/">https://sites.lsa.umich.edu/fastlab/yale-food-addiction-scale/</a>



## SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	2
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3, 8
	2b	All items from the World Health Organization Trial Registration Data Set	NA
Protocol version	3	Date and version identifier	-
Funding	4	Sources and types of financial, material, and other support	32
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1, 31
	5b	Name and contact information for the trial sponsor	1
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	30
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	NA

1	<b>Introduction</b>			
2				
3	Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4 – 8
4		6b	Explanation for choice of comparators	14, 15
5	Objectives	7	Specific objectives or hypotheses	8
6		8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	8
7				
8	<b>Methods: Participants, interventions, and outcomes</b>			
9				
10	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	8
11	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	9, 10
12		11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	10 - 20
13	Interventions	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	8
14		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	19, 20
15	Outcomes	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	NA
16		12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	20 - 27
17				
18	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	11 (Table 1)
19				
20				
21				
22				
23				
24				
25				
26				
27				
28				
29				
30				
31				
32				
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	27
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	9
5				
6	<b>Methods: Assignment of interventions (for controlled trials)</b>			
7				
8	Allocation:			
9				
10	Sequence	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	13, 14
11	generation			
12				
13				
14				
15				
16	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	13, 14
17	concealment			
18	mechanism			
19				
20	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	13, 14
21				
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	13, 14
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	NA
28				
29				
30				
31	<b>Methods: Data collection, management, and analysis</b>			
32				
33	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	19, 20, 21 - 29, suppl
34	methods			
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	13
40				
41				
42				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	28, 29
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	27, 28
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	27, 28
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	28
11				
12				
13				
14	<b>Methods: Monitoring</b>			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	29
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	NA
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	29
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	29
29				
30				
31				
32	<b>Ethics and dissemination</b>			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	8, 31
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	NA
38				
39				
40				
41				
42				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	9, 10, 12
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	NA
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	28, 29
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	33
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	28, 29
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	NA
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	31
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	NA
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	31
27				
28				
29	<b>Appendices</b>			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Suppl.
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	NA
35				
36				

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons [“Attribution-NonCommercial-NoDerivs 3.0 Unported”](https://creativecommons.org/licenses/by-nc-nd/3.0/) license.



# BMJ Open

## Examining the efficacy of a telehealth intervention targeting addictive eating in Australian adults (the TRACE program): a randomised controlled trial protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-064151.R2
Article Type:	Protocol
Date Submitted by the Author:	04-May-2023
Complete List of Authors:	Skinner, Janelle; The University of Newcastle, School of Health Whatnall, Megan; The University of Newcastle, School of Health Leary, Mark; The University of Newcastle, Collins, Rebecca; The University of Newcastle, School of Health Pursey, Kirrilly; The University of Newcastle, School of Health Verdejo-García, Antonio; Monash University Hay, Phillipa ; Western Sydney University Baker, Amanda; The University of Newcastle, Hides, Leanne; University of Queensland, Paxton, Susan; La Trobe University Wood, Lisa; The University of Newcastle, Respiratory Medicine Colyvas, Kim; The University of Newcastle, School of Mathematical and Physical Sciences Collins, Clare; The University of Newcastle Burrows, Tracy; The University of Newcastle; The University of Newcastle Hunter Medical Research Institute
<b>Primary Subject Heading</b>:	Addiction
Secondary Subject Heading:	Mental health
Keywords:	NUTRITION & DIETETICS, PUBLIC HEALTH, Eating disorders < PSYCHIATRY

SCHOLARONE™  
Manuscripts

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

**Article type:** Protocol

**Title:** Examining the efficacy of a telehealth intervention targeting addictive eating in Australian adults (the TRACE program): a randomised controlled trial protocol

**Authors:** Janelle A Skinner<sup>1,2</sup>, Megan Whatnall<sup>1,2</sup>, Mark Leary<sup>1,2</sup>, Rebecca A Collins<sup>1,2</sup>, Kirrilly M Pursey<sup>1,2</sup>, Antonio Verdejo-Garcia<sup>3</sup>, Phillipa J Hay<sup>4</sup>, Amanda L Baker<sup>2,5</sup>, Leanne Hides<sup>6</sup>, Susan J Paxton<sup>7</sup>, Lisa G Wood<sup>2,8</sup>, Kim Colyvas<sup>1</sup>, Clare E Collins<sup>1,2</sup>, Tracy L Burrows<sup>1,2\*</sup>

**Institutions:**

<sup>1</sup>School of Health Sciences, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan NSW 2308, Australia

<sup>2</sup>Hunter Medical Research Institute, University of Newcastle, New Lambton Heights, NSW, 2305, Australia

<sup>3</sup>School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Clayton, VIC 3800, Australia

<sup>4</sup>Translational Health Research Institute, Western Sydney University, Campbelltown, NSW, 2751, Australia

<sup>5</sup>School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW 2308, Australia

<sup>6</sup>School of Psychology, University of Queensland, St Lucia, QLD, 4072, Australia

<sup>7</sup>Department of Psychology and Counselling, Latrobe University, Melbourne, VIC, 3086

<sup>8</sup>School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan NSW 2308, Australia

**\*Corresponding Author:** Professor Tracy Burrows. Mailing address: School of Health Sciences, University Drive, University of Newcastle, Callaghan, NSW, Australia, 2308. Ph: +610249215514. Email: [tracy.burrows@newcastle.edu.au](mailto:tracy.burrows@newcastle.edu.au)

**Word count:** 7843

**Key words:** addictive eating, food addiction, Yale Food Addiction Scale

## ARTICLE SUMMARY

**Title:** Examining the efficacy of a telehealth intervention targeting addictive eating in Australian adults (the TRACE program): a randomised controlled trial protocol

### Abstract

**Introduction** Approximately 15-20% of the adult population self-report symptoms of addictive eating. There are currently limited options for management. Motivational interviewing-based interventions, containing personalised coping skills training, have been found to be effective for behaviour change in addictive disorders (e.g. alcohol). This project builds upon foundations of an addictive eating feasibility study previously conducted, and co-design process involving consumers. The primary aim of this study is to examine the efficacy of a telehealth intervention targeting addictive eating symptoms in Australian adults compared to passive intervention and control groups. **Methods and analysis** This three-arm randomised controlled trial will recruit participants, 18-85 years, endorsing  $\geq 3$  symptoms on the Yale Food Addiction Scale 2.0, with BMI  $>18.5\text{kg/m}^2$ . Addictive eating symptoms are assessed at baseline (pre-intervention), 3-months (post-intervention) and 6-months. Other outcomes include dietary intake and quality, depression, anxiety, stress, quality of life, physical activity, and sleep hygiene. Using a multicomponent clinician-led approach, the active intervention consists of five telehealth sessions (15-45min each) delivered by a dietitian over 3-months. The intervention uses personalised feedback, skill-building exercises, reflective activities, and goal setting. Participants are provided with a workbook and website access. The passive intervention group receive the intervention via a self-guided approach with access to the workbook and website (no telehealth). The control group receive personalised written dietary feedback at baseline and participants advised to follow their usual dietary pattern for 6-months. The control group will be offered the passive intervention after 6-months. The primary endpoint is YFAS symptom scores at 3-months. A cost consequence analysis will determine intervention costs alongside mean change outcomes. **Ethics and dissemination** Human Research Ethics Committee of

1  
2  
3 61 University of Newcastle Australia provided approval: H-2021-0100. Findings will be  
4  
5 62 disseminated via publication in peer-reviewed journals, conference presentations, community  
6  
7 63 presentations and student theses. Trial registration: Australia New Zealand Clinical Trial  
8  
9 64 Registry (ANZCTR) ACTRN12621001079831.  
10  
11  
12 65

13  
14 66 **Strengths and Limitations of this study**

- 15  
16 67     • Targeting addictive risk factors through personalised tailoring of coping strategies and  
17  
18 68       use of motivational interviewing for management of symptoms of addictive eating  
19  
20 69     • Co-design approach taken, with both consumers and multidisciplinary health  
21  
22 70       professionals, to inform program development  
23  
24 71     • Detailed assessment of eating behaviours, mental health and lifestyle factors with  
25  
26 72       personalised feedback provided to participants during the telehealth intervention  
27  
28 73     • Fidelity outcomes will be assessed, and cost consequence analysis conducted  
29  
30 74       regarding implementation  
31  
32 75     • Limitations include participants being excluded with severe mental illnesses or  
33  
34 76       complex health conditions  
35  
36  
37 77  
38  
39 78  
40  
41 79  
42  
43 80  
44  
45 81  
46  
47 82  
48  
49 83  
50  
51 84  
52  
53 85  
54  
55 86  
56  
57 87

58 87 **INTRODUCTION**  
59  
60

Research in addictive eating has increased rapidly in recent years. Addictive eating, theorised as being on the severe end of a spectrum of overeating,[1] is a phenotype of eating behaviour marked by the chronic excessive and dysregulated consumption of food.[2, 3] Addictive eating, not categorised as a distinct disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM)[4] or the International Classification of Disease[5] systems, is most commonly assessed using the Yale Food Addiction Scale (YFAS).[6] The YFAS adapts the DSM criteria for 'substance-related and addictive disorders' to specific foods.[4] Developed in 2009[2] and revised in 2016 (YFAS 2.0)[6] according to the DSM-5 criteria, this psychometric tool assesses the presence of 11 symptoms of addictive eating. Symptoms include craving, loss of control, tolerance and withdrawal associated with eating behaviours, the repeated unsuccessful attempts to reduce the consumption of specific foods and maintenance of these behaviours despite adverse physical/emotional/social/interpersonal consequences.[6] The YFAS 2.0 provides two scoring options: a continuous symptom score, reflecting the number of endorsed addiction-like symptoms; and a dichotomous diagnosis of 'food addiction'. [6] Using this self-report survey, approximately 15-20% of the adult population endorse  $\geq$  three YFAS symptoms for addictive eating. [7-9]

Higher prevalence rates of addictive eating have been reported in individuals with higher Body Mass Indexes (BMI) classified as overweight or obese compared to lower BMIs.[8, 10] Although addictive eating is not exclusive to those with higher weight status.[11] It has been suggested that addictive eating in those with underweight may be related to dietary restriction practices (e.g., consuming more than intended that breaches self-imposed dietary rules, intense craving resulting from extreme dieting practices).[11, 12] Irrespective of weight status, results from recent research indicate that individuals with addictive eating have significantly lower diet quality and higher intakes of highly processed foods.[9, 13, 14] Poor diet is a significant contributor to early death globally[15] and addressing addictive eating may contribute to the prevention or management of adverse health outcomes.

1  
2  
3 116 Addictive eating is a complex issue often overlapping with other health conditions, and likely  
4  
5 117 transdiagnostic.[16, 17] There is evidence that addictive eating commonly co-occurs with  
6  
7 118 mental health co-morbidities, particularly depression and anxiety, as well as overlapping with  
8  
9 119 eating disorders, specifically binge eating disorder (BED).[7, 14] Approximately 50% of  
10  
11 120 individuals with BED meet criteria for 'food addiction' according to the YFAS.[7] The present  
12  
13 121 state of the literature demonstrates there is considerable overlap between BED and addictive  
14  
15 122 eating.[18, 19] Commonalities include the loss of control over consumption, continued overuse  
16  
17 123 despite negative consequences, and repeated failed attempts to reduce consumption.[19] At  
18  
19 124 this time, it is unclear if addictive eating will emerge as a severe subtype of BED or be regarded  
20  
21 125 as a distinct form of an addiction disorder. This distinction will be important to allow for targeted  
22  
23 126 treatment and prevention strategies in susceptible individuals.  
24  
25  
26  
27

28 128 Current treatment options for addictive eating largely stem from online self-help groups such  
29  
30 129 as Food Addicts Anonymous[20] and Overeaters Anonymous.[21] Originating in the United  
31  
32 130 States, they now have 10 000+ members worldwide and have been in existence for many  
33  
34 131 years, demonstrating a need for services.[22] A 2021 systematic review[23] found there is  
35  
36 132 limited evidence supporting implementation of feasible and effective dietary interventions run  
37  
38 133 by clinicians, for the management of addictive eating.[24] Of the nine studies reviewed, five  
39  
40 134 studies that included lifestyle modification,[25] medication,[26, 27] or bariatric surgery[28, 29]  
41  
42 135 were found to improve symptoms of addictive eating.[23] Since publication of this review, a  
43  
44 136 further four intervention studies (a behavioural weight loss program, [30] a brief telephone-  
45  
46 137 based cognitive behavioural therapy intervention,[31] a low carbohydrate dietary program,[32]  
47  
48 138 and a probiotic supplement placebo-controlled trial[33]) have been trialled with improvement  
49  
50 139 in YFAS addictive eating symptomatology immediately following the intervention. To date,  
51  
52 140 most studies have been limited in sample size and therefore not been powered to detect a  
53  
54 141 change in addictive eating symptoms.[23] Given the limited number of treatment options for  
55  
56 142 addictive eating, there is a clear need for services, and development and testing of  
57  
58  
59  
60

1  
2  
3 143 interventions. It has been suggested that interventions based on substance use addiction  
4  
5 144 models may be effective at facilitating changes in eating behaviour.[34]  
6

7 145  
8  
9 146 Motivational interviewing (MI) based interventions for addictive disorders, such as alcohol use,  
10  
11 147 in combination with coping skills training for traits associated with risk of addictive behaviour,  
12  
13 148 have found to be effective.[35, 36] The traits that have been linked to addictive eating include  
14  
15 149 impulsivity, sensation seeking, and anxiety and depression proneness.[37-41] Findings  
16  
17 150 suggest that individuals with addictive eating may be highly aware of emotions, but lack the  
18  
19 151 skills needed to cope with negative affect.[42] Using personalised coping skills for traits  
20  
21 152 associated with personality and the risk of addictive behaviour in combination with MI, a  
22  
23 153 communication approach used to identify and resolve ambivalence between desired  
24  
25 154 behaviors and actual behaviors to increase motivation,[43] may be affective to facilitate  
26  
27 155 behaviour change in individuals with addictive eating.  
28  
29  
30

31 156  
32  
33 157 Telehealth has been shown to be a strategy to increase reach, with virtual sessions being  
34  
35 158 comparable to face-to-face programs, and to increase access to services without  
36  
37 159 compromising effectiveness.[44] Telehealth will allow participants from anywhere in Australia  
38  
39 160 to participate from home, and will reduce the demands on time and cost of travel.[44]  
40  
41 161 Additionally, telehealth may overcome client-centred barriers by allowing a safe atmosphere  
42  
43 162 for some participants to better engage and discuss more sensitive topics that they would not  
44  
45 163 normally raise.[45] Although the effectiveness of telehealth has not been explicitly explored in  
46  
47 164 populations with addictive eating, recent research demonstrates that telehealth can be as  
48  
49 165 effective as in-person care for the management of mental health conditions,[46] including  
50  
51 166 substance use disorders[47] and eating disorders.[48]  
52

53 167  
54  
55 168 This project builds on a program of work that included an initial feasibility study for the  
56  
57 169 management of addictive eating in adults (Australia New Zealand Clinical Trial Registry  
58  
59 170 ACTRN12619001540101).[24] Results from the initial study indicated that the program was



1  
2  
3 171 feasible in the target population. Feedback, received from program participants and  
4  
5 172 facilitators, identified a need for a greater number of program sessions and improved  
6  
7 173 strategies for increasing retention. As a result, the program was further refined with consumers  
8  
9 174 using an integrated knowledge translation (iKT) framework.[49] This co-design phase included  
10  
11 175 consumers with lived experience, as well as health professionals from a range of disciplines  
12  
13 176 to ensure the culmination of multidisciplinary evidence-based strategies were included. This  
14  
15 177 was unique as previous reports omit this co-design step or are siloed in their approach.[49]  
16  
17 178 The co-design process used a series of interviews and workshops to gain input into the  
18  
19 179 program overview, aims, content and materials. Subsequent changes were made to the  
20  
21 180 program content, language used, and materials were created or refined to improve  
22  
23 181 acceptability. The resultant behaviour change intervention, the TRACE (Targeted Research  
24  
25 182 on Addictive and Compulsive Eating) program, is a complex intervention and previously  
26  
27 183 described using the Medical Research Council TiDier (Template for Intervention Description  
28  
29 184 and Replication) checklist for complex interventions.[50] (See [49] for the TiDier checklist of  
30  
31 185 the intervention).  
32  
33  
34  
35 186  
36  
37 187 To the authors knowledge, the TRACE program is the first MI-based telehealth intervention  
38  
39 188 used in combination with personalised coping skills training for the management of addictive  
40  
41 189 eating in adults. The aim of the current study is to determine the efficacy of a telehealth  
42  
43 190 intervention (active intervention) to reduce symptoms of addictive eating in adults, relative to  
44  
45 191 passive intervention and control (no intervention) groups. It is hypothesised that both the active  
46  
47 192 and passive intervention groups will achieve a reduction in addictive eating symptoms relative  
48  
49 193 to the control group. Potential moderators (e.g., participant sociodemographics) and mediators  
50  
51 194 (e.g., physical activity, diet, and sleep) of intervention efficacy will also be evaluated.  
52  
53  
54 195

55  
56 196 **METHODS**

57  
58 197 **Study trial design**  
59  
60

The TRACE program is a randomised controlled trial with three parallel arms. Assessments will be carried out at three timepoints: 1) baseline (pre-intervention), 2) 3-month post-baseline (primary time point), and 3) 6-month post-baseline follow-up assessment. This project was approved by The University of Newcastle Human Research Ethics Committee (H-2021-0100) and prospectively registered with the Australian New Zealand Clinical Trials Registry (ACTRN12621001079831). The study protocol was developed in accordance with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines.[51] The design, conduct and reporting of the studies will adhere to the CONSORT (Consolidated Standards of Reporting Trials) guidelines.[52] All participants will provide informed electronic consent (see Supplementary Material 1 for a copy of the consent form) to participate and can withdraw at any time for any reason. The funding bodies had no role in the design, conduct or reporting of the study.

## Setting

The active intervention will be delivered via telehealth sessions, conducted in Australia, and supported by a program workbook, and website containing materials relevant to the intervention.

## Recruitment

Participants will be recruited using a range of strategies including media releases, advertising via local and national newspapers, and social-media releases. Informed by our iKT process, a range of recruitment videos (tailored for gender) were also created in addition to written material which will be released via Twitter and Facebook. A non-probability sampling technique (voluntary response sampling)[53] will be used, and recruitment will continue until the desired number of participants is achieved. Recruitment commenced in August 2021 and was completed in April 2022. Recruitment materials will direct individuals to the study information sheet and eligibility survey. The eligibility survey takes approximately 15 mins to

complete (Table 1). Online informed consent will be obtained prior to completing the eligibility survey.

**Eligibility**

To be eligible for inclusion in the study individuals must:

1. Be aged between 18 years and 85 years
2. Endorse  $\geq 3$  symptoms on the Yale Food Addiction Scale 2.0 (i.e. exhibiting mild to severe addictive eating)[6]
3. Have a self-reported weight and height consistent with a body mass index (BMI)  $\geq 18.5$  kg/m<sup>2</sup>
4. Be competent in the English language
5. Live in Australia
6. Have access to the internet

Individuals will be excluded from participating in the study if they:

1. Are pregnant or lactating
2. Report having a severe mental illness (including schizophrenia or bipolar disorder) or have a health condition that necessitates taking medications which affect dietary intake or weight status
3. Report purging behaviours as identified by the Eating Disorder Examination Questionnaire – Short form (EDE-QS)[54]

*Methodological considerations for eligibility criteria:* The eligibility screener excludes individuals with a BMI below 18.5kg/m<sup>2</sup>. This measure was put in place to reduce the likelihood of recruiting participants with at-risk restrictive eating practices that may be influencing a relatively low weight status. The value of  $<18.5$  kg/m<sup>2</sup> was chosen as this is below the current healthy weight range in national guidelines for Australians[55] and The Centre of Disease Control and Prevention (CDC) in the USA.[56] Additionally, the eligibility screener includes the

Eating Disorder Examination Questionnaire Short Form (EDE-QS).[54] This 12-item validated tool is commonly used to identify potential eating disorders. Based on the research team consensus, individuals who have compensatory behaviours such as bingeing/purging (specifically asked in question 7 on the EDE-QS), who may be at risk of an eating disorder and are medically compromised, will be deemed not eligible for the current study. Purging is related to higher levels of appearance dissatisfaction, anxiety and depressive symptoms and self-concept instability.[57, 58] As per the ethics protocol, participants endorsing any response to this question, indicating these compensatory behaviours will be excluded from the study. The tools for eating disorders and psychological health[54, 59-63] used in the study have been widely used in research in the areas of eating disorders, dietary interventions, substance use and mental health and are considered standard tools for their specific measures. Study information as well as at completion of surveys participants are provided with contact information if they experience or further assistance with health behaviours.

**Table 1.** Schedule of measurements

Variable	Instrument	Enrolment	Timepoint post allocation		
Primary study		Eligibility Screening	t <sub>1</sub> Baseline	t <sub>2</sub> 3-months	t <sub>3</sub> 6-months
<b>Sample characteristics</b>					
Demographics	Age, sex, postcode, mental health status	✓			
Socioeconomic factors	Education, income, marital status, employment status, occupation and living/accommodation status	✓			
Anthropometrics	Self-report height and weight	✓		✓	✓
Smoking and substance use	Alcohol, Smoking and Substance Involvement Screening Test - Version 3.0[59]		✓	✓	✓
Purging behaviours	Eating Disorder Examination Questionnaire Short form (EDE-QS)[54]	✓			
<b>Primary Outcomes</b>					
Addictive eating symptoms and severity	Yale Food Addiction Scale 2.0[6]	✓		✓	✓
<b>Secondary Outcomes</b>					
Dietary intake and quality	Australian Eating Survey[64, 65]		✓	✓	✓
Depression, anxiety and stress	Patient Health Questionnaire-8,[63] Generalized Anxiety Disorder 7,[60] Perceived Stress Scale[61]	✓		✓	✓
<b>Mediators/moderators</b>					
Trait/s associated with risk of addictive behaviour	Substance Use Risk Profile Scale[66]		✓		
Eating Behaviours	Eating Disorder Examination Questionnaire 6.0,[62] Binge Eating		✓	✓	✓

1				
2				
3		Scale,[67] Short Inventory of		
4		Grazing,[68] Reward-Based Eating		
5		Drive Scale[69]		
6	Participant activation level	Patient Activation Measure 13[70]	✓	✓
7	Usage and engagement	Google Analytics (Google LLC) to		✓
8	with program website	record number of site visits, visit	◆	◆
9		durations, number of page views,		
10		and links accessed/resources		
11	Usage and engagement	Number of participants to join group;		◆
12	with Facebook group	number of views, likes and		◆
13		comments per post manually		
14		recorded		
15	<b>Other outcomes</b>			
16	Quality of life	EQ-5D-5L[71]	✓	✓
17	Physical activity level	Active Australia Survey[72]	✓	✓
18	Sleep hygiene behaviours	Pittsburgh Sleep Quality Index[73]	✓	✓
19	Health care utilisation	Consumer Services Receipt	✓	✓
20		Inventory[74]		✓
21	'Control' and 'Compulsion'	Qualitative analysis of a segment of	✓	
22	associated with addictive	the first telehealth session		
23	eating			

23  
24 267 Eligibility Screening = assessment of inclusion/exclusion criteria, Baseline = pre-intervention, 3-months =  
25 268 immediate post-intervention, 6-months = 3-months post-intervention.

26  
27 269  
28  
29 270 **Study procedure**

30  
31 271 Prospective participants will complete the eligibility survey. This will include demographic  
32  
33 272 questions (e.g., sex, postcode, marital status, level of education, employment status); the Yale  
34  
35 273 Food Addiction Scale 2.0[6] to confirm endorsement of ≥ 3 addictive eating symptoms; the  
36  
37 274 EDE-QS<sup>31</sup> to confirm the absence of purging behaviours. While not necessary to determine  
38  
39 275 eligibility, the Patient Health Questionnaire-8 (PHQ-8),[63] Generalized Anxiety Disorder-7  
40  
41 276 (GAD-7),[60] Perceived Stress Scale-4,[61] Patient Activation Measure 13,[70] and two  
42  
43 277 questions relating to previous treatments sought for addictive eating, will also be completed  
44  
45 278 by potential participants. These questions have been specifically added to extend our  
46  
47 279 previously reported research[75] regarding the types of individuals recruited into interventions  
48  
49 280 for addictive eating.

50  
51 281  
52  
53 282 Participants deemed eligible will proceed to the online consent form (Figure 1. Overview of  
54  
55 283 study schedule). Participants will be given a two-week period to consider participation. After  
56  
57 284 this time, a member of the research team will contact any individuals via email who have not  
58  
59  
60

completed the consent form to determine their interest in participating. Following this, no other contact will be made. Participants who provide electronic written consent will complete the baseline assessment surveys measuring dietary intake and eating habits, traits associated with personality and risk of addictive behaviour, quality of life and healthcare service utilisation (Table 1. Schedule of measurements). The surveys take approximately 40 minutes to complete. On completion of baseline surveys, participants will be randomly allocated to one of three groups (Group 1: active intervention; Group 2: passive intervention; or Group 3: control; see *Intervention* description) and informed of their group allocation via email.

#### Figure 1. Overview of the study schedule

Following randomisation (see *Randomisation and Blinding*), a member of the research team will contact participants in Group 1 via telephone or email to arrange an appointment time for their initial telehealth session. Groups 1 and 2 will be emailed a copy of the program workbook (printable and fillable PDF versions); a hard copy is available for participants on request; and be provided with password protected access to the program website at this time. Telehealth sessions 2 – 5, for participants allocated to the active intervention group (Group 1), will be arranged during their first telehealth session.

Participants from all three groups will receive results from the eligibility and/or baseline surveys by the research team via email. On survey completion, Groups 1 and 2 will receive feedback on dominant trait/s that may be associated with increased risk for addictive behaviours (e.g., anxiety-proneness, impulsivity-proneness); symptoms of addictive eating; dietary, caffeine and alcohol intake; sleep hygiene and physical activity levels. At this timepoint, Group 3 will only receive feedback on dietary intake via email. At 6-months post study commencement, Group 3 will be provided with feedback on trait/s associated with personality and risk of addictive behaviour; symptoms of addictive eating; sleep hygiene and physical activity levels, along with access to the workbook and website (the passive intervention that Group 2 received

1  
2  
3 313 at baseline). To ensure consistency across participants, email templates and standardised  
4  
5 314 reports will be used by the research team. Group 2 will be guided with written instructions in  
6  
7 315 their workbook on how to utilise their survey results to allow personalised goal setting  
8  
9 316 regarding their dietary intake and eating patterns.  
10

11 317  
12  
13 318 The primary and secondary outcomes will be assessed at 3-months (primary endpoint,  
14  
15 319 immediate post-active intervention period) and 6-months (follow-up) where participants will  
16  
17 320 complete post-program surveys (Table 1. Schedule of measurements). Participants will be  
18  
19 321 sent reminder emails to complete their surveys. They will be reminded a maximum of three  
20  
21 322 times at each time point. If no contact is received after such time, no further contact will be  
22  
23 323 made. Participants will be remunerated with a gift voucher to the value of AUD20 at the  
24  
25 324 completion of baseline, 3-month and 6-month surveys, corresponding to a maximum of AUD60  
26  
27 325 per participant over the course of the study.  
28  
29  
30 326

31  
32  
33 327 **Randomisation and Blinding**

34  
35 328 Following completion of baseline assessments, participants will be stratified into 4 groups by  
36  
37 329 sex and mental health status (presence or absence, based on either depression, scale PHQ-  
38  
39 330 8 scores  $\geq 15$  or below 15, or anxiety scale GAD-7 scores  $\geq 11$  or below 11). Participants within  
40  
41 331 each of these four groups will be randomised to one of the three study groups in equal ratios  
42  
43 332 using permuted block randomisation, with block sizes of six. Randomisation will promote group  
44  
45 333 balance on these variables shown to be important in past cross-sectional research (for  
46  
47 334 example, [7, 8, 10, 75]). The randomisation sequence will be generated by an independent  
48  
49 335 statistician and implemented by a designated study co-ordinator. The allocation list will be  
50  
51 336 stored in a password protected computer file and accessed only by the study co-ordinator.  
52

53 337  
54  
55 338 Due to the telehealth nature of the active intervention, blinding of participants and dietitians to  
56  
57 339 intervention group allocation in this study will not be possible. However, several strategies will  
58  
59 340 be employed to reduce the risk of bias. First, participants will only be provided with partial  
60



information on the study hypotheses. Second, all communication between participants and research staff during the period of intervention (i.e., scheduling concerns, questions regarding the intervention) will be done directly between participants and the 'study co-ordinator' or their respective 'telehealth clinician'. Lastly, statistical analyses will be conducted by researchers who are blind to group allocation prior to analysis.

## Intervention

The intervention study arms are:

- Group 1. Active intervention: targeting change in addictive eating behaviours using a multicomponent clinician led approach (telehealth sessions, program workbook and program website)
- Group 2. Passive intervention: targeting change in addictive eating behaviours using a multicomponent self-guided approach (program workbook and program website)
- Group 3. Control: dietary feedback, via paper-based report, provided at baseline and participants follow their usual dietary pattern for six months.

The comparator groups were chosen to provide a passive delivery option of the program which would be consistent with a self-guided Cognitive Behaviour Therapy approach (Group 2), and a control group consistent with a standard version of dietary feedback (Group 3). The control group is not a wait list control, however participants in this group will be offered access to the passive intervention (i.e., program workbook and program website) after the completion of the 6-month assessment.

**TRACE Active Intervention (Group 1):** Participants will receive five standardised one-on-one telehealth/phone sessions with an Accredited Practising Dietitian, with training in behaviour change and eating disorders, over a 3-month period (i.e., weeks 1, 2, 4, 8 and 12). Additionally, dietitians leading the intervention delivery will have extensive experience in private practice work and working with clients including those with disordered eating and those



with mental health conditions. Sessions will range from 15-45 mins. Telehealth sessions will be provided via the VSee platform ([www.vsee.com](http://www.vsee.com)). The active intervention uses personalised feedback, skill-building exercises, and goal setting to help individuals reduce their symptoms of addictive eating and improve their dietary intake, and relationship with food (see Table 2 for *Overview of intervention sessions*). The intervention is personalised based on an individual's dominant trait/s associated with personality and risk of addictive behaviour (i.e., the traits: depression proneness, anxiety proneness, sensation proneness and/or impulsivity proneness; measured via The Substance Use Risk Profile Scale<sup>37</sup> which the individual scores the most highly for) and addresses a range of factors that influence behaviour, both internal and external. Further, dominant trait/s associated with personality and risk of addictive behaviour are mapped to specific coping skill strategies which are in turn incorporated into the goal setting process. As part of session 1, the first 15 mins of the consultation will be audio recorded to enable qualitative analysis of responses to standardised questions regarding two elements of 'control' and 'compulsion' around the participant's food intake. These two themes were previously identified, through thematic analysis of the feasibility study data,[76] as having an influential relationship with addictive eating behaviours. On completion of the five telehealth sessions, participants will be invited to join a closed Facebook group from 3-months post commencement of the intervention until the 6-month outcome survey measures are conducted. Joining the Facebook group is voluntary.

**Table 2.** Overview of intervention sessions

Session	Session aims
1) Personality (Week 1: 45 mins)	<ul style="list-style-type: none"><li>• Introduce the intervention</li><li>• Determine participant's main concerns with their food intake</li><li>• Provide feedback on baseline scores of addictive eating</li><li>• Discuss what this means when attempting and preparing to make changes</li><li>• Provide feedback on traits associated with personality and risk of addictive behaviour</li></ul>

Session	Session aims
	<ul style="list-style-type: none"> <li>• Discuss how personality traits may relate to food intake and addictive eating, and what this means for the individual</li> <li>• Discuss coping strategies based on personality traits and complete 'Urge Surfing' activity</li> <li>• Introduce 'Distraction List'</li> <li>• Set homework task: choose and practice 2 coping strategy exercises</li> <li>• Provide session summary</li> </ul>
<b>2) Food</b> <b>(Week 2: 45 min)</b>	<ul style="list-style-type: none"> <li>• Review session 1</li> <li>• Check in for episodes of overeating</li> <li>• Discuss progress with homework task - coping strategies</li> <li>• Provide feedback on dietary intake</li> <li>• Discuss core vs non-core food intake (Optional: discuss alcohol intake)</li> <li>• Develop 3 nutrition goals using <i>SMARTER Goal Checklist</i> <ol style="list-style-type: none"> <li>1) Positive – increase core foods</li> <li>2) Reduction – decrease non-core foods</li> <li>3) 'Eating awareness' – using strategies to delay or halt overeating</li> </ol> </li> <li>• Discuss enablers/barriers when making changes to eating habits</li> <li>• Discuss 'No Money No Time' website (<a href="http://www.nomoneynotime.com.au">www.nomoneynotime.com.au</a>)</li> <li>• Discuss 'Practical Strategies to Achieve Goals'</li> <li>• Set homework task: complete 'Triggers for Overeating Checklist'</li> <li>• Provide session summary</li> </ul>
<b>3) Skills</b> <b>(Week 4: 30 min)</b>	<ul style="list-style-type: none"> <li>• Review session 2</li> <li>• Assess progress with SMARTER goals</li> <li>• Check in for episodes of overeating</li> <li>• Discuss homework task - 'Triggers for Overeating'</li> <li>• Explore strategies to overcome triggers, building on previous coping strategies and 'Practical Strategies to Achieve Goals'</li> <li>• Discuss and determine a 'food line' to identify when eating is no longer enjoyable or not tasting food</li> <li>• Discuss strategies to stay below the 'food line'</li> <li>• Set homework task: complete 'Mood Monitor' worksheet</li> </ul>

Session	Session aims
	<ul style="list-style-type: none"><li>● Provide session summary</li></ul>
<b>4) Confidence (Week 8: 30 min)</b>	<ul style="list-style-type: none"><li>● Review session 3</li><li>● Discuss progress with plan to stay below 'food line' and for episodes of overeating</li><li>● Explore enablers/barriers to achieving goals</li><li>● Discuss homework task - 'Mood Monitor', and explore emotions that participant has difficulty coping with</li><li>● Discuss seeing emotions differently</li><li>● Explore coping strategies for difficult emotions</li><li>● Discuss importance of sleep, physical activity, and responsible intake of alcohol for emotional health</li><li>● Discuss implementing coping skills plan to achieve SMARTER goals (i.e. consolidate information from sessions 1 – 4)</li><li>● Set homework task: practice implementation of coping skills plan to achieve goals</li><li>● Provide session summary</li></ul>
<b>5) Moving forward (Week 12: 20 mins)</b>	<ul style="list-style-type: none"><li>● Review session 4</li><li>● Check in/briefly problem solve and encourage participant to continue with goals and strategies</li><li>● Discuss topics from previous sessions (participant led)</li><li>● Reassess confidence to achieve goals</li><li>● Provide final <i>Addictive Eating Action Plan</i></li><li>● Discuss how support group on Facebook works and encourage sign up</li></ul>

*Participant Workbook and Program Website:* Participants will have access to a participant workbook and password protected access to a study specific website, both built for the study to support the materials discussed in the intervention sessions. To further facilitate the co-design process, the workbook and website content was piloted with end users (n=2) with lived experience of addictive eating, who participated in the iKT interviews/workshops. The end users reported the workbook and website to be highly usable in terms of the content, and the language used throughout as appropriate with only minor modifications made. Additionally, the piloting process allowed the estimated time to complete each workbook module to be calculated.

400

401 *Program Workbook:* The workbook consists of five modules: 1) Personality; 2) Food; 3) Skills;  
402 4) Confidence; and 5) Moving forward. The content of the five modules mirrors that of the  
403 telehealth sessions. The workbook also contains reflective activities/worksheets, discussed  
404 during the telehealth sessions, for the participants to complete. These elements were deemed  
405 important during the iKT process. The amount of time spent completing activities in the  
406 workbook each week, between telehealth sessions, will take approximately 30 - 60 minutes.  
407 However, the time to complete each module may vary from person to person, and participants  
408 are advised to work through the workbook at a pace that is right for them.

409

410 *Program Website:* The website includes the following pages: 1) Home/Landing page: brief  
411 information about the program and login; 2) Dashboard: navigation page to access each of  
412 the program's module pages; 3) Module pages: each of the five modules within the  
413 intervention has a separate page on the website. This includes additional resources to  
414 complement the telehealth sessions and workbook; and 4) About us: brief information about  
415 the research/clinician team behind the program, including contact information (email). The  
416 website will be available for a period of 12 months from study commencement. All data  
417 captured from the website will be encrypted and stored securely on a server.

418 *Program Facebook Group:* This is a voluntary part of the study which aims to further support  
419 participants with behaviour change. The Facebook forum is set up as a private Facebook  
420 group. Participants can use their standard Facebook login, or alternatively, create a new login  
421 (a pseudo account) that does not identify them if they wish to remain anonymous. Participants  
422 will be prompted with information related to the intervention for the 3-month duration in the  
423 form of short posts, blogs, and polls. The Facebook group will allow participants to engage  
424 with other participants from the program, as well as serve as a communication method to  
425 remind participants about assessments for the study.

426

1  
2  
3 427 The Facebook forum has the following restrictions: 1) Membership will be by invitation only;  
4  
5 428 2) The group will not appear in search results or the participants Facebook profile; and 3) Only  
6  
7 429 group members will be able to see the group information and group posts. Participants will be  
8  
9 430 advised of the appropriate use of language and etiquette for using the social media/discussion  
10  
11 431 forum in the workbook and reminded at the final telehealth session. The Facebook group will  
12  
13 432 be moderated by a member of the research team via the TRACE research Facebook account.  
14  
15  
16 433  
17  
18 434 *Intervention fidelity:* A detailed clinician manual will be used by the dietitian for all telehealth  
19  
20 435 sessions to maintain treatment fidelity. Dietitians administering the intervention will be trained  
21  
22 436 by the principal investigator prior to study implementation. Dietitians will also follow each  
23  
24 437 session as outlined in the manual and keep a dietitian log of participants telehealth sessions.  
25  
26 438 Further, five participants allocated to Group 1, with their consent, will have all their telehealth  
27  
28 439 sessions audio recorded. The dietitian log and audio recordings will be reviewed by an  
29  
30 440 independent researcher to ensure the intervention was delivered as intended. Regular  
31  
32 441 supervisory meetings will be conducted with the dietitians and program coordinator led by the  
33  
34 442 principal investigator. Participant adherence to the intervention will be assessed by a session  
35  
36 443 attendance checklist completed by a member of the research team. Dietitians administering  
37  
38 444 the telehealth sessions will monitor completion of homework tasks and workbook activities at  
39  
40 445 the start of telehealth sessions 2 to 5. Assistance will be provided by the dietitian at this time  
41  
42 446 if participants experienced any difficulties completing the homework tasks/activities.  
43  
44 447 Additionally, to assist with adherence, on completion of each telehealth session the dietitian  
45  
46 448 will email a personalised ‘Addictive Eating Action Plan’, completed on a standardised template,  
47  
48 449 to the participant.  
49  
50  
51 450  
52  
53 451 **TRACE Passive Intervention (Group 2):** Participants will receive the intervention via self-  
54  
55 452 guided approach, with access to the five-module workbook and website (as described above),  
56  
57 453 but without the telehealth consults. The content of the workbook modules mirrors the content  
58  
59 454 of the five telehealth sessions. In addition to the written materials provided, the workbook  
60

contains spaces for reflective activities, documenting goals and monitoring progress. Participants will be asked, on receipt of the workbook, to complete the workbook within a 3-month period. The proportion of the workbook completed by participants in the passive intervention arm will not be monitored. Following the 3-month self-guided learning period, participants will be invited to join the closed Facebook group as described above.

**Control (Group 3):** Participants will receive personalised dietary feedback on baseline surveys, provided by an automated report, generated from the Australian Eating Survey. This is consistent with standard dietary feedback from a dietitian. Participants in the control group will be offered access to the participant workbook and study website after the completion of the 6-month assessment.

### **Patient and public involvement**

Consumer (i.e., individuals with lived experience of addictive eating who participated in the pilot study) input was received on the pilot version of the intervention (FoodFix process evaluation[24]) that directly guided the enhancement of the TRACE telehealth sessions. The TRACE program workbook and website for the current study was developed following the pilot study. A sample of consumer representatives (individuals with lived experience of addictive eating and healthcare experts including clinicians and managers), independent of those involved in the pilot study, were involved in the review of the program and program materials.[49]

Consumer representatives were interviewed to:

- Identify what individuals with addictive eating need and want more accurately
- Gather information about what works well and what needs improving, first-hand from consumers who may use them
- Openly consider different or opposing views about aspects of the research project

- Test resources during development and refine resources making sure they will work well in practice
- Detect any unforeseen consequences of a particular decision or direction that has been made regarding the project
- Gain support of consumers to implement changes to the research project

The opinion of consumers has been considered to create a program that:

- Aligns to the needs of the people it is trying to help i.e., individuals with addictive eating
- Is beneficial in terms of delivering meaningful outcomes for individuals with addictive eating
- Is conducted in a way that is sensitive to peoples' needs

Consumers were not involved in the design of the current study, the selection of outcome measurements, research questions or the recruitment of additional participants. However, consumers were involved in the overall concepts employed in the study and may be called upon at the dissemination stage. For example, to review plain language summaries of the results, provide advice on ways to communicate/translate our findings, or present our findings to the community. Participants of the current study can request a plain English summary of the study outcomes on its completion.

**Outcome measures**

All outcome measures are completed at baseline, 3 months (immediate post-active intervention period) and 6 months (follow-up) via online surveys. The same survey tools will be used at each time point. Participants will receive assessment reminders by email. (Reference to where data collection forms can be found is included in Supplementary Material 2)

## 509 **Primary outcomes**

510 **Addictive eating symptoms and severity:** The Yale Food Addiction Scale (YFAS 2.0)[6] will  
511 be used to assess the change in addictive eating symptomatology and severity. The YFAS  
512 2.0 is a validated self-report 35-item questionnaire. The YFAS 2.0 asks participants to think of  
513 specific foods they have had difficulty controlling the consumption of within the past 3 months  
514 (e.g., ice cream, chocolate, chips, hamburgers). The YFAS 2.0 provides an addictive eating  
515 symptom score ranging from zero to 11. Additionally, two items assess clinically significant  
516 impairment or distress from eating. A 'food addiction diagnosis' can be given when  $\geq 2$   
517 symptoms are endorsed, and clinically significant impairment or distress is present. However,  
518 for the purpose of this study a 'food addiction diagnosis' will not be given, and severity of  
519 addictive eating will be classified in accordance with YFAS scoring instructions as follows:  
520 "mild" = 3 symptoms, "moderate" = 4-5 symptoms or "severe"  $\geq 6$  symptoms. The YFAS 2.0  
521 has been found to be a robust and psychometrically sound measure of addictive eating  
522 symptomatology in non-clinical[2, 77] and clinical populations with good test/retest validity.[78]  
523 Preliminary evidence[23, 24] suggests that YFAS scores are sensitive to change and are  
524 decreased after intervention.

## 526 **Secondary outcomes**

527 **Dietary intake and quality:** Changes in dietary intake and quality will be measured using the  
528 Australian Eating Survey (AES).[64] The following dietary outcomes will be measured: (1) core  
529 foods and non-core foods percentage contribution to total energy intake; (2) average daily  
530 energy intake, proportion of total energy intake contributed by macronutrients, micronutrient  
531 intakes; and (3) overall diet quality. The AES is a validated 120-item semi-quantitative Food  
532 Frequency Questionnaire that assesses usual food and nutrient intakes over the previous 3-6  
533 months. The AES includes a comprehensive list of foods, including drinks, milk and dairy  
534 foods, breads and cereals, sweet and savoury snacks, main meals, other foods, vegetables  
535 and fruit. Frequency response options for each food, or food type, range from 'never' to ' $\geq 7$   
536 times per day'. The AES has been assessed for comparative validity relative to weighed food



1  
2  
3 537 records and for fruit and vegetable intakes using plasma carotenoids.[64, 65] Standard portion  
4  
5 538 sizes for adult men and women have been determined for each AES item in the survey, using  
6  
7 539 data from the most recent Australian National Nutrition Survey. The food and beverage weight  
8  
9 540 per serving, used in the calculation of food group servings (as serves per day) is consistent  
10  
11 541 with sizes specified in the Australian Guide to Healthy Eating.[64, 65, 79] Nutrient intakes from  
12  
13 542 the AES Food Frequency Questionnaire were computed using data in the AUSNUT 2011–13  
14  
15 543 database.[80] The AES also provides an Australian Recommended Food Score (ARFS),  
16  
17 544 derived from a subset of 70 AES questions, as a measure of diet quality that reflects the overall  
18  
19 545 healthiness and nutritional quality of an individual's usual eating pattern.[65] The ARFS is  
20  
21 546 based on the frequency of consumption of core foods, recommended in the Australian Dietary  
22  
23 547 Guidelines,[81] with foods awarded one point for a consumption frequency of  $\geq$ once per week.  
24  
25 548 The total score is calculated by summing the points for each item and scores can range from  
26  
27 549 zero to 73, with higher scores awarded for greater dietary variety.[65]  
28  
29  
30  
31

32  
33 551 **Depression, anxiety and stress:** Changes in symptom scores for depression, anxiety and  
34  
35 552 stress will be measured using the Patient Health Questionnaire (PHQ-8),[63] the Generalized  
36  
37 553 Anxiety Disorder 7 (GAD-7)[60] and the Perceived Stress Scale (PSS-4),[61] respectively. The  
38  
39 554 PHQ-8 is a validated self-report 8-item tool that asks the individual to rate the severity of  
40  
41 555 depressive symptoms over the past two weeks from 0 ('not at all') to 3 ('nearly every day').  
42  
43 556 Total scores for the 8 items range from 0 to 24, and severity will be determined using the  
44  
45 557 following cut-offs: 0-4 = minimal, 5-9 = mild, 10-14 = moderate, 15-19 = moderately severe,  
46  
47 558 and 20-24 = severe.[63] The GAD-7 is a validated self-report 7-item tool that asks the  
48  
49 559 individual to rate the severity of symptoms over the past two weeks from 0 ('not at all sure') to  
50  
51 560 3 ('nearly every day'). GAD-7 total scores range from 0 to 21, and severity is determined using  
52  
53 561 the following cut-offs: 0-5 = mild, 6-10 = moderate, 11-15 = moderately severe, and 15-21 =  
54  
55 562 severe.[60] The PSS-4 is a validated self-report 4-item tool that assesses the degree to which  
56  
57 563 a person perceives life as stressful.[61] The questions have been designed to assess how  
58  
59 564 unpredictable, uncontrollable, and overloaded a person feels their life to be. Frequency over  
60

the previous month is rated on a five-point Likert scale ranging from 'Never' to 'Very often'. PSS-4 total scores range from 0 to 16, and higher scores indicate greater stress.[61] Currently, there is no established cut-off for the PSS-4 score to indicate adverse levels of stress.

### **Other outcomes**

A selection of other outcomes was chosen based on co-occurring health conditions (see Table 1 for schedule of measurements).

**Quality of Life:** Changes in subjective quality of life will be measured using the EQ-5D-5L.[71] The EQ5D-5L is a validated self-report 5-item tool to assess health-related quality of life. A descriptive system comprising five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems (labelled 1–3). Participants are asked to indicate their health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results into a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes respondent's health state. The EQ-5D-5 L will be analysed to produce an index score between 0 (state of death) and 1 (perfect health).

**Physical activity level:** Changes in physical activity level will be measured using the Active Australia Survey (AAS).[72] The AAS is a validated self-report tool containing eight core questions to assess participation (hours/mins per week) in moderate and vigorous intensity physical activity and walking for recreation, over the previous week.

**Sleep hygiene behaviours:** Changes in sleep hygiene behaviours will be measured using the Pittsburgh Sleep Quality Index (PSQI).[73] The PSQI is a validated self-report survey with 19 self-rated items and 5 items rated by the bed partner or roommate (if applicable). The tool assesses seven components of sleep to provide one global score. Components measured

1  
2  
3 593 include 1) Subjective sleep quality, 2) Sleep latency, 3) Sleep duration, 4) Habitual sleep, 5)  
4  
5 594 Sleep disturbances, 6) Use of sleeping medication, and 7) Daytime dysfunction. The overall  
6  
7 595 global score of sleep quality will be calculated, and the subcomponents reported.  
8  
9  
10 596

11 597 **Health care utilisation:** For the purpose of conducting a cost analysis the Consumer Services  
12  
13 598 Receipt Inventory (CSRI)[74] will be completed by participants at each time point. The CSRI  
14  
15 599 is an adaptable tool that ensures the format, language, scope and content is compatible with  
16  
17 600 the research aims, context, participants' likely circumstances, and the quantity and precision  
18  
19 601 of information required.[82] Health care utilisation is captured through self-report and includes  
20  
21 602 information on the number of appointments and type of health care services used in the  
22  
23 603 preceding 3 months.  
24  
25

26 604  
27  
28 605 **Cost analysis:** A cost-consequence analysis will be conducted including calculating the cost  
29  
30 606 of each intervention (i.e., active, passive and control) and reporting intervention costs  
31  
32 607 alongside mean change outcomes. Intervention costs will be recorded in terms of cost of  
33  
34 608 intervention development, intervention delivery and the operating costs of the RCT. Outcomes  
35  
36 609 to be reported as part of the cost analysis will include mean change in addictive eating  
37  
38 610 symptom scores assessed using the YFAS (i.e. the primary outcome), as well as mean change  
39  
40 611 in the number of health care appointments in the past 3-months assessed using the CSRI,  
41  
42 612 and mean change in Quality Adjusted Life Years (QALYs) assessed using the EQ-5D-5L. This  
43  
44 613 approach was selected to provide a comprehensive and transparent overview of intervention  
45  
46 614 costs, given the lack of cost analysis data in this area of research.[83, 84]  
47  
48  
49

50 615  
51  
52 616 **Mediators/Moderators**

53 617 The following potential mediators and moderators of intervention efficacy will be examined:  
54  
55 618  
56  
57 619 **Trait/s associated with personality and risk of addictive behaviour:** Participant's will  
58  
59 620 complete the Substance Use Risk Profile Scale (SURPS)[66] at baseline to determine their  
60

dominant trait/s. The SURPS is a validated self-report 23-item survey that assess four traits associated with increased risk for addictive behaviours (Impulsivity proneness, Sensation proneness, Depression proneness, and Anxiety proneness).

**Eating behaviours:** Eating behaviours that have been shown to have overlap with addictive eating will be measured. This includes eating disorders, binge eating, grazing behaviours and reward driven eating. Eating disorders will be measured using the Eating Disorder Examination Questionnaire 6.0 (EDEQ-6.0)[62] The EDEQ-6.0 is a validated self-report 28-item questionnaire that assesses the occurrence and frequencies of key eating disorder behaviours with cognitive subscales related to eating disorders (restraint, eating concern, shape concern, and weight concern) and behavioural symptoms related to these concerns (e.g. frequency of binge eating, vomiting, use of laxatives or diuretics, and overexercise). Subscale and global scores reflect the severity of eating disorder psychopathology. Binge eating will be measured using the Binge Eating Scale (BES).[67] The BES is a validated self-report 16-item questionnaire to assess the presence of certain binge eating behaviours, over the past 28 days, which may be indicative of an eating disorder. Each item contains 3-4 statements about behaviours, thoughts, and emotional states. Grazing behaviours will be measured using the Short Inventory of Grazing (SIG).[68] The SIG is a validated self-report 2-item measure to assess 1) the presence and frequency of grazing in general, and 2) the presence and frequency of grazing accompanied by a sense of loss of control. Reward driven eating will be measured using the Reward-Based Eating Drive Scale (REDX-5).[69] The REDX-5 is a validated self-report 5-item questionnaire, in 5-point Likert scale format from 1 (strongly disagree) to 5 (strongly agree), that assesses reward-driven eating (loss of control over eating, lack of satiety, and preoccupation with food).

**Participant Activation Level:** Participant's underlying knowledge, skills and confidence in managing their addictive eating behaviours and overall health will be measured using the Patient Activation Measure (PAM-13).[85] The PAM-13 is a validated self-report 13-item scale

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

649 that draws on concepts such as health locus of control, self-efficacy in managing health  
650 behaviours and readiness to change health behaviours.[70, 86] Higher PAM-13 scores  
651 indicate that individuals have higher levels of activation, and understand their role in the self-  
652 management process and feel capable of fulfilling that role.[87] Research has demonstrated  
653 that a single point change in PAM score is meaningful.[88]

**Engagement and use of the program website and Facebook group:** Interaction with the  
656 website will be objectively tracked throughout the study (baseline to 6 months i.e., timepoints  
657 1 to 3) using Google Analytics (Google LLC). Measures of engagement and usage will include  
658 number of website visits, website visit duration, number of page views and links  
659 accessed/resources downloaded.

660  
661 Interaction with the Facebook group will be measured throughout the post-intervention period  
662 (3 to 6 months from baseline i.e., timepoints 2 to 3). Measures of engagement and usage will  
663 include number of participants to join the Facebook group, and number of views, likes and  
664 comments per post.

**Study sample characteristics**

667 Sociodemographic data will be collected by online questionnaire at baseline. Participants will  
668 provide information on their age, sex, marital status, postal code, years of education,  
669 employment status and current living situation. Index of Relative Socio-Economic  
670 Disadvantage (IRSD) score,[89] based on the Australian Bureau of Statistics census data and  
671 reflecting a proxy index of socioeconomic status, will be determined by postal code of  
672 residence. Current smoking and substance use will be measured using the Alcohol, Smoking  
673 and Substance Involvement Screening Test - Version 3.0.[59] Additionally, previous treatment  
674 sought for overeating from health professionals or products used to treat overeating will be  
675 collected.

Anthropometric data (self-reported height and weight) will be collected by online questionnaire at baseline. BMI will be calculated using standardised techniques and categorised according to the World Health Organization adult cut-off points.[90]

680

### 681 **Sample size**

The sample size for the study was calculated based on data from the feasibility study,[24] given the absence of other intervention studies. Through guidance with statisticians, a large effect size was chosen and needed to enable the possibility of a clinically meaningful result. A clinically meaningful difference in symptoms of addictive eating was selected as a decrease of 2 symptoms, given this would correspond to a change in severity classification on the YFAS 2.0 tool. To detect a mean 2-unit difference ( $SD = 2.2$ ) in the YFAS symptoms between the active intervention group and the passive intervention group or control group and using a standardised effect size of  $d=0.91$ , a sample size of 32 individuals per group (total sample size  $n=96$ ) is required to detect this change with a power of 0.90 and a type 1 error rate set at 0.025 to account for multiple testing. However, allowing for a 30% dropout rate from the pilot, a sample size of 46 individuals per group (total sample size  $n=138$ ) would be required. Therefore, a total sample size of 150 individuals, with 50 per group, was chosen to remain conservative.

695

### 696 **Statistical analysis plan**

Data analysis will be conducted by a researcher blinded to the intervention conditions. Descriptive statistics of sample characteristics will be presented. For the primary YFAS outcome a Linear Mixed Model (LMM) will be based on a model with main effects for group (active intervention, passive intervention, control) and time (treated as categorical at levels baseline, 3 and 6 months), and the group-by-time interaction. An unstructured residual covariance structure will be used to allow for correlation between the repeated measurements for a subject. The primary outcome effect will be reported as the difference between means at baseline and 3 months, with a 95% CI for the difference. Mental health condition and BMI will

1  
2  
3 705 be examined for possible moderating effects on the effect size, and if so adjustment for them  
4  
5 706 will be carried out. Secondary descriptive analysis will be carried out to identify whether  
6  
7 707 specific symptoms were predominantly associated with reductions in YFAS score.  
8  
9  
10 708

11 709 A secondary outcome will be a categorical variable, clinically significant change from baseline  
12  
13 710 to 3 months, where significant requires a reduction of 2 or more symptoms in the YFAS. This  
14  
15 711 will be analysed using logistic regression with group being the only factor. Additional  
16  
17 712 secondary outcomes will include dietary outcomes (average daily energy intake, proportion of  
18  
19 713 total energy intake contributed by core foods and non-core foods intakes, macronutrients  
20  
21 714 intakes, micronutrient intakes; and overall diet quality) and mental health status (depression,  
22  
23 715 anxiety and stress scores). These will also be analysed using LMMs as per the approach  
24  
25 716 above. All available data will be used with no imputation of missing values at 3 and 6 months,  
26  
27 717 however baseline scores will be kept. The participants will be analysed according to their  
28  
29 718 allocated randomisation group consistent with an intention-to-treat analysis. Statistical  
30  
31 719 significance will be set at 0.05.  
32  
33  
34  
35 720

36  
37 721 **Data management and monitoring**

38  
39 722 Online survey data will be managed using REDCap electronic data capture tools[91, 92]  
40  
41 723 hosted at the University of Newcastle. REDCap (Research Electronic Data Capture) is a  
42  
43 724 secure, web-based software platform designed to support data capture for research studies,  
44  
45 725 providing 1) an intuitive interface for validated data capture; 2) audit trails for tracking data  
46  
47 726 manipulation and export procedures; 3) automated export procedures for seamless data  
48  
49 727 downloads to common statistical packages; and 4) procedures for data integration and  
50  
51 728 interoperability with external sources.  
52  
53  
54 729

55  
56 730 All data captured from the study website will be encrypted and stored securely on the server.  
57  
58 731 All other data collected will be entered into a password protected central database which is  
59  
60 732 hosted on secure university-based servers, which comply with robust security standards for

clinical data and are subject to daily backups and regular offsite backups. Only authorised members of the research team will have access to the database. Research staff handling study data are trained in procedures for handling sensitive information, accurate data entry, surveillance and intervention-specific data storage and data archive. Facilitators of the telehealth sessions are responsible for the electronic storage of study forms on the central database. All completed forms will be checked for completeness and accuracy, first by data collectors and later by a member of the research team responsible for data management. Throughout the study period (at 25% and 50% of required participants) approximately 5% of records will be randomly selected for data quality checks of accuracy and completeness by an independent reviewer.

A Data Safety Monitoring Board will not be established for this study as all elements of the intervention have been previously explored and used in interventions. To monitor for potential risks, the study co-ordinator managing the day-to-day conduct of the trial, and facilitators of the telehealth sessions, will report weekly to the Chief Investigator. Oversight concerning the overall conduct of the trial will be provided by our multi-disciplinary research team. This will include regular meetings to review protocol adherence, participant retention rates and safety reports. For the entire study period, any adverse events, of any kind, that might be related to either the trial intervention or trial procedures will be logged in an adverse event log and reported to the Human Research Ethics Committee by the Chief Investigator. To maintain the welfare of participants, with their consent, relevant survey results from the GAD-7[60] and PHQ-8[63] will be sent to the participant's nominated General Practitioner/ health professional if they score in the severe category for either anxiety (GAD-7 scores  $\geq 16$ ) or depression (PHQ-8 scores  $\geq 20$ ) if participants consent to this disclosure.

## **Study sponsorship and organisation**



1  
2  
3 759 The sponsor of the trial is the University of Newcastle, and funding was provided by the  
4  
5 760 National Health and Medical Research Council (NHMRC). The trial will be conducted and  
6  
7 761 evaluated independent of the study sponsor and funder. The study is coordinated  
8  
9 762 independently of the study sponsor and funder, by researchers at the University of Newcastle,  
10  
11 763 Australia with the study overseen by the trial management committee comprising the chief  
12  
13 764 investigators.  
14  
15  
16 765

17  
18 766 **Ethics and dissemination**

19  
20 767 The trial will be undertaken in compliance with the Declaration of Helsinki and approval to  
21  
22 768 conduct the study was received from the University of Newcastle Human Research Ethics  
23  
24 769 Committee (H-2021-0100). This trial adheres to the SPIRIT guidelines for randomised trials  
25  
26 770 protocols[51] and the results will be reported in accordance with CONSORT guidelines  
27  
28 771 (TIDieR checklist and guide[50]). Protocol modifications will be registered with the Ethics  
29  
30 772 Committee and trial register. All participants will provide electronic consent to participate prior  
31  
32 773 to completing the eligibility and baseline surveys. Results of the study will be disseminated via  
33  
34 774 peer-reviewed publications and presentations at national and international conferences and  
35  
36 775 will also form part of student dissertations. Data from the TRACE study may be made available  
37  
38 776 in the future for collaborative research questions. Such requests must be authorised by the  
39  
40 777 principal investigators and the appropriate Human Research Ethics Committees.  
41  
42  
43 778

44  
45 779 **Limitations**

46  
47 780 Limitations of the study include the level of experience required of the dietitians administering  
48  
49 781 the telehealth sessions, which may impact the scalability of the intervention. However,  
50  
51 782 dietitians are highly trained professionals in behaviour change and extra care was taken given  
52  
53 783 the uniqueness of the intervention. The fidelity outcomes assessed as part of the trial will  
54  
55 784 provide important information regarding future implementation. Additional limitations include  
56  
57 785 the exclusion of individuals with severe mental illnesses or complex health conditions. The  
58  
59 786 current intervention is not designed for complex co-morbidities. It is envisaged that for these

787 individuals a more complex care model is required where the TRACE program could be  
788 implemented alongside other approaches or treatments.

789

790 Currently there are few published interventions, run by dietitians and/or other health clinicians,  
791 for addictive eating demonstrating the clear need for services and trialing of interventions that  
792 may be effective at facilitating changes in addictive eating behaviours. The TRACE program  
793 was designed to raise awareness, and support behaviour change, of addictive eating. If  
794 successful, our study will provide essential evidence regarding the efficacy of behavioural and  
795 dietary improvement in the management of addictive eating, thus allowing for the  
796 implementation of management strategies for addictive eating into community and clinical  
797 healthcare services. Further, if both the active and passive interventions are found to be  
798 effective it will provide evidence of different levels of care that could be utilised within these  
799 services.

800

801 **Author Contributions:** TLB conceptualised the study, and TLB, JAS, MW, ML, RC, KMP,  
802 AVG, PJH, ALB, LH, SJP, LGW, KC and CEC contributed to the study protocol. TLB, JAS,  
803 MW, ML, RC, KMP, AVG, PJH, ALB, LH, SJP, and CEC contributed to the intervention  
804 development and design, intervention resources and assessment methodology. JAS wrote  
805 the initial manuscript draft. TLB, JAS, MW, ML, RC, KMP, AVG, PJH, ALB, LH, SJP, LGW,  
806 KC and CEC contributed to the writing of the final manuscript and/or provided critical  
807 comments during revisions. All authors approved the final version prior to submission. TLB,  
808 JAS, MW, ML and RC will be responsible for recruitment, data collection and intervention  
809 delivery.

810 **Competing interests:** None declared.

811

812 **Funding:** This work was supported by the National Health and Medical Research Council  
813 (NHMRC) grant number [G1801414].

814

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**References**

1. Davis C. From Passive Overeating to “Food Addiction”: A Spectrum of Compulsion and Severity. *International Scholarly Research Notices Obesity*. 2013; 435027: 1-20. <http://dx.doi.org/10.1155/2013/435027>.

2. Gearhardt AN, Corbin WR, and Brownell KD. Preliminary validation of the Yale Food Addiction Scale. *Appetite*. 2009; 52(2): 430-436. <https://doi.org/10.1016/j.appet.2008.12.003>.

3. Gearhardt AN, Davis C, Kuschner R, et al. The Addiction Potential of Hyperpalatable Foods. *Current Drug Abuse Reviews*. 2011; 4: 140-145. doi: 10.2174/1874473711104030140.

4. American Psychiatric Association, *Diagnostic and statistical manual of mental disorders*. 5th ed. 2013, Arlington: VA American Psychiatric Publishing.

5. World Health Organization. International statistical classification of diseases and related health problems (11th ed.). 2019. <https://icd.who.int/>.

6. Gearhardt AN, Corbin WR, and Brownell KD. Development of the Yale Food Addiction Scale Version 2.0. *Psychology of Addictive Behaviors*. 2016; 30(1): 113-121. <https://doi.org/10.1037/adb0000136>.

7. Burrows T, Kay-Lambkin F, Pursey K, et al. Food addiction and associations with mental health symptoms: a systematic review with meta-analysis. *Journal of Human Nutrition and Dietetics*. 2018; 31(4): 544-572. <https://doi.org/10.1111/jhn.12532>.

8. Pursey K, Stanwell P, Gearhardt A, et al. The prevalence of food addiction as assessed by the Yale Food Addiction Scale: a systematic review. *Nutrients* 2014; 6(10): 4552–4590. <https://doi.org/10.3390/nu6104552>.

9. Pursey KM, Collins CE, Stanwell P, et al. Foods and dietary profiles associated with ‘food addiction’ in young adults. *Addictive Behaviors Reports* 2015; 2: 41–48. <http://dx.doi.org/10.1016/j.abrep.2015.05.007>.

- 841 10. Skinner J, Jebeile H, and Burrows T. Food addiction and mental health in  
842 adolescents: a systematic review. *The Lancet. Child and adolescent health*. 2021;  
843 5(10): 751-766. [https://doi.org/10.1016/S2352-4642\(21\)00126-7](https://doi.org/10.1016/S2352-4642(21)00126-7).
- 844 11. Sanchez I, Lucas I, Munguía I, et al. Food addiction in anorexia nervosa: Implications  
845 for the understanding of crossover diagnosis. *European Eating Disorders Review*.  
846 2022; 30(3): 278–288. <https://doi.org/10.1002/erv.2897>.
- 847 12. Schulte EM and Gearhardt AN. Associations of Food Addiction in a Sample  
848 Recruited to Be Nationally Representative of the United States. *European Eating  
849 Disorders Review*. 2018; 26(2): 112–119. <https://doi.org/10.1002/erv.2575>.
- 850 13. Pursey KM, Skinner J, Leary M, et al. The Relationship between Addictive Eating and  
851 Dietary Intake: A Systematic Review. *Nutrients*. 2021(1): 164.  
852 <https://doi.org/10.3390/nu14010164>.
- 853 14. Burrows T, Hides L, Brown R, et al. Differences in Dietary Preferences, Personality  
854 and Mental Health in Australian Adults with and without Food Addiction. *Nutrients*  
855 2017; 9 (3): E285. <https://doi.org/10.3390/nu9030285>.
- 856 15. GBD 2017 Diet Collaborators. Health effects of dietary risks in 195 countries, 1990-  
857 2017: a systematic analysis for the Global Burden of Disease Study 2017. . *Lancet  
858 (London, England)*,. 2019; 393(10184): 1958–1972. [https://doi.org/10.1016/S0140-  
859 6736\(19\)30041-8](https://doi.org/10.1016/S0140-6736(19)30041-8).
- 860 16. Treasure J, Leslie M, Chami R, et al. Are trans diagnostic models of eating disorders  
861 fit for purpose? A consideration of the evidence for food addiction. *European Eating  
862 Disorder Review*. 2018; 26(2): 83-91. doi: 10.1002/erv.2578.
- 863 17. Wiss DA and Brewerton TD. Incorporating food addiction into disordered eating: the  
864 disordered eating food addiction nutrition guide (DEFANG). *Eating and Weight  
865 Disorders*. 2017; 22(1): 49-59. doi: 10.1007/s40519-016-0344-y.
- 866 18. Burrows T, Skinner J, McKenna R, et al. Food Addiction, Binge Eating Disorder, and  
867 Obesity: Is There a Relationship? *Behavioral Sciences*. 2017; 7(3): pii: E54.  
868 <https://doi.org/10.3390/bs7030054>.

- 869 19. Bao K, French EN, Schleyer B, et al. Food addiction is associated with greater  
870 objective binge eating and eating disorder psychopathology, and higher body mass  
871 index in youth, a meta-analysis. *Psychiatry Research Communications*. 2022; 2(3):  
872 100067. <https://doi.org/10.1016/j.psychom.2022.100067>.
- 873 20. Food Addicts Anonymous. [Homepage]. [cited 2022 24 March]; Available from:  
874 <https://faacanhelpp.org/>.
- 875 21. Overeaters Anonymous. [Homepage]. [cited 2022 24 March]; Available from:  
876 <https://oa.org/>.
- 877 22. McKenna RA, Rollo ME, Skinner JA, et al. Food Addiction Support: Website Content  
878 Analysis. *JMIR Cardio*. 2018; 2(1): e10. <https://doi.org/10.2196/cardio.8718>.
- 879 23. Leary M, Pursey KM, Verdejo-Garcia A, et al. Current Intervention Treatments for  
880 Food Addiction: A Systematic Review. *Behavioral Sciences* 2021; 11(6): 80.  
881 <https://doi.org/10.3390/bs11060080>.
- 882 24. Burrows T, Collins R, Rollo M, et al. The feasibility of a personality targeted  
883 intervention for addictive overeating: FoodFix. *Appetite*. 2021; 156(104974).  
884 <https://doi.org/10.1016/j.appet.2020.104974>.
- 885 25. Chao AM, Wadden TA, Tronieri JS, et al. Effects of addictive-like eating behaviors on  
886 weight loss with behavioral obesity treatment. *Journal of Behavioral Medicine*. 2019;  
887 42(2): 246–255. <https://doi.org/10.1007/s10865-018-9958-z>.
- 888 26. Carbone EA, Caroleo M, Rania M, et al. An open-label trial on the efficacy and  
889 tolerability of naltrexone/bupropion SR for treating altered eating behaviours and  
890 weight loss in binge eating disorder. *Eating and Weight Disorders*. 2021; 26(3): 779–  
891 788. <https://doi.org/10.1007/s40519-020-00910-x>.
- 892 27. Epstein DH, Kennedy AP, Furnari M, et al. Effect of the CRF1-receptor antagonist  
893 pexacerfont on stress-induced eating and food craving. *Psychopharmacology*. 2016;  
894 233(23-24): 3921–3932. <https://doi.org/10.1007/s00213-016-4424-5>.

- 895 28. Sevinçer GM, Konuk N, Bozkurt S, et al. Food addiction and the outcome of bariatric  
896 surgery at 1-year: Prospective observational study. *Psychiatry Research*. 2016; 244:  
897 159–164. <https://doi.org/10.1016/j.psychres.2016.07.022>.
- 898 29. Murray SM, Tweardy S, Geliebter A, et al. A Longitudinal Preliminary Study of  
899 Addiction-Like Responses to Food and Alcohol Consumption Among Individuals  
900 Undergoing Weight Loss Surgery. *Obesity Surgery*. 2019; 29(8): 2700–2703.  
901 <https://doi.org/10.1007/s11695-019-03915-3>.
- 902 30. Gordon EL, Merlo LJ, Durning PE, et al. Longitudinal Changes in Food Addiction  
903 Symptoms and Body Weight among Adults in a Behavioral Weight-Loss Program.  
904 *Nutrients*. 2020; 12(12): 3687. <https://doi.org/10.3390/nu12123687>.
- 905 31. Cassin S, Leung S, Hawa R, et al. Food Addiction Is Associated with Binge Eating  
906 and Psychiatric Distress among Post-Operative Bariatric Surgery Patients and May  
907 Improve in Response to Cognitive Behavioural Therapy. *Nutrients*. 2020; 12(10):  
908 2905. <https://doi.org/10.3390/nu12102905>.
- 909 32. Unwin J, Delon C, Giæver H, et al. Low carbohydrate and psychoeducational  
910 programs show promise for the treatment of ultra-processed food addiction. *Frontiers*  
911 *in Psychiatry*. 2022; 13: 1005523. <https://doi.org/10.3389/fpsy.2022.1005523>.
- 912 33. Carlos LO, Ramos MRZ, Wagner NRF, et al. Probiotic Supplementation attenuates  
913 binge eating and food addiction 1 year after roux-en-y gastric bypass: a randomized,  
914 double-blind, placebo controlled trial. *Arquivos brasileiros de cirurgia digestiva*. 35:  
915 e1659. <https://doi.org/10.1590/0102-672020210002e1659>.
- 916 34. Cassin SE, Sijercic I, and Montemarano V. Psychosocial Interventions for Food  
917 Addiction: A Systematic Review *Current Addiction Reports*. 2020; 7: 9–19.  
918 <https://doi.org/10.1007/s40429-020-00295-y>.
- 919 35. Hides L, Kavanagh DJ, Daglish M, et al. The Quik Fix study: a randomised controlled  
920 trial of brief interventions for young people with alcohol-related injuries and illnesses  
921 accessing emergency department and crisis support care. *BMC Emergency*  
922 *Medicine*. 2014; 14(19). <https://doi.org/10.1186/1471-227X-14-19>.



- 1
- 2
- 3 923 36. Hides L, Wilson H, Quinn C, et al. QuikFix: enhanced motivational interviewing
- 4
- 5 924 interventions for youth substance use. *Advances in Dual Diagnosis*. 2016; 9(2/3):
- 6
- 7 925 53-65. <https://doi.org/10.1108/ADD-03-2016-0008>.
- 8
- 9 926 37. Murphy CM, Stojek MK, and MacKillop J. Interrelationships among impulsive
- 10
- 11 927 personality traits, food addiction, and body mass index. *Appetite*. 2014; 73: 45–50.
- 12
- 13 928 <https://doi.org/10.1016/j.appet.2013.10.008>.
- 14
- 15
- 16 929 38. Davis C. A narrative review of binge eating and addictive behaviors: shared
- 17
- 18 930 associations with seasonality and personality factors. *Frontiers in Psychiatry*. 2013;
- 19
- 20 931 4: 183. <https://doi.org/10.3389/fpsy.2013.00183>.
- 21
- 22 932 39. Brunault P, Ducluzeau PH, Courtois R, et al. Food Addiction is Associated with
- 23
- 24 933 Higher Neuroticism, Lower Conscientiousness, Higher Impulsivity, but Lower
- 25
- 26 934 Extraversion in Obese Patient Candidates for Bariatric Surgery. *Substance Use and*
- 27
- 28 935 *Misuse*. 2018; 53(11): 1919–1923. <https://doi.org/10.1080/10826084.2018.1433212>.
- 29
- 30 936 40. Ouellette AS, Rodrigue C, Lemieux S, et al. An examination of the mechanisms and
- 31
- 32 937 personality traits underlying food addiction among individuals with severe obesity
- 33
- 34 938 awaiting bariatric surgery. *Eating and Weight Disorders*. 22(4): 633–640.
- 35
- 36 939 <https://doi.org/10.1007/s40519-017-0440-7>.
- 37
- 38
- 39 940 41. Jiménez-Murcia S, Agüera Z, Paslakis G, et al. Food Addiction in Eating Disorders
- 40
- 41 941 and Obesity: Analysis of Clusters and Implications for Treatment. *Nutrients*. 2019;
- 42
- 43 942 11(11): 2633. <https://doi.org/10.3390/nu11112633>.
- 44
- 45 943 42. Bunio LK, Battles JA, and Loverich TM. The nuances of emotion regulation difficulties
- 46
- 47 944 and mindfulness in food addiction. *Addiction Research and Theory*. 2021; 29(1): 11-
- 48
- 49 945 17. <https://doi.org/10.1080/16066359.2020.1714038>.
- 50
- 51 946 43. Miller W and Rollnick S. Motivational Interviewing. 3rd ed. New York, NY: Guilford
- 52
- 53 947 Press. 2013.
- 54
- 55
- 56 948 44. Kelly JT, Allman-Farinelli M, Chen J, et al. Dietitians Australia position statement on
- 57
- 58 949 telehealth. *Nutrition and Dietetics: the journal of the Dietitians Association of*
- 59
- 60 950 *Australia*. 2020; 77(4): 406-415. <https://doi.org/10.1111/1747-0080.12619>.

- 1  
2  
3 951 45. Reynolds DJ Jr, Stiles WB, Bailer AJ, et al. Impact of exchanges and client-therapist  
4 952 alliance in online-text psychotherapy. *Cyberpsychology, Behavior and Social*  
5 953 *Networking*. 2013; 16(5): 370–377. <https://doi.org/10.1089/cyber.2012.0195>.  
6  
7  
8 954 46. Scott AM, Clark J, Greenwood H, et al. Telehealth v. face-to-face provision of care to  
9 955 patients with depression: a systematic review and meta-analysis. *Psychological*  
10 956 *Medicine*. 2022; 52(14): 2852–2860. <https://doi.org/10.1017/S0033291722002331>.  
11  
12  
13 957 47. Mark TL, Treiman K, Padwa H, et al. Addiction Treatment and Telehealth: Review of  
14 958 Efficacy and Provider Insights During the COVID-19 Pandemic. *Psychiatric Services*.  
15 959 2022; 73(5): 481-598. <https://doi.org/10.1176/appi.ps.202100088>.  
16  
17  
18 960 48. Gorrell S, Reilly EE, Brosf L, et al. Use of Telehealth in the Management of  
19 961 Adolescent Eating Disorders: Patient Perspectives and Future Directions Suggested  
20 962 from the COVID-19 Pandemic. *Adolescent health, medicine and therapeutics*. 2022;  
21 963 13: 45–53. <https://doi.org/10.2147/AHMT.S334977>.  
22  
23  
24 964 49. Leary M, Pursey KM, Verdejo-Garcia A, et al. Designing an online intervention for  
25 965 adults with addictive eating: A qualitative Integrated Knowledge Translation  
26 966 approach. *BMJ Open*. 2022; 12(6): e060196. [https://doi.org/10.1136/bmjopen-2021-](https://doi.org/10.1136/bmjopen-2021-060196)  
27 967 060196.  
28  
29  
30 968 50. Hoffmann T, Glasziou P, Boutron I, et al. Better reporting of interventions: template  
31 969 for intervention description and replication (TIDieR) checklist and guide. *BMJ*. 2014;  
32 970 348: g1687. <https://doi.org/10.1136/bmj.g1687>.  
33  
34  
35 971 51. Chan A-W, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 Statement: Defining standard  
36 972 protocol items for clinical trials. *Annals of Internal Medicine*. 2013; 158(3): 200-207.  
37 973 <https://doi.org/10.7326/0003-4819-158-3-201302050-00583>.  
38  
39  
40 974 52. Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 statement: updated  
41 975 guidelines for reporting parallel group randomised trials. *BMJ*. 2010; 340(c332).  
42 976 <https://doi.org/10.1136/bmj.c332>.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

977 53. Purna Singh A, Vadakedath S, and Kandi V. Clinical Research: A Review of Study  
978 Designs, Hypotheses, Errors, Sampling Types, Ethics, and Informed Consent.  
979 *Cureus*. 2023; 5(1): e33374. <https://doi.org/10.7759/cureus.33374>.

980 54. Prnjak K, Mitchison D, Griffiths S, et al. Further development of the 12-item EDE-QS:  
981 identifying a cut-off for screening purposes. *BMC Psychiatry*. 2020; 20(1): 146.  
982 <https://doi.org/10.1186/s12888-020-02565-5>.

983 55. Australian Government Department of Health. Body mass index (BMI) and waist  
984 measurement. 2021 [cited 2022 8 March]; Available from:  
985 <https://www.health.gov.au/health-topics/overweight-and-obesity/bmi-and-waist>.

986 56. Centers for Disease Control and Prevention (CDC). Healthy Weight, Nutrition, and  
987 Physical Activity: Assessing Your Weight. 2021 [cited 2022 8 March]; Available from:  
988 <https://www.cdc.gov/healthyweight/assessing/index.html>.

989 57. Mond J, Hay P, Rodgers B, et al. Use of extreme weight control behaviors with and  
990 without binge eating in a community sample: implications for the classification of  
991 bulimic-type eating disorders. *International Journal of Eating Disorders*. 2006; 39(4):  
992 294-302. <https://doi.org/10.1002/eat.20265>.

993 58. Mond JJ, Hay PJ, Rodgers B, et al. Correlates of the use of purging and non-purging  
994 methods of weight control in a community sample of women. *The Australian and New  
995 Zealand Journal of Psychiatry*. 2006; 40(2): 136-142. [https://doi.org/10.1080/j.1440-  
996 1614.2006.01760.x](https://doi.org/10.1080/j.1440-1614.2006.01760.x).

997 59. WHO ASSIST Working Group. The Alcohol, Smoking and Substance Involvement  
998 Screening Test (ASSIST): development, reliability and feasibility. *Addiction*. 2002;  
999 97(9): 1183-1194. <https://doi.org/10.1046/j.1360-0443.2002.00185.x>.

1000 60. Spitzer RL, Kroenke K, Williams JBW, et al. A Brief Measure for Assessing  
1001 Generalized Anxiety Disorder (The GAD-7). *Archives of Internal Medicine*. 2006;  
1002 166(10): 1092–1097 <https://doi.org/10.1001/archinte.166.10.1092>.

- 1003 61. Ingram PB 4th, Clarke E, and Lichtenberg JW. Confirmatory Factor Analysis of the  
1004 Perceived Stress Scale-4 in a Community Sample. *Stress Health*. 2016; 32(2): 173–  
1005 176. <https://doi.org/10.1002/smi.2592>.
- 1006 62. Fairburn C, Cooper Z, and O'Connor M, *Eating disorders examination (16.0D)* in *In:*  
1007 *Cognitive behavior therapy and eating disorders*, Fairburn C (Ed.), Editor. 2008,  
1008 Guilford Press: New York.
- 1009 63. Kroenke K, Strine TW, Spitzer RL, et al. The PHQ-8 as a measure of current  
1010 depression in the general population. *Journal of affective disorders*. 2009; 114(1-3):  
1011 163-173. <https://doi.org/10.1016/j.jad.2008.06.026>.
- 1012 64. Collins CE, Boggess MM, Watson JF, et al. Reproducibility and comparative validity  
1013 of a food frequency questionnaire for Australian adults. *Clinical Nutrition*. 2014; 33(5):  
1014 906-914. <https://doi.org/10.1016/j.clnu.2013.09.015>.
- 1015 65. Ashton L, Williams R, Wood L, et al. Comparison of Australian Recommended Food  
1016 Score (ARFS) and Plasma Carotenoid Concentrations: A Validation Study in Adults.  
1017 *Nutrients*. 2017; 9(8): 888. <http://doi.org/10.3390/nu9080888>.
- 1018 66. Woicik PA, Stewart SH, Pihl RO, et al. The Substance Use Risk Profile Scale: a  
1019 scale measuring traits linked to reinforcement-specific substance use profiles.  
1020 *Addictive Behaviors*. 2009; 34(12): 1042-1055.  
1021 <https://doi.org/10.1016/j.addbeh.2009.07.001>.
- 1022 67. Gormally J, Black S, Daston S, et al. The assessment of binge eating severity among  
1023 obese persons. *Addictive Behaviors*. 1982; 7(1): 47-55. [https://doi.org/10.1016/0306-](https://doi.org/10.1016/0306-4603(82)90024-7)  
1024 [4603\(82\)90024-7](https://doi.org/10.1016/0306-4603(82)90024-7).
- 1025 68. Heriseanu AI, Hay P, and Touyz S. The short inventory of grazing (SIG):  
1026 development and validation of a new brief measure of a common eating behaviour  
1027 with a compulsive dimension. *Journal of Eating Disorders*. 2019; 7(4).  
1028 <https://doi.org/10.1186/s40337-019-0234-6>.
- 1029 69. Vainik U, Han C, Epel ES, et al. Rapidly assessing reward-related eating: The RED-  
1030 X5. *Obesity*. 2019; 27(2): 325–331. <https://doi.org/10.1002/oby.22374>.

- 1031 70. Hibbard JH, Stockard J, Mahoney ER, et al. Development of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers. *Health Services Research*. 2004; 39(4 Pt 1): 1005–1026. <https://doi.org/10.1111/j.1475-6773.2004.00269.x>.
- 1032
- 1033
- 1034
- 1035 71. Rabin R and de Charro F. EQ-5D: a measure of health status from the EuroQol Group. *Annals of Medicine*. 2001; 33(5): 337-343. <https://doi.org/10.3109/07853890109002087>.
- 1036
- 1037
- 1038 72. Australian Institute of Health and Welfare (AIHW). The Active Australia Survey: a guide and manual for implementation, analysis and reporting. 2003; Available from: <https://www.aihw.gov.au/reports/physical-activity/active-australia-survey/summary>.
- 1039
- 1040
- 1041 73. Buysse DJ, Reynolds CF 3rd, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Research*. 1989; 28(2): 193–213. [https://doi.org/10.1016/0165-1781\(89\)90047-4](https://doi.org/10.1016/0165-1781(89)90047-4).
- 1042
- 1043
- 1044 74. Beecham J and Knapp M, *Costing psychiatric interventions*, in *Measuring Mental Health Needs (2nd edition)*, Thornicroft G, Editor. 2001, Gaskell: London. p. 200-224.
- 1045
- 1046 75. Pursey KM, Collins R, Skinner J, et al. Characteristics of individuals seeking addictive eating treatment. *Eating and Weight Disorders*. 2021; 26(8): 2779-2786. <https://doi.org/10.1007/s40519-021-01147-y>.
- 1047
- 1048
- 1049 76. Collins R, Haracz K, Leary M, et al. No control and overwhelming cravings: Australian adults' perspectives on the experience of food addiction. *Appetite*. 2021; 59(105054). <https://doi.org/10.1016/j.appet.2020.105054>.
- 1050
- 1051
- 1052 77. Pedram P, Wadden D, Amini P, et al. Food addiction: its prevalence and significant association with obesity in the general population. *PLOS One*. 2013; 8(9): e74832. <https://doi.org/10.1371/journal.pone.0074832>.
- 1053
- 1054
- 1055 78. Lemeshow AR, Gearhardt AN, Genkinger JM, et al. Assessing the psychometric properties of two food addiction scales *Eating Behaviors*. 2016; 23: 110–114. <https://doi.org/10.1016/j.eatbeh.2016.08.005>.
- 1056
- 1057

- 1058 79. National Health and Medical Research Council (NHMRC). Australian Guide to  
1059 Healthy Eating. 2017; Available from:  
1060 <https://www.eatforhealth.gov.au/guidelines/australian-guide-healthy-eating>.  
1061 80. Food Standards Australia New Zealand (FSANZ). AUSNUT 2011–13–Australian  
1062 Food Composition Database. 2014 [cited 2021 31 May]; Available from:  
1063 <http://foodstandards.gov.au/>.  
1064 81. National Health and Medical Research Council. Australian Dietary Guidelines.  
1065 Canberra. 2013; Available from: [www.nhmrc.gov.au/guidelines-publications/n55](http://www.nhmrc.gov.au/guidelines-publications/n55).  
1066 82. Personal Social Services Research Unit (PSSRU). 2022 [cited 2022 14 April];  
1067 Available from: <https://www.pssru.ac.uk/csri/client-service-receipt-inventory/>.  
1068 83. Mauskopf JA, Paul JE, Grant DM, et al. The role of cost-consequence analysis in  
1069 healthcare decision-making. *Pharmacoeconomics*. 1998; 13(3): 277-288.  
1070 <https://doi.org/10.2165/00019053-199813030-00002>.  
1071 84. Hunter R and Shearer J. Cost-consequences analysis - an underused method of  
1072 economic evaluation. [cited 2022 8 March]; Available from: [https://www.rds-](https://www.rds-london.nihr.ac.uk/wpcms/wp-content/uploads/2018/09/Cost-consequences-analysis-an-underused-method.pdf)  
1073 [london.nihr.ac.uk/wpcms/wp-content/uploads/2018/09/Cost-consequences-analysis-](https://www.rds-london.nihr.ac.uk/wpcms/wp-content/uploads/2018/09/Cost-consequences-analysis-an-underused-method.pdf)  
1074 [an-underused-method.pdf](https://www.rds-london.nihr.ac.uk/wpcms/wp-content/uploads/2018/09/Cost-consequences-analysis-an-underused-method.pdf).  
1075 85. Hibbard JH, Mahoney ER, Stockard J, et al. Development and testing of a short form  
1076 of the patient activation measure. *Health Services Research*. 2005; 40(6 Pt 1): 1918-  
1077 1930. <https://doi.org/10.1111/j.1475-6773.2005.00438.x>.  
1078 86. Greene J and Hibbard JH. Why does patient activation matter? An examination of the  
1079 relationships between patient activation and health-related outcomes. *Journal of*  
1080 *General Internal Medicine*. 2012; 27(5): 520–526. [https://doi.org/10.1007/s11606-](https://doi.org/10.1007/s11606-011-1931-2)  
1081 [011-1931-2](https://doi.org/10.1007/s11606-011-1931-2).  
1082 87. Insignia Health, *Patient activation measure (PAM) 13 TM Licence Materials*  
1083 *copyright*. 2011, LLC: Insignia Health.  
1084 88. Remmers C, Hibbard J, Mosen DM, et al. Is patient activation associated with future  
1085 health outcomes and healthcare utilization among patients with diabetes? *The*

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1086 *Journal of Ambulatory Care Management*. 2009; 32(4): 320-327.

1087 <https://doi.org/10.1097/JAC.0b013e3181ba6e77>.

1088 89. Australian Bureau of Statistics (ABS). 2033.0.55.001 - Socio-Economic Indexes for

1089 Areas (SEIFA). 2016 [cited 2021 14 September]; Available from: [www.abs.gov.au](http://www.abs.gov.au).

1090 90. World Health Organization (WHO). Body mass index - BMI. c2018 [cited 2021

1091 September 1]; Available from: [http://www.euro.who.int/en/health-topics/disease-](http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi)

1092 [prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi](http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi).

1093 91. Harris PA, Taylor R, Minor BL, et al. REDCap Consortium. The REDCap consortium:

1094 Building an international community of software platform partners. *Journal of*

1095 *Biomedical Informatics*. 2019; 95(103208). <https://doi.org/10.1016/j.jbi.2019.103208>.


1096 92. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap) – A

1097 metadata-driven methodology and workflow process for providing translational

1098 research informatics support. *Journal of Biomedical Informatics*. 2009; 42(2): 377-

1099 381. <https://doi.org/10.1016/j.jbi.2008.08.010>.

1100



1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

WELCOME BACK!As you have been found eligible to participate in the personality based intervention for addictive eating, it is important that you carefully read the following information and give consent at the bottom if you wish to continue to the baseline surveys.

---

I have read the previous Participant Information Statement and give my consent to participate in this study?

☐ Yes

☐ No

---

I understand that it is possible that some questionnaires may identify potential health issues that may require follow-up with my GP. I give consent for a copy of the relevant results to be sent to my local doctor/GP or other Health Professional

☐ Yes

☐ No

---

Please provide Health Professional details (e.g Name, Phone number)

---

I agree to participate in the Personality based intervention for Addictive Eating Behaviours study and give my consent freely.

I understand that the project will be conducted as described in the previous Participant Information Statement, a copy of which I have had the opportunity to download.

I understand I can withdraw from the project at any time and do not have to give any reason for withdrawing. I am aware I have an equal chance of being allocated into one of three intervention groups. If allocated to:

- Group 1, I consent to completing online questionnaires at the beginning of the study and after 3 and 6 months, and to participating in five telehealth/phone consultations of 30-45mins with an Accredited Practising Dietitian.
- Group 2, I consent to completing online questionnaires at the beginning of the study and after 3 and 6 months, and to complete the self-guided workbook and access the study website.
- Group 3, I consent to completing online questionnaires at the beginning of the study and after 3 and 6 months, and to follow my usual dietary intake for the study duration. I understand that after 6 months I will have access to complete the self-guided workbook and access to the study website.

---

If allocated to group 1, I consent for my five sessions with the dietitian to be recorded for quality and training purposes.

☐ Yes

☐ No

---

Please provide your First Name:

---

Please provide your Last Name:

---

Please sign:

---

Do you wish to continue to the Baseline Surveys?

☐ Yes

☐ No



**Title:** Examining the efficacy of a telehealth intervention targeting addictive eating in Australian adults (the TRACE program): a randomised controlled trial protocol

### Reference to where data collection forms can be found

Survey	Assessment tool	Reference	Available from
<b>AAS</b>	<b>Active Australia Survey</b>	Australian Institute of Health and Welfare (AIHW) 2003. The Active Australia Survey: a guide and manual for implementation, analysis and reporting. Canberra: AIHW.	<a href="https://www.aihw.gov.au/reports/physical-activity/active-australia-survey/summary">https://www.aihw.gov.au/reports/physical-activity/active-australia-survey/summary</a>
<b>AES</b>	<b>Australian Eating Survey</b>	Ashton L, Williams R, Wood L, Schumacher T, Burrows T, Rollo M, et al. Comparison of Australian Recommended Food Score (ARFS) and Plasma Carotenoid Concentrations: A Validation Study in Adults. <i>Nutrients</i> . 2017;9(8):888. <a href="http://doi.org/10.3390/nu9080888">http://doi.org/10.3390/nu9080888</a>  Collins CE, Boggess MM, Watson JF, Guest M, Duncanson K, Pezdirc K, et al. Reproducibility and comparative validity of a food frequency questionnaire for Australian adults. <i>Clinical Nutrition</i> . 2014;33(5):906-14. doi: 10.1016/j.clnu.2013.09.015	<a href="https://australianeatingsurvey.com.au/">https://australianeatingsurvey.com.au/</a>
<b>ASSIST</b>	<b>Alcohol, Smoking and Substance Involvement Screening Test - Version 3.0</b>	WHO ASSIST Working Group (2002) The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. <i>Addiction</i> , 97:1183-1194. doi: 10.1046/j.1360-0443.2002.00185.x	<a href="https://www.who.int/publications/i/item/978924159938-2">https://www.who.int/publications/i/item/978924159938-2</a>
<b>BES</b>	<b>Binge Eating Scale</b>	Gormally J, Black S, Daston S, Rardin D. The assessment of binge eating severity among obese persons. <i>Addictive Behaviors</i> . 1982;7(1):47-55. <a href="https://doi.org/10.1016/0306-4603(82)90024-7">https://doi.org/10.1016/0306-4603(82)90024-7</a>	Available in the publication
<b>CSRI</b>	<b>Consumer Services Receipt Inventory</b>	Beecham J and Knapp M. (2001) Costing psychiatric interventions, in G. Thornicroft (ed.) <i>Measuring Mental Health Needs</i> , Gaskell, 2nd edition, 200-224.	<a href="https://www.pssru.ac.uk/csri/what-is-the-csri/">https://www.pssru.ac.uk/csri/what-is-the-csri/</a>
<b>EDE-Q 6.0</b>	<b>Eating Disorder</b>	Fairburn C, Cooper Z, O'Connor M. Eating disorders examination (16.0D) In: Fairburn C (Ed.), editor. In:	<a href="https://nedc.com.au/assets/Medicare-related-forms/Eating-Disorder-Examination-Questionnaire-Smart-PDF.pdf">https://nedc.com.au/assets/Medicare-related-forms/Eating-Disorder-Examination-Questionnaire-Smart-PDF.pdf</a>



	<b>Examination Questionnaire 6.0</b>	Cognitive behavior therapy and eating disorders. New York: Guilford Press; 2008.	
<b>EDE-QS</b>	<b>Eating Disorder Examination Questionnaire Short Form</b>	Prnjak K, Mitchison D, Griffiths S, Mond J, Gideon N, Serpell L, Hay P. Further development of the 12-item EDE-QS: identifying a cut-off for screening purposes. BMC Psychiatry. 2020;20:146. <a href="https://doi.org/10.1186/s12888-020-02565-5">https://doi.org/10.1186/s12888-020-02565-5</a>	Available as Supporting Information accompanying the publication
<b>EQ5D-5L</b>	<b>EQ5D-5L</b>	Brazier J, Ratcliffe J, Tsuchiya A, Salomon J. Measuring and Valuing Health Benefits for Economic Evaluation. 2nd ed. Oxford: Oxford University Press; 2016. doi: 10.1093/med/9780198725923.001.0001.	<a href="https://aci.health.nsw.gov.au/_data/assets/pdf_file/0003/632847/EuroQol-5-Dimension.pdf">https://aci.health.nsw.gov.au/_data/assets/pdf_file/0003/632847/EuroQol-5-Dimension.pdf</a>
<b>GAD-7</b>	<b>Generalized Anxiety Disorder 7</b>	Spitzer RL, Kroenke K, Williams JBW, Löwe B. A Brief Measure for Assessing Generalized Anxiety Disorder (The GAD-7). Archives of Internal Medicine. 2006;166(10):1092–7 <a href="https://doi.org/10.1001/archinte.166.10.1092">https://doi.org/10.1001/archinte.166.10.1092</a>	<a href="https://adaa.org/sites/default/files/GAD-7_Anxiety-updated_0.pdf">https://adaa.org/sites/default/files/GAD-7_Anxiety-updated_0.pdf</a>
<b>PAM-13</b>	<b>Patient Activation Measure 13-item</b>	Hibbard JH, Stockard J, Mahoney ER, Tusler M. (2004). Development of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers. Health services research. 2004;39(4 Pt 1): 1005–1026. <a href="https://doi.org/10.1111/j.1475-6773.2004.00269.x">https://doi.org/10.1111/j.1475-6773.2004.00269.x</a>	<a href="https://www.insigniahealth.com/products/pam">https://www.insigniahealth.com/products/pam</a>
<b>PQH-8</b>	<b>Patient Health Questionnaire</b>	Kroenke K, et al., The PHQ-8 as a measure of current depression in the general population. Journal of affective disorders, 2009. 114(1-3): p. 163-173 <a href="https://doi.org/10.1016/j.jad.2008.06.026">https://doi.org/10.1016/j.jad.2008.06.026</a>	<a href="https://www.psychologywizard.net/uploads/2/6/6/4/26640833/kroenke_phq8.pdf">https://www.psychologywizard.net/uploads/2/6/6/4/26640833/kroenke_phq8.pdf</a>
<b>PSQI</b>	<b>Pittsburgh Sleep Quality Index</b>	Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Research. 1989;28(2): 193–213. <a href="https://doi.org/10.1016/0165-1781(89)90047-4">https://doi.org/10.1016/0165-1781(89)90047-4</a>	<a href="https://www.med.upenn.edu/cbti/assets/user-content/documents/Pittsburgh%20Sleep%20Quality%20Index%20(PSQI).pdf">https://www.med.upenn.edu/cbti/assets/user-content/documents/Pittsburgh%20Sleep%20Quality%20Index%20(PSQI).pdf</a>
<b>PSS-4</b>	<b>Perceived Stress Scale</b>	Ingram PB 4th, Clarke E, Lichtenberg JW. Confirmatory Factor Analysis of the Perceived Stress Scale-4 in a Community Sample. Stress Health. 2016; 32(2): 173–176. <a href="https://doi.org/10.1002/smi.2592">https://doi.org/10.1002/smi.2592</a>	<a href="https://scholar.harvard.edu/files/bettina.hoeppner/files/pss-4.pdf">https://scholar.harvard.edu/files/bettina.hoeppner/files/pss-4.pdf</a>

<b>REDX-5</b>	<b>Reward-Based Eating Drive Scale</b>	Vainik U, Han C, Epel ES, Dagher A, Mason AE. Rapid assessment of reward-related eating: The RED-X5. Obesity. 2019;27(2):325–31. doi:10.1002/oby.22374	<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352904/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352904/</a>
<b>SURPS</b>	<b>Substance Use Risk Profile Scale</b>	Woicik PA, Stewart SH, Pihl RO, Conrod PJ. The Substance Use Risk Profile Scale: a scale measuring traits linked to reinforcement-specific substance use profiles. Addictive Behaviors. 2009;34(12): 1042-55. doi: 10.1016/j.addbeh.2009.07.001	Available on request from the corresponding author: Woicik can be contacted at Neuropsychomaging Group, Brookhaven National Laboratory, Medical Department, Building 490, Upton, New York, 11973, United States. Tel.: +1 631 344 4472. Conrod, NIHR Biomedical Research Centre, Section of Addiction, Department of Psychological Medicine and Psychiatry, King's College London, 4 Windsor Walk, Denmark Hill, London, SE5 8BB, United Kingdom. Tel.: +44 207 848 0836; fax: +44 207 701 8584. <a href="mailto:p.conrod@iop.kcl.ac.uk">p.conrod@iop.kcl.ac.uk</a>
<b>YFAS 2.0</b>	<b>Yale Food Addiction Scale 2.0</b>	Gearhardt AN, Corbin WR, Brownell KD. Development of the Yale Food Addiction Scale Version 2.0. Psychology of Addictive Behaviors. 2016;30(1):113-21. doi: 10.1037/adb0000136	<a href="https://sites.lsa.umich.edu/fastlab/yale-food-addiction-scale/">https://sites.lsa.umich.edu/fastlab/yale-food-addiction-scale/</a>



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	2
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3, 8
	2b	All items from the World Health Organization Trial Registration Data Set	NA
Protocol version	3	Date and version identifier	-
Funding	4	Sources and types of financial, material, and other support	32
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1, 32
	5b	Name and contact information for the trial sponsor	1
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	32
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	NA

## Introduction

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4 – 7
	6b	Explanation for choice of comparators	14
Objectives	7	Specific objectives or hypotheses	7
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	8
<b>Methods: Participants, interventions, and outcomes</b>			
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	8
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	9, 10
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	14 - 20
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	8
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	18, 19
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	NA
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	21 - 27
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	10 - 11 (Table 1)

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including	28
2			clinical and statistical assumptions supporting any sample size calculations	
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	8 - 9
5				
6	<b>Methods: Assignment of interventions (for controlled trials)</b>			
7				
8	Allocation:			
9				
10	Sequence	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any	13, 14
11	generation		factors for stratification. To reduce predictability of a random sequence, details of any planned restriction	
12			(eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants	
13			or assign interventions	
14				
15				
16	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered,	13, 14
17	concealment		opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	
18	mechanism			
19				
20	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to	13, 14
21			interventions	
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome	13, 14
25			assessors, data analysts), and how	
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's	NA
28			allocated intervention during the trial	
29				
30				
31	<b>Methods: Data collection, management, and analysis</b>			
32				
33	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related	21 - 30, suppl
34	methods		processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of	
35			study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known.	
36			Reference to where data collection forms can be found, if not in the protocol	
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be	11 - 13
40			collected for participants who discontinue or deviate from intervention protocols	
41				
42				
43				
44				
45				
46				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	29, 30
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	28, 29
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	28, 29
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	29
11				
12				
13				
14	<b>Methods: Monitoring</b>			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	29, 30
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	NA
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	30
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	30
29				
30				
31				
32	<b>Ethics and dissemination</b>			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	8, 31
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	NA
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and	11, 12
2			how (see Item 32)	
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary	NA
5			studies, if applicable	
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained	29, 30
8			in order to protect confidentiality before, during, and after the trial	
9				
10	Declaration of	28	Financial and other competing interests for principal investigators for the overall trial and each study site	32
11	interests			
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that	29, 30
14			limit such access for investigators	
15				
16	Ancillary and post-	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial	NA
17	trial care		participation	
18				
19	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals,	31
20			the public, and other relevant groups (eg, via publication, reporting in results databases, or other data	
21			sharing arrangements), including any publication restrictions	
22				
23		31b	Authorship eligibility guidelines and any intended use of professional writers	NA
24				
25		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	31
26				
27				
28				
29	<b>Appendices</b>			
30				
31	Informed consent	32	Model consent form and other related documentation given to participants and authorised surrogates	Suppl.
32	materials			
33				
34	Biological	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular	NA
35	specimens		analysis in the current trial and for future use in ancillary studies, if applicable	
36				

37 \*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.  
38 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons  
39 “[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)” license.  
40  
41  
42